|
G |
Abcc2 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 |
multiple interactions |
ISO |
Dideoxyadenosine inhibits the reaction [[EGF protein co-treated with 1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone] results in decreased activity of ABCC2 protein]; Dideoxyadenosine inhibits the reaction [Taurolithocholic Acid affects the localization of ABCC2 protein]; Dideoxyadenosine inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein] |
CTD |
PMID:25813982 PMID:31300867 |
|
NCBI chr19:43,782,308...43,838,332
Ensembl chr19:43,782,192...43,840,740
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
Dideoxyadenosine inhibits the reaction [[EGF protein co-treated with 1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone] results in decreased activity of ABCC2 protein] |
CTD |
PMID:25813982 |
|
NCBI chr 3:129,677,574...129,755,322
Ensembl chr 3:129,677,565...129,755,316
|
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A (P21) |
decreases expression |
ISO |
2'-deoxyadenosine results in decreased expression of CDKN1A mRNA |
CTD |
PMID:24211769 |
|
NCBI chr17:29,090,979...29,100,722
Ensembl chr17:29,090,976...29,100,727
|
|
G |
Polb |
polymerase (DNA directed), beta |
multiple interactions |
ISO |
[diepoxybutane binds to 2'-deoxyadenosine] which results in decreased activity of POLB protein |
CTD |
PMID:26098310 |
|
NCBI chr 8:22,628,119...22,653,464
Ensembl chr 8:22,628,126...22,653,435
|
|
G |
Poli |
polymerase (DNA directed), iota |
multiple interactions |
ISO |
[diepoxybutane binds to 2'-deoxyadenosine] which results in decreased activity of POLI protein; POLN protein inhibits the reaction [[diepoxybutane binds to 2'-deoxyadenosine] which results in decreased activity of POLI protein] |
CTD |
PMID:26098310 |
|
NCBI chr18:70,508,680...70,534,950
Ensembl chr18:70,508,680...70,530,620
|
|
G |
Polk |
polymerase (DNA directed), kappa |
multiple interactions |
ISO |
[diepoxybutane binds to 2'-deoxyadenosine] which results in decreased activity of POLK protein |
CTD |
PMID:26098310 |
|
NCBI chr13:96,480,687...96,542,579
Ensembl chr13:96,480,690...96,542,579
|
|
G |
Poln |
DNA polymerase N |
multiple interactions |
ISO |
[diepoxybutane binds to 2'-deoxyadenosine] which results in decreased activity of POLN protein; POLN protein inhibits the reaction [[diepoxybutane binds to 2'-deoxyadenosine] which results in decreased activity of POLI protein] |
CTD |
PMID:26098310 |
|
NCBI chr 5:34,007,179...34,169,526
Ensembl chr 5:34,007,179...34,169,448
|
|
G |
Slc29a1 |
solute carrier family 29 (nucleoside transporters), member 1 |
multiple interactions |
EXP |
2'-deoxyadenosine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine] |
CTD |
PMID:11085929 |
|
NCBI chr17:45,585,200...45,599,618
Ensembl chr17:45,585,200...45,599,606
|
|
G |
Slc29a2 |
solute carrier family 29 (nucleoside transporters), member 2 |
multiple interactions |
EXP |
2'-deoxyadenosine inhibits the reaction [SLC29A2 protein results in increased uptake of Uridine] |
CTD |
PMID:11085929 |
|
NCBI chr19:5,019,057...5,031,972
Ensembl chr19:5,023,860...5,031,972
|
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[9-deaza-9-(3-thienylmethyl)guanine co-treated with Deoxyguanosine] results in increased activity of CASP3 protein; Deoxycytidine inhibits the reaction [[9-deaza-9-(3-thienylmethyl)guanine co-treated with Deoxyguanosine] results in increased activity of CASP3 protein] |
CTD |
PMID:9297556 PMID:9403342 |
|
NCBI chr 8:46,617,291...46,639,698
Ensembl chr 8:46,617,291...46,639,689
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
CYP1A1 protein promotes the reaction [Aflatoxin B1 binds to Deoxyguanosine] |
CTD |
PMID:21907773 |
|
NCBI chr 9:57,687,928...57,703,824
Ensembl chr 9:57,687,928...57,703,824
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
CYP1A2 protein promotes the reaction [Aflatoxin B1 binds to Deoxyguanosine]; CYP1A2 protein promotes the reaction [Estrone binds to Deoxyguanosine] |
CTD |
PMID:21907773 |
|
NCBI chr 9:57,676,937...57,683,655
Ensembl chr 9:57,676,937...57,683,703
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
CYP1B1 protein promotes the reaction [Aflatoxin B1 binds to Deoxyguanosine] |
CTD |
PMID:21907773 |
|
NCBI chr17:79,706,940...79,715,061
Ensembl chr17:79,701,537...79,715,061
|
|
G |
Cyp3a11 |
cytochrome P450, family 3, subfamily a, polypeptide 11 |
multiple interactions |
ISO |
CYP3A4 protein promotes the reaction [Aflatoxin B1 binds to Deoxyguanosine]; CYP3A4 protein promotes the reaction [Estrone binds to Deoxyguanosine] |
CTD |
PMID:21907773 |
|
NCBI chr 5:145,854,607...145,879,854
Ensembl chr 5:145,854,426...145,879,964
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
decreases activity |
ISO |
Deoxyguanosine analog results in decreased activity of MGMT protein |
CTD |
PMID:17880193 |
|
NCBI chr 7:136,894,463...137,128,193
Ensembl chr 7:136,894,614...137,130,266
|
|
|
G |
Ace |
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 |
affects activity |
ISO |
Puromycin Aminonucleoside affects the activity of ACE protein |
CTD |
PMID:1318808 |
|
NCBI chr11:105,967,948...105,989,964
Ensembl chr11:105,967,945...105,989,964
|
|
G |
Acmsd |
amino carboxymuconate semialdehyde decarboxylase |
decreases activity |
ISO |
Puromycin Aminonucleoside results in decreased activity of ACMSD protein |
CTD |
PMID:16711654 |
|
NCBI chr 1:127,729,413...127,767,564
Ensembl chr 1:127,729,413...127,767,978
|
|
G |
Actb |
actin, beta |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of ACTB protein |
CTD |
PMID:19264907 |
|
NCBI chr 5:142,903,115...142,907,976
Ensembl chr 5:142,903,115...142,906,754
|
|
G |
Actg1 |
actin, gamma, cytoplasmic 1 |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of ACTG1 protein |
CTD |
PMID:19264907 |
|
NCBI chr11:120,345,687...120,348,495
Ensembl chr11:120,345,690...120,348,542
|
|
G |
Actr2 |
ARP2 actin-related protein 2 |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of ACTR2 mRNA; Puromycin Aminonucleoside results in increased expression of ACTR2 protein |
CTD |
PMID:19617259 |
|
NCBI chr11:20,062,304...20,112,951
Ensembl chr11:20,062,304...20,112,913
|
|
G |
Actr3 |
ARP3 actin-related protein 3 |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of ACTR3 protein |
CTD |
PMID:19264907 |
|
NCBI chr 1:125,392,905...125,435,727
Ensembl chr 1:125,392,905...125,435,727
|
|
G |
Agt |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
affects expression decreases expression increases expression multiple interactions |
ISO |
Puromycin Aminonucleoside affects the expression of AGT protein Puromycin Aminonucleoside results in decreased expression of AGT protein Puromycin Aminonucleoside results in increased expression of AGT mRNA [Puromycin Aminonucleoside co-treated with Cholesterol] results in increased expression of AGT mRNA |
CTD |
PMID:2236972 PMID:8446257 PMID:12495295 |
|
NCBI chr 8:124,556,587...124,569,706
Ensembl chr 8:124,556,534...124,569,706
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
multiple interactions increases expression |
ISO |
[Puromycin Aminonucleoside co-treated with Cholesterol] results in increased expression of AGTR2 mRNA Puromycin Aminonucleoside results in increased expression of AGTR2 mRNA |
CTD |
PMID:12495295 |
|
NCBI chr X:21,484,624...21,488,833
Ensembl chr X:21,484,544...21,489,164
|
|
G |
Agxt2 |
alanine-glyoxylate aminotransferase 2 |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of AGXT2 protein |
CTD |
PMID:19264907 |
|
NCBI chr15:10,358,516...10,410,158
Ensembl chr15:10,358,532...10,410,153
|
|
G |
Aifm1 |
apoptosis-inducing factor, mitochondrion-associated 1 |
multiple interactions affects localization |
EXP |
Dexamethasone inhibits the reaction [Puromycin Aminonucleoside affects the localization of AIFM1 protein] |
CTD |
PMID:15987750 |
|
NCBI chr X:48,474,944...48,513,563
Ensembl chr X:48,474,944...48,513,563
|
|
G |
Alb |
albumin |
affects transport increases secretion increases expression affects localization decreases expression |
EXP ISO |
Puromycin Aminonucleoside affects the transport of ALB protein Puromycin Aminonucleoside results in increased secretion of ALB protein Puromycin Aminonucleoside results in increased expression of ALB mRNA; Puromycin Aminonucleoside results in increased expression of ALB protein Puromycin Aminonucleoside affects the localization of ALB protein Puromycin Aminonucleoside results in decreased expression of ALB protein |
CTD |
PMID:1453496 PMID:3301049 PMID:8413769 PMID:15798086 PMID:19264907 PMID:20438795 PMID:20540862 |
|
NCBI chr 5:90,460,870...90,476,602
Ensembl chr 5:90,460,897...90,476,602
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase family 1, subfamily A2 |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of ALDH1A2 mRNA |
CTD |
PMID:12660332 |
|
NCBI chr 9:71,215,789...71,296,243
Ensembl chr 9:71,215,789...71,296,243
|
|
G |
Angpt1 |
angiopoietin 1 |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of ANGPT1 mRNA |
CTD |
PMID:17667850 |
|
NCBI chr15:42,424,667...42,676,977
Ensembl chr15:42,424,723...42,676,977
|
|
G |
Apex1 |
apurinic/apyrimidinic endonuclease 1 |
multiple interactions increases expression |
EXP |
1,3-dimethylthiourea inhibits the reaction [Puromycin Aminonucleoside results in increased expression of APEX1 protein] |
CTD |
PMID:17035936 |
|
NCBI chr14:50,924,949...50,927,188
Ensembl chr14:50,924,968...50,927,139
|
|
G |
Apoa1 |
apolipoprotein A-I |
decreases response to substance increases expression |
ISO |
APOA1 protein results in decreased susceptibility to Puromycin Aminonucleoside Puromycin Aminonucleoside results in increased expression of APOA1 mRNA; Puromycin Aminonucleoside results in increased expression of APOA1 protein |
CTD |
PMID:7066357 PMID:7442475 PMID:7595070 PMID:8412754 PMID:8413767 PMID:8506949 PMID:9059516 |
|
NCBI chr 9:46,228,630...46,230,469
Ensembl chr 9:46,228,580...46,230,466
|
|
G |
Apoa2 |
apolipoprotein A-II |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of APOA2 protein |
CTD |
PMID:7442475 |
|
NCBI chr 1:171,221,564...171,226,379
Ensembl chr 1:171,225,054...171,226,379
|
|
G |
Apoa4 |
apolipoprotein A-IV |
decreases expression increases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of APOA4 protein Puromycin Aminonucleoside results in increased expression of APOA4 mRNA; Puromycin Aminonucleoside results in increased expression of APOA4 protein |
CTD |
PMID:7442475 PMID:8412754 |
|
NCBI chr 9:46,240,844...46,243,458
Ensembl chr 9:46,240,696...46,243,459
|
|
G |
Apob |
apolipoprotein B |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of APOB protein |
CTD |
PMID:2725289 PMID:7442475 PMID:8506949 |
|
NCBI chr12:7,977,629...8,016,839
Ensembl chr12:7,977,648...8,016,835
|
|
G |
Apoe |
apolipoprotein E |
decreases response to substance increases expression affects expression |
EXP ISO |
APOE protein results in decreased susceptibility to Puromycin Aminonucleoside Puromycin Aminonucleoside results in increased expression of APOE protein Puromycin Aminonucleoside affects the expression of APOE mRNA |
CTD |
PMID:7442475 PMID:8413767 PMID:12472773 |
|
NCBI chr 7:19,696,244...19,701,310
Ensembl chr 7:19,696,109...19,699,188
|
|
G |
Aqp2 |
aquaporin 2 |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of AQP2 protein |
CTD |
PMID:9013444 |
|
NCBI chr15:99,579,056...99,584,545
Ensembl chr15:99,579,055...99,584,547
|
|
G |
Aqp3 |
aquaporin 3 |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of AQP3 protein |
CTD |
PMID:9013444 |
|
NCBI chr 4:41,092,724...41,098,183
Ensembl chr 4:41,092,722...41,098,183
|
|
G |
Arc |
activity regulated cytoskeletal-associated protein |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of ARC mRNA |
CTD |
PMID:19617259 |
|
NCBI chr15:74,669,081...74,672,570
Ensembl chr15:74,669,083...74,672,570
|
|
G |
Atp1a1 |
ATPase, Na+/K+ transporting, alpha 1 polypeptide |
decreases expression increases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of ATP1A1 protein Puromycin Aminonucleoside results in increased expression of ATP1A1 mRNA |
CTD |
PMID:11675400 PMID:15075188 |
|
NCBI chr 3:101,576,219...101,604,707
Ensembl chr 3:101,576,219...101,604,684
|
|
G |
Atp1b1 |
ATPase, Na+/K+ transporting, beta 1 polypeptide |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of ATP1B1 mRNA |
CTD |
PMID:11675400 |
|
NCBI chr 1:164,437,099...164,458,355
Ensembl chr 1:164,437,109...164,458,355
|
|
G |
Atp2a2 |
ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of ATP2A2 mRNA; Puromycin Aminonucleoside results in decreased expression of ATP2A2 protein |
CTD |
PMID:17457379 |
|
NCBI chr 5:122,453,513...122,502,225
Ensembl chr 5:122,453,513...122,502,225
|
|
G |
Avp |
arginine vasopressin |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of AVP protein |
CTD |
PMID:7810534 |
|
NCBI chr 2:130,580,620...130,582,588
Ensembl chr 2:130,580,620...130,582,554
|
|
G |
Bax |
BCL2-associated X protein |
increases expression multiple interactions |
EXP ISO |
Puromycin Aminonucleoside results in increased expression of BAX protein Dinoprostone inhibits the reaction [Puromycin Aminonucleoside results in increased expression of BAX protein] Dexamethasone inhibits the reaction [Puromycin Aminonucleoside results in increased expression of BAX protein] |
CTD |
PMID:15113391 PMID:15987750 PMID:16152783 PMID:16396944 |
|
NCBI chr 7:45,461,695...45,466,903
Ensembl chr 7:45,461,697...45,466,898
|
|
G |
Bcat2 |
branched chain aminotransferase 2, mitochondrial |
decreases activity decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased activity of BCAT2 protein Puromycin Aminonucleoside results in decreased expression of BCAT2 mRNA |
CTD |
PMID:9399633 |
|
NCBI chr 7:45,568,967...45,589,710
Ensembl chr 7:45,570,153...45,589,711
|
|
G |
Bche |
butyrylcholinesterase |
increases activity |
ISO |
Puromycin Aminonucleoside results in increased activity of BCHE protein |
CTD |
PMID:1462003 |
|
NCBI chr 3:73,635,805...73,708,436
Ensembl chr 3:73,635,808...73,708,415
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions increases expression |
ISO |
[Puromycin Aminonucleoside co-treated with Melatonin] results in increased expression of BCL2 protein Puromycin Aminonucleoside results in increased expression of BCL2 protein |
CTD |
PMID:14993511 PMID:15113391 PMID:16152783 |
|
NCBI chr 1:106,538,176...106,714,290
Ensembl chr 1:106,538,178...106,714,274
|
|
G |
Bcl2l1 |
BCL2-like 1 |
multiple interactions decreases expression |
EXP ISO |
[Puromycin Aminonucleoside co-treated with pifithrin] results in increased expression of BCL2L1 protein; Dexamethasone inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of BCL2L1 protein] Dinoprostone affects the reaction [Puromycin Aminonucleoside results in decreased expression of BCL2L1 protein] |
CTD |
PMID:15987750 PMID:16396944 |
|
NCBI chr 2:152,758,732...152,833,803
Ensembl chr 2:152,780,668...152,831,728
|
|
G |
Bglap |
bone gamma carboxyglutamate protein |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of BGLAP protein |
CTD |
PMID:9154658 |
|
NCBI chr 3:88,383,495...88,384,466
Ensembl chr 3:88,383,501...88,384,464
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of BIRC5 mRNA; Puromycin Aminonucleoside results in increased expression of BIRC5 protein |
CTD |
PMID:19617259 |
|
NCBI chr11:117,849,237...117,855,743
Ensembl chr11:117,849,251...117,855,743
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
multiple interactions decreases expression |
ISO |
1,25-dihydroxyvitamin D inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of BMP7 mRNA]; 1,25-dihydroxyvitamin D inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of BMP7 protein] Puromycin Aminonucleoside results in decreased expression of BMP7 mRNA; Puromycin Aminonucleoside results in decreased expression of BMP7 protein |
CTD |
PMID:19594554 |
|
NCBI chr 2:172,868,012...172,940,321
Ensembl chr 2:172,868,012...172,940,321
|
|
G |
Bmpr2 |
bone morphogenetic protein receptor, type II (serine/threonine kinase) |
multiple interactions increases expression |
ISO |
Drugs, Chinese Herbal inhibits the reaction [Puromycin Aminonucleoside results in increased expression of BMPR2 mRNA]; Fosinopril inhibits the reaction [Puromycin Aminonucleoside results in increased expression of BMPR2 mRNA] |
CTD |
PMID:17803470 |
|
NCBI chr 1:59,764,279...59,878,081
Ensembl chr 1:59,763,400...59,879,014
|
|
G |
C3 |
complement component 3 |
multiple interactions increases expression decreases expression |
ISO |
cobra venom factor inhibits the reaction [Puromycin Aminonucleoside results in increased expression of C3 protein]; mizoribine inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of C3 protein] |
CTD |
PMID:8919236 PMID:9250166 |
|
NCBI chr17:57,203,967...57,228,136
Ensembl chr17:57,203,970...57,228,136
|
|
G |
C9 |
complement component 9 |
multiple interactions |
ISO |
CR1 inhibits the reaction [Puromycin Aminonucleoside results in increased expression of [C5 protein alternative form binds to C9 protein]] cobra venom factor inhibits the reaction [Puromycin Aminonucleoside results in increased expression of [C5 protein alternative form binds to C9 protein]]; Puromycin Aminonucleoside results in increased expression of [C5 protein alternative form binds to C9 protein] |
CTD |
PMID:9250166 |
|
NCBI chr15:6,445,346...6,498,825
Ensembl chr15:6,445,327...6,498,751
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO |
Colforsin inhibits the reaction [Puromycin Aminonucleoside results in increased activity of CASP3 protein]; Dinoprostone inhibits the reaction [Puromycin Aminonucleoside results in increased activity of CASP3 protein]; L-161982 promotes the reaction [Puromycin Aminonucleoside results in increased activity of CASP3 protein] |
CTD |
PMID:16396944 |
|
NCBI chr 8:46,617,291...46,639,698
Ensembl chr 8:46,617,291...46,639,689
|
|
G |
Cat |
catalase |
increases activity decreases activity decreases expression affects activity multiple interactions |
EXP ISO |
Puromycin Aminonucleoside results in increased activity of CAT protein Puromycin Aminonucleoside results in decreased activity of CAT protein Puromycin Aminonucleoside results in decreased expression of CAT mRNA Puromycin Aminonucleoside affects the activity of CAT protein [Methylprednisolone co-treated with Puromycin Aminonucleoside] results in increased activity of CAT protein; Cyclosporine inhibits the reaction [Puromycin Aminonucleoside results in decreased activity of CAT protein]; Puromycin Aminonucleoside results in decreased expression of and results in decreased activity of CAT protein; sho-saiko-to-kyo-shokyo-ka-oren-bukuryo inhibits the reaction [Puromycin Aminonucleoside results in decreased activity of CAT protein] |
CTD |
PMID:1744988 PMID:1942778 PMID:6246912 PMID:8289993 PMID:9355075 PMID:10468195 PMID:15113391 PMID:15496159 PMID:20685819 |
|
NCBI chr 2:103,453,904...103,485,153
Ensembl chr 2:103,453,849...103,485,160
|
|
G |
Ccl1 |
chemokine (C-C motif) ligand 1 |
affects expression |
ISO |
Puromycin Aminonucleoside affects the expression of CCL1 mRNA |
CTD |
PMID:10867541 |
|
NCBI chr11:82,176,666...82,179,812
Ensembl chr11:82,176,657...82,305,690
|
|
G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
multiple interactions increases expression affects expression |
ISO |
fluvastatin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of CCL2 mRNA]; Tretinoin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of CCL2 protein] Puromycin Aminonucleoside results in increased expression of CCL2 mRNA; Puromycin Aminonucleoside results in increased expression of CCL2 protein Puromycin Aminonucleoside affects the expression of CCL2 mRNA |
CTD |
PMID:10867541 PMID:12813006 PMID:16452496 |
|
NCBI chr11:82,035,577...82,037,452
Ensembl chr11:82,035,571...82,037,453
|
|
G |
Ccl3 |
chemokine (C-C motif) ligand 3 |
affects expression |
ISO |
Puromycin Aminonucleoside affects the expression of CCL3 mRNA |
CTD |
PMID:10867541 |
|
NCBI chr11:83,647,843...83,649,378
Ensembl chr11:83,647,844...83,649,355
|
|
G |
Ccl7 |
chemokine (C-C motif) ligand 7 |
affects expression |
ISO |
Puromycin Aminonucleoside affects the expression of CCL7 mRNA |
CTD |
PMID:10867541 |
|
NCBI chr11:82,045,712...82,047,525
Ensembl chr11:82,045,712...82,047,525
|
|
G |
Cd2ap |
CD2-associated protein |
multiple interactions decreases expression |
ISO |
celecoxib inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of CD2AP mRNA] |
CTD |
PMID:19194550 |
|
NCBI chr17:42,748,887...42,876,707
Ensembl chr17:42,792,951...42,876,665
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions increases expression |
EXP ISO |
Puromycin Aminonucleoside results in increased expression of and results in increased glycosylation of CD36 protein Puromycin Aminonucleoside results in increased expression of CD36 mRNA |
CTD |
PMID:19264907 |
|
NCBI chr 5:17,781,690...17,888,959
Ensembl chr 5:17,781,690...17,888,801
|
|
G |
Cd44 |
CD44 antigen |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of CD44 protein |
CTD |
PMID:8635280 |
|
NCBI chr 2:102,811,141...102,901,669
Ensembl chr 2:102,811,141...102,901,665
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A (P21) |
multiple interactions increases expression |
EXP ISO |
1,3-dimethylthiourea inhibits the reaction [Puromycin Aminonucleoside results in increased expression of CDKN1A protein] |
CTD |
PMID:17035936 |
|
NCBI chr17:29,090,979...29,100,722
Ensembl chr17:29,090,976...29,100,727
|
|
G |
Chst11 |
carbohydrate sulfotransferase 11 |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of CHST11 mRNA |
CTD |
PMID:15585670 |
|
NCBI chr10:82,984,440...83,195,904
Ensembl chr10:82,985,498...83,195,900
|
|
G |
Chsy1 |
chondroitin sulfate synthase 1 |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of CHSY1 mRNA |
CTD |
PMID:15585670 |
|
NCBI chr 7:66,109,492...66,173,798
Ensembl chr 7:66,109,515...66,173,798
|
|
G |
Cldn6 |
claudin 6 |
affects localization |
ISO |
Puromycin Aminonucleoside affects the localization of CLDN6 protein |
CTD |
PMID:18367650 |
|
NCBI chr17:23,679,348...23,682,446
Ensembl chr17:23,679,249...23,682,446
|
|
G |
Clic5 |
chloride intracellular channel 5 |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of CLIC5 protein |
CTD |
PMID:19264907 |
|
NCBI chr17:44,134,762...44,280,169
Ensembl chr17:44,188,584...44,280,172 Ensembl chr17:44,188,584...44,280,172
|
|
G |
Col1a1 |
collagen, type I, alpha 1 |
multiple interactions increases expression |
ISO |
4-(4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)benzamide inhibits the reaction [Puromycin Aminonucleoside results in increased expression of COL1A1 mRNA] |
CTD |
PMID:9527400 PMID:16570917 |
|
NCBI chr11:94,936,224...94,953,042
Ensembl chr11:94,936,224...94,953,042
|
|
G |
Col3a1 |
collagen, type III, alpha 1 |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of COL3A1 mRNA |
CTD |
PMID:9527400 |
|
NCBI chr 1:45,311,538...45,349,706
Ensembl chr 1:45,311,538...45,349,706
|
|
G |
Col4a1 |
collagen, type IV, alpha 1 |
multiple interactions increases expression |
ISO |
Enalapril inhibits the reaction [Puromycin Aminonucleoside results in increased expression of COL4A1 mRNA]; FR 139317 inhibits the reaction [Puromycin Aminonucleoside results in increased expression of COL4A1 mRNA]; Methylprednisolone inhibits the reaction [Puromycin Aminonucleoside results in increased expression of COL4A1 mRNA] |
CTD |
PMID:1762292 PMID:9175058 |
|
NCBI chr 8:11,198,423...11,312,889
Ensembl chr 8:11,198,423...11,312,826
|
|
G |
Corin |
corin, serine peptidase |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of CORIN mRNA; Puromycin Aminonucleoside results in decreased expression of CORIN protein |
CTD |
PMID:20613715 |
|
NCBI chr 5:72,299,948...72,504,540
Ensembl chr 5:72,300,025...72,504,473
|
|
G |
Ctnnb1 |
catenin (cadherin associated protein), beta 1 |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of CTNNB1 protein |
CTD |
PMID:12065681 |
|
NCBI chr 9:120,933,400...120,960,507
Ensembl chr 9:120,929,216...120,960,507
|
|
G |
Ctsb |
cathepsin B |
decreases activity |
ISO |
Puromycin Aminonucleoside results in decreased activity of CTSB protein |
CTD |
PMID:10394110 |
|
NCBI chr14:63,122,462...63,145,923
Ensembl chr14:63,122,462...63,145,923
|
|
G |
Ctsd |
cathepsin D |
increases activity |
ISO |
Puromycin Aminonucleoside results in increased activity of CTSD protein |
CTD |
PMID:6497855 |
|
NCBI chr 7:142,375,910...142,387,827
Ensembl chr 7:142,375,911...142,388,038
|
|
G |
Ctsh |
cathepsin H |
decreases activity |
ISO |
Puromycin Aminonucleoside results in decreased activity of CTSH protein |
CTD |
PMID:10394110 |
|
NCBI chr 9:90,054,267...90,076,095
Ensembl chr 9:90,054,152...90,076,089
|
|
G |
Ctsl |
cathepsin L |
decreases response to substance multiple interactions decreases activity affects expression |
EXP ISO |
CTSL gene mutant form results in decreased susceptibility to Puromycin Aminonucleoside Puromycin Aminonucleoside results in increased activity of and results in increased expression of CTSL protein Puromycin Aminonucleoside results in decreased activity of CTSL protein Puromycin Aminonucleoside affects the expression of CTSL mRNA; Puromycin Aminonucleoside affects the expression of CTSL protein |
CTD |
PMID:10394110 PMID:15197181 |
|
NCBI chr13:64,361,890...64,370,772
Ensembl chr13:64,359,337...64,370,890
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions decreases expression |
ISO |
[FSHB protein co-treated with CGB3 protein] inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of CYP11A1 mRNA]; CGB3 protein inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of CYP11A1 mRNA]; FSHB protein inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of CYP11A1 mRNA] |
CTD |
PMID:16574160 |
|
NCBI chr 9:57,998,024...58,027,031
Ensembl chr 9:58,006,411...58,027,023
|
|
G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of CYP24A1 mRNA |
CTD |
PMID:19297354 |
|
NCBI chr 2:170,482,957...170,497,145
Ensembl chr 2:170,482,708...170,497,145
|
|
G |
Cyp27b1 |
cytochrome P450, family 27, subfamily b, polypeptide 1 |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of CYP27B1 mRNA |
CTD |
PMID:19297354 |
|
NCBI chr10:127,048,246...127,054,884
Ensembl chr10:127,048,250...127,053,006
|
|
G |
Cyp2b10 |
cytochrome P450, family 2, subfamily b, polypeptide 10 |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of CYP2B1 protein |
CTD |
PMID:12806184 |
|
NCBI chr 7:25,897,658...25,926,624
Ensembl chr 7:25,897,620...25,926,624
|
|
G |
Ddc |
dopa decarboxylase |
decreases activity |
ISO |
Puromycin Aminonucleoside results in decreased activity of DDC protein |
CTD |
PMID:16204272 |
|
NCBI chr11:11,814,101...11,898,144
Ensembl chr11:11,814,101...11,898,144
|
|
G |
Ddn |
dendrin |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of DDN protein |
CTD |
PMID:20588063 |
|
NCBI chr15:98,803,782...98,807,925
Ensembl chr15:98,803,777...98,809,490
|
|
G |
Des |
desmin |
increases expression multiple interactions |
ISO |
Puromycin Aminonucleoside results in increased expression of DES protein triptolide inhibits the reaction [Puromycin Aminonucleoside results in increased expression of DES protein] |
CTD |
PMID:2183627 PMID:18509322 |
|
NCBI chr 1:75,360,292...75,368,579
Ensembl chr 1:75,360,329...75,368,579
|
|
G |
Dnm3 |
dynamin 3 |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of DNM3 mRNA |
CTD |
PMID:19617259 |
|
NCBI chr 1:161,982,450...162,478,321
Ensembl chr 1:161,982,453...162,478,034
|
|
G |
Ece1 |
endothelin converting enzyme 1 |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of ECE1 mRNA; Puromycin Aminonucleoside results in increased expression of ECE1 protein |
CTD |
PMID:12972712 |
|
NCBI chr 4:137,862,237...137,965,229
Ensembl chr 4:137,862,237...137,965,229
|
|
G |
Echs1 |
enoyl Coenzyme A hydratase, short chain, 1, mitochondrial |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of ECHS1 protein |
CTD |
PMID:19264907 |
|
NCBI chr 7:140,105,710...140,116,421
Ensembl chr 7:140,105,710...140,116,476
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions increases expression |
ISO |
Enalapril inhibits the reaction [Puromycin Aminonucleoside results in increased expression of EDN1 mRNA]; FR 139317 inhibits the reaction [Puromycin Aminonucleoside results in increased expression of EDN1 mRNA]; Methylprednisolone inhibits the reaction [Puromycin Aminonucleoside results in increased expression of EDN1 mRNA]; Puromycin Aminonucleoside inhibits the reaction [EDN1 protein results in increased abundance of Cyclic GMP] |
CTD |
PMID:7756592 PMID:9175058 PMID:12972712 |
|
NCBI chr13:42,301,476...42,307,990
Ensembl chr13:42,301,476...42,307,990
|
|
G |
Edn3 |
endothelin 3 |
multiple interactions |
ISO |
Puromycin Aminonucleoside promotes the reaction [EDN3 protein results in increased abundance of Cyclic GMP] |
CTD |
PMID:12972712 |
|
NCBI chr 2:174,760,619...174,784,042
Ensembl chr 2:174,760,619...174,784,042
|
|
G |
Ednra |
endothelin receptor type A |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of EDNRA mRNA |
CTD |
PMID:12972712 |
|
NCBI chr 8:77,663,029...77,724,452
Ensembl chr 8:77,663,031...77,724,464
|
|
G |
Ednrb |
endothelin receptor type B |
multiple interactions increases expression |
ISO |
Methylprednisolone inhibits the reaction [Puromycin Aminonucleoside results in increased expression of EDNRB mRNA] |
CTD |
PMID:7756592 |
|
NCBI chr14:103,814,615...103,844,508
Ensembl chr14:103,814,625...103,844,402
|
|
G |
Etfa |
electron transferring flavoprotein, alpha polypeptide |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of ETFA protein |
CTD |
PMID:19264907 |
|
NCBI chr 9:55,454,436...55,512,243
Ensembl chr 9:55,454,508...55,512,243
|
|
G |
Etfb |
electron transferring flavoprotein, beta polypeptide |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of ETFB protein |
CTD |
PMID:19264907 |
|
NCBI chr 7:43,444,072...43,457,800
Ensembl chr 7:43,444,083...43,457,800
|
|
G |
Ezr |
ezrin |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of EZR protein |
CTD |
PMID:19264907 |
|
NCBI chr17:6,738,131...6,782,780
Ensembl chr17:6,738,041...6,782,784
|
|
G |
Fas |
Fas (TNF receptor superfamily member 6) |
multiple interactions increases expression |
ISO |
Melatonin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of FAS protein] |
CTD |
PMID:14993511 PMID:16152783 |
|
NCBI chr19:34,290,647...34,327,775
Ensembl chr19:34,290,666...34,327,772
|
|
G |
Fasl |
Fas ligand (TNF superfamily, member 6) |
increases expression multiple interactions |
ISO |
Puromycin Aminonucleoside results in increased expression of FASL protein Melatonin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of FASLG protein] |
CTD |
PMID:14993511 PMID:16152783 |
|
NCBI chr 1:161,780,691...161,788,495
Ensembl chr 1:161,780,689...161,788,495
|
|
G |
Fat1 |
FAT atypical cadherin 1 |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of FAT1 mRNA; Puromycin Aminonucleoside results in increased expression of FAT1 protein |
CTD |
PMID:16014031 |
|
NCBI chr 8:44,933,100...45,052,257
Ensembl chr 8:44,935,447...45,052,257
|
|
G |
Flt1 |
FMS-like tyrosine kinase 1 |
increases expression affects expression |
ISO |
Puromycin Aminonucleoside results in increased expression of FLT1 protein Puromycin Aminonucleoside affects the expression of FLT1 mRNA |
CTD |
PMID:11744811 PMID:14752241 |
|
NCBI chr 5:147,561,604...147,726,438
Ensembl chr 5:147,561,604...147,726,011
|
|
G |
Fn1 |
fibronectin 1 |
increases expression multiple interactions |
ISO |
Puromycin Aminonucleoside results in increased expression of FN1 mRNA; Puromycin Aminonucleoside results in increased expression of FN1 protein Tretinoin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of FN1 protein] |
CTD |
PMID:9527400 PMID:12813006 |
|
NCBI chr 1:71,585,473...71,653,280
Ensembl chr 1:71,585,520...71,653,200
|
|
G |
Fshb |
follicle stimulating hormone beta |
multiple interactions decreases expression |
ISO |
[FSHB protein co-treated with CGB3 protein] inhibits the reaction [Puromycin Aminonucleoside results in decreased abundance of Estradiol]; [FSHB protein co-treated with CGB3 protein] inhibits the reaction [Puromycin Aminonucleoside results in decreased abundance of Progesterone]; [FSHB protein co-treated with CGB3 protein] inhibits the reaction [Puromycin Aminonucleoside results in decreased abundance of Testosterone]; [FSHB protein co-treated with CGB3 protein] inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of CYP11A1 mRNA]; [FSHB protein co-treated with CGB3 protein] inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of STAR mRNA]; FSHB protein inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of CYP11A1 mRNA]; Puromycin Aminonucleoside inhibits the reaction [GNRH1 protein results in increased secretion of FSHB protein] Puromycin Aminonucleoside results in decreased expression of FSHB protein |
CTD |
PMID:12269381 PMID:16574160 |
|
NCBI chr 2:107,055,986...107,059,651
Ensembl chr 2:107,056,140...107,059,656
|
|
G |
Gnaq |
guanine nucleotide binding protein, alpha q polypeptide |
increases response to substance |
EXP |
GNAQ protein results in increased susceptibility to Puromycin Aminonucleoside |
CTD |
PMID:16267159 |
|
NCBI chr19:16,132,684...16,388,520
Ensembl chr19:16,132,831...16,387,463
|
|
G |
Gnrh1 |
gonadotropin releasing hormone 1 |
multiple interactions |
ISO |
Puromycin Aminonucleoside inhibits the reaction [GNRH1 protein results in increased secretion of FSHB protein]; Puromycin Aminonucleoside inhibits the reaction [GNRH1 protein results in increased secretion of LHB protein] |
CTD |
PMID:12269381 |
|
NCBI chr14:67,745,181...67,749,440
Ensembl chr14:67,745,181...67,749,439
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions increases expression |
ISO |
[Methylprednisolone co-treated with Puromycin Aminonucleoside] results in increased activity of GPX1 protein Puromycin Aminonucleoside results in increased expression of GPX1 mRNA |
CTD |
PMID:1942778 PMID:20685819 |
|
NCBI chr 9:108,339,080...108,340,342
Ensembl chr 9:108,338,903...108,340,343
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of GPX3 mRNA |
CTD |
PMID:20685819 |
|
NCBI chr11:54,902,854...54,910,387
Ensembl chr11:54,902,453...54,910,377
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions increases phosphorylation |
ISO |
mizoribine inhibits the reaction [Puromycin Aminonucleoside results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:20502051 |
|
NCBI chr16:38,089,001...38,246,084
Ensembl chr16:38,089,001...38,246,084
|
|
G |
Gstp1 |
glutathione S-transferase, pi 1 |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of GSTP1 protein |
CTD |
PMID:19264907 |
|
NCBI chr19:4,035,411...4,037,912
Ensembl chr19:4,035,407...4,037,985
|
|
G |
Guca2b |
guanylate cyclase activator 2b (retina) |
increases expression affects expression |
ISO |
Puromycin Aminonucleoside results in increased expression of GUCA2B protein Puromycin Aminonucleoside affects the expression of GUCA2B mRNA |
CTD |
PMID:15590761 |
|
NCBI chr 4:119,656,601...119,658,945
Ensembl chr 4:119,656,607...119,658,954
|
|
G |
Hadh |
hydroxyacyl-Coenzyme A dehydrogenase |
decreases expression |
EXP ISO |
Puromycin Aminonucleoside results in decreased expression of HADH protein |
CTD |
PMID:19264907 |
|
NCBI chr 3:131,233,419...131,272,101
Ensembl chr 3:131,233,419...131,272,101
|
|
G |
Hc |
hemolytic complement |
multiple interactions |
ISO |
CR1 inhibits the reaction [Puromycin Aminonucleoside results in increased expression of [C5 protein alternative form binds to C9 protein]] cobra venom factor inhibits the reaction [Puromycin Aminonucleoside results in increased expression of [C5 protein alternative form binds to C9 protein]]; Puromycin Aminonucleoside results in increased expression of [C5 protein alternative form binds to C9 protein] |
CTD |
PMID:9250166 |
|
NCBI chr 2:34,983,329...35,068,506
Ensembl chr 2:34,983,331...35,061,438
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-Coenzyme A reductase |
increases activity |
ISO |
Puromycin Aminonucleoside results in increased activity of HMGCR protein |
CTD |
PMID:3794548 |
|
NCBI chr13:96,648,962...96,670,936
Ensembl chr13:96,648,967...96,670,936
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
[piperine co-treated with Cimetidine co-treated with Pyruvates] inhibits the reaction [Puromycin Aminonucleoside results in increased expression of HMOX1 protein] Puromycin Aminonucleoside results in increased expression of HMOX1 mRNA; Puromycin Aminonucleoside results in increased expression of HMOX1 protein |
CTD |
PMID:12806184 PMID:20685819 |
|
NCBI chr 8:75,093,618...75,100,593
Ensembl chr 8:75,093,621...75,100,589
|
|
G |
Hpse |
heparanase |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of HPSE mRNA; Puromycin Aminonucleoside results in increased expression of HPSE protein |
CTD |
PMID:11576343 |
|
NCBI chr 5:100,679,484...100,719,716
Ensembl chr 5:100,679,484...100,719,716
|
|
G |
Hs3st1 |
heparan sulfate (glucosamine) 3-O-sulfotransferase 1 |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of HS3ST1 mRNA |
CTD |
PMID:15585670 |
|
NCBI chr 5:39,613,935...39,645,592
Ensembl chr 5:39,613,935...39,755,475
|
|
G |
Hs6st1 |
heparan sulfate 6-O-sulfotransferase 1 |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of HS6ST1 mRNA |
CTD |
PMID:15585670 |
|
NCBI chr 1:36,068,400...36,106,446
Ensembl chr 1:36,068,400...36,106,446
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
decreases activity |
ISO |
Puromycin Aminonucleoside results in decreased activity of HSD11B2 protein |
CTD |
PMID:11981059 |
|
NCBI chr 8:105,518,746...105,523,988
Ensembl chr 8:105,518,755...105,523,988
|
|
G |
Hspa5 |
heat shock protein 5 |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of HSPA5 protein |
CTD |
PMID:19264907 |
|
NCBI chr 2:34,772,090...34,776,529
Ensembl chr 2:34,771,970...34,777,547
|
|
G |
Hspa8 |
heat shock protein 8 |
affects localization |
ISO |
Puromycin Aminonucleoside affects the localization of HSPA8 protein |
CTD |
PMID:1614035 |
|
NCBI chr 9:40,801,276...40,805,202
Ensembl chr 9:40,800,984...40,810,087
|
|
G |
Hspd1 |
heat shock protein 1 (chaperonin) |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of HSPD1 protein |
CTD |
PMID:19264907 |
|
NCBI chr 1:55,077,833...55,088,243
Ensembl chr 1:55,077,835...55,088,243
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of ICAM1 protein |
CTD |
PMID:8635280 |
|
NCBI chr 9:21,015,940...21,028,814
Ensembl chr 9:21,015,985...21,028,817
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of IL1B mRNA |
CTD |
PMID:17457379 |
|
NCBI chr 2:129,364,569...129,371,164
Ensembl chr 2:129,364,570...129,371,139
|
|
G |
Ilk |
integrin linked kinase |
multiple interactions increases activity |
ISO |
mizoribine inhibits the reaction [Puromycin Aminonucleoside results in increased activity of ILK protein] |
CTD |
PMID:20502051 |
|
NCBI chr 7:105,736,590...105,742,925
Ensembl chr 7:105,736,592...105,742,925
|
|
G |
Itga3 |
integrin alpha 3 |
decreases expression affects expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of ITGA3 mRNA; Puromycin Aminonucleoside results in decreased expression of ITGA3 protein Puromycin Aminonucleoside affects the expression of ITGA3 protein |
CTD |
PMID:9249603 PMID:10845833 PMID:11274237 PMID:15197181 |
|
NCBI chr11:95,044,475...95,076,844
Ensembl chr11:95,044,474...95,076,801
|
|
G |
Itgb1 |
integrin beta 1 (fibronectin receptor beta) |
decreases expression increases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of ITGB1 mRNA; Puromycin Aminonucleoside results in decreased expression of ITGB1 protein Puromycin Aminonucleoside results in increased expression of ITGB1 protein |
CTD |
PMID:11274237 PMID:12065681 PMID:14559718 |
|
NCBI chr 8:128,685,654...128,733,579
Ensembl chr 8:128,685,654...128,733,200
|
|
G |
Kdr |
kinase insert domain protein receptor |
affects expression increases expression decreases expression |
ISO |
Puromycin Aminonucleoside affects the expression of KDR mRNA Puromycin Aminonucleoside results in increased expression of KDR mRNA; Puromycin Aminonucleoside results in increased expression of KDR protein Puromycin Aminonucleoside results in decreased expression of KDR mRNA |
CTD |
PMID:11744811 PMID:14752241 PMID:17667850 |
|
NCBI chr 5:75,932,827...75,979,072
Ensembl chr 5:75,932,827...75,978,458
|
|
G |
Kirrel |
kirre like nephrin family adhesion molecule 1 |
decreases expression multiple interactions |
EXP |
Puromycin Aminonucleoside results in decreased expression of KIRREL mRNA Y 27632 inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of KIRREL mRNA] |
CTD |
PMID:18367845 |
|
NCBI chr 3:87,078,593...87,174,777
Ensembl chr 3:87,078,593...87,174,747
|
|
G |
Krt7 |
keratin 7 |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of KRT7 mRNA; Puromycin Aminonucleoside results in decreased expression of KRT7 protein |
CTD |
PMID:19617259 |
|
NCBI chr15:101,412,403...101,427,806
Ensembl chr15:101,411,043...101,430,313
|
|
G |
Lamb1 |
laminin B1 |
multiple interactions increases expression |
ISO |
Enalapril inhibits the reaction [Puromycin Aminonucleoside results in increased expression of LAMB1 mRNA]; FR 139317 inhibits the reaction [Puromycin Aminonucleoside results in increased expression of LAMB1 mRNA]; Methylprednisolone inhibits the reaction [Puromycin Aminonucleoside results in increased expression of LAMB1 mRNA] |
CTD |
PMID:1762292 PMID:9175058 |
|
NCBI chr12:31,265,146...31,329,644
Ensembl chr12:31,265,234...31,329,644
|
|
G |
Lamb2 |
laminin, beta 2 |
multiple interactions increases expression |
ISO |
Enalapril inhibits the reaction [Puromycin Aminonucleoside results in increased expression of LAMB2 mRNA]; FR 139317 inhibits the reaction [Puromycin Aminonucleoside results in increased expression of LAMB2 mRNA]; Methylprednisolone inhibits the reaction [Puromycin Aminonucleoside results in increased expression of LAMB2 mRNA] |
CTD |
PMID:1762292 PMID:9175058 |
|
NCBI chr 9:108,479,847...108,490,530
Ensembl chr 9:108,479,736...108,490,530
|
|
G |
Lcn2 |
lipocalin 2 |
increases secretion |
ISO |
Puromycin Aminonucleoside results in increased secretion of LCN2 protein |
CTD |
PMID:20438795 |
|
NCBI chr 2:32,384,637...32,387,739
Ensembl chr 2:32,384,633...32,388,252
|
|
G |
Lgals1 |
lectin, galactose binding, soluble 1 |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of LGALS1 protein |
CTD |
PMID:19079321 |
|
NCBI chr15:78,926,725...78,930,465
Ensembl chr15:78,926,725...78,930,465
|
|
G |
Lhb |
luteinizing hormone beta |
multiple interactions decreases expression |
ISO |
[FSHB protein co-treated with CGB3 protein] inhibits the reaction [Puromycin Aminonucleoside results in decreased abundance of Estradiol]; [FSHB protein co-treated with CGB3 protein] inhibits the reaction [Puromycin Aminonucleoside results in decreased abundance of Progesterone]; [FSHB protein co-treated with CGB3 protein] inhibits the reaction [Puromycin Aminonucleoside results in decreased abundance of Testosterone]; [FSHB protein co-treated with CGB3 protein] inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of CYP11A1 mRNA]; [FSHB protein co-treated with CGB3 protein] inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of STAR mRNA]; CGB3 protein inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of CYP11A1 mRNA]; Puromycin Aminonucleoside inhibits the reaction [GNRH1 protein results in increased secretion of LHB protein] Puromycin Aminonucleoside results in decreased expression of LHB protein |
CTD |
PMID:12269381 PMID:16574160 |
|
NCBI chr 7:45,417,608...45,421,855
Ensembl chr 7:45,420,820...45,421,897 Ensembl chr 7:45,420,820...45,421,897
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions |
ISO |
Puromycin Aminonucleoside results in increased expression of and results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:14559718 |
|
NCBI chr16:16,983,382...17,047,453
Ensembl chr16:16,983,382...17,047,453
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions |
ISO |
Puromycin Aminonucleoside results in increased expression of and results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:14559718 |
|
NCBI chr 7:126,759,626...126,765,816
Ensembl chr 7:126,759,601...126,765,819
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
Puromycin Aminonucleoside binds to and results in increased activity of MAPK8 protein |
CTD |
PMID:15351692 |
|
NCBI chr14:33,377,898...33,447,353
Ensembl chr14:33,377,898...33,447,158
|
|
G |
Mdk |
midkine |
multiple interactions decreases expression |
ISO |
Tretinoin inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of MDK mRNA] |
CTD |
PMID:12660332 |
|
NCBI chr 2:91,929,805...91,932,297
Ensembl chr 2:91,929,805...91,932,297
|
|
G |
Mme |
membrane metallo endopeptidase |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of MME protein |
CTD |
PMID:19885019 |
|
NCBI chr 3:63,295,211...63,383,713
Ensembl chr 3:63,241,537...63,386,030
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions increases expression |
ISO |
FR 139317 inhibits the reaction [Puromycin Aminonucleoside results in increased expression of MMP2 mRNA] |
CTD |
PMID:9175058 |
|
NCBI chr 8:92,827,290...92,853,421
Ensembl chr 8:92,827,291...92,853,420
|
|
G |
Msn |
moesin |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of MSN protein |
CTD |
PMID:19264907 |
|
NCBI chr X:96,096,045...96,168,553
Ensembl chr X:96,096,042...96,168,552
|
|
G |
mt-Co1 |
cytochrome c oxidase I, mitochondrial |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of COX1 protein |
CTD |
PMID:16609681 |
|
NCBI chr MT:5,328...6,872
Ensembl chr MT:5,328...6,872
|
|
G |
Myh10 |
myosin, heavy polypeptide 10, non-muscle |
increases expression affects expression |
ISO |
Puromycin Aminonucleoside results in increased expression of MYH10 protein Puromycin Aminonucleoside affects the expression of MYH10 mRNA; Puromycin Aminonucleoside affects the expression of MYH10 protein |
CTD |
PMID:7671567 PMID:8918620 |
|
NCBI chr11:68,691,915...68,816,626
Ensembl chr11:68,691,559...68,816,632
|
|
G |
Myh6 |
myosin, heavy polypeptide 6, cardiac muscle, alpha |
affects expression |
ISO |
Puromycin Aminonucleoside affects the expression of MYH6 mRNA |
CTD |
PMID:17457379 |
|
NCBI chr14:54,941,921...54,968,017
Ensembl chr14:54,941,921...54,966,927
|
|
G |
Napsa |
napsin A aspartic peptidase |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of NAPSA mRNA; Puromycin Aminonucleoside results in increased expression of NAPSA protein |
CTD |
PMID:12501893 |
|
NCBI chr 7:44,572,445...44,586,846
Ensembl chr 7:44,572,380...44,586,862
|
|
G |
Ndst1 |
N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1 |
decreases expression affects expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of NDST1 mRNA Puromycin Aminonucleoside affects the expression of NDST1 mRNA |
CTD |
PMID:14966466 |
|
NCBI chr18:60,684,494...60,749,035
Ensembl chr18:60,684,494...60,748,650
|
|
G |
Nebl |
nebulette |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of NEBL mRNA |
CTD |
PMID:19617259 |
|
NCBI chr 2:17,342,673...17,734,949
Ensembl chr 2:17,343,909...17,731,464
|
|
G |
Nedd4l |
neural precursor cell expressed, developmentally down-regulated gene 4-like |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of NEDD4L protein |
CTD |
PMID:16020936 |
|
NCBI chr18:64,884,480...65,217,826
Ensembl chr18:64,887,705...65,217,828
|
|
G |
Nos1 |
nitric oxide synthase 1, neuronal |
multiple interactions increases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of and results in decreased activity of NOS1 protein Puromycin Aminonucleoside results in increased expression of NOS1 mRNA |
CTD |
PMID:15039144 |
|
NCBI chr 5:117,866,839...117,958,840
Ensembl chr 5:117,781,032...117,958,840
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of NOS2 mRNA |
CTD |
PMID:15039144 |
|
NCBI chr11:78,920,787...78,960,226
Ensembl chr11:78,920,787...78,960,254
|
|
G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
increases expression multiple interactions |
ISO |
Puromycin Aminonucleoside results in increased expression of NOS3 mRNA Puromycin Aminonucleoside results in decreased expression of and results in decreased activity of NOS3 protein |
CTD |
PMID:15039144 |
|
NCBI chr 5:24,364,816...24,384,474
Ensembl chr 5:24,364,810...24,384,474
|
|
G |
Nphs2 |
nephrosis 2, podocin |
decreases expression multiple interactions affects expression |
EXP ISO |
Puromycin Aminonucleoside results in decreased expression of NPHS2 protein triptolide inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of NPHS2 protein] Puromycin Aminonucleoside affects the expression of NPHS2 mRNA; Puromycin Aminonucleoside affects the expression of NPHS2 protein |
CTD |
PMID:12065681 PMID:15363039 PMID:18509322 |
|
NCBI chr 1:156,310,535...156,328,035
Ensembl chr 1:156,310,727...156,328,035
|
|
G |
Nppa |
natriuretic peptide type A |
affects metabolic processing increases response to substance increases expression multiple interactions affects expression |
ISO |
Puromycin Aminonucleoside affects the metabolism of NPPA protein Puromycin Aminonucleoside results in increased susceptibility to NPPA protein Puromycin Aminonucleoside results in increased expression of NPPA mRNA; Puromycin Aminonucleoside results in increased expression of NPPA protein Puromycin Aminonucleoside inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP] Puromycin Aminonucleoside affects the expression of NPPA protein |
CTD |
PMID:2526952 PMID:12972712 PMID:15590761 PMID:19885019 PMID:20613715 |
|
NCBI chr 4:148,000,722...148,002,074
Ensembl chr 4:148,000,722...148,002,079
|
|
G |
Nppb |
natriuretic peptide type B |
affects expression |
ISO |
Puromycin Aminonucleoside affects the expression of NPPB mRNA |
CTD |
PMID:17457379 |
|
NCBI chr 4:147,985,786...147,987,205
Ensembl chr 4:147,985,788...147,987,205
|
|
G |
Npr1 |
natriuretic peptide receptor 1 |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of NPR1 mRNA |
CTD |
PMID:19885019 |
|
NCBI chr 3:90,450,591...90,465,928
Ensembl chr 3:90,450,591...90,465,866
|
|
G |
Npr3 |
natriuretic peptide receptor 3 |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of NPR3 mRNA |
CTD |
PMID:19885019 |
|
NCBI chr15:11,839,896...11,907,837
Ensembl chr15:11,839,896...11,907,287
|
|
G |
Nrf1 |
nuclear respiratory factor 1 |
affects expression |
ISO |
Puromycin Aminonucleoside affects the expression of NRF1 mRNA |
CTD |
PMID:16609681 |
|
NCBI chr 6:30,047,985...30,153,458
Ensembl chr 6:30,047,988...30,153,458
|
|
G |
Optn |
optineurin |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of OPTN protein |
CTD |
PMID:25096716 |
|
NCBI chr 2:5,020,521...5,064,399
Ensembl chr 2:5,020,642...5,064,051
|
|
G |
Pdpn |
podoplanin |
decreases expression |
EXP ISO |
Puromycin Aminonucleoside results in decreased expression of PDPN mRNA; Puromycin Aminonucleoside results in decreased expression of PDPN protein |
CTD |
PMID:9327748 PMID:12032185 |
|
NCBI chr 4:143,267,409...143,299,564
Ensembl chr 4:143,267,431...143,299,564
|
|
G |
Plekhh2 |
pleckstrin homology domain containing, family H (with MyTH4 domain) member 2 |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of PLEKHH2 protein |
CTD |
PMID:20588063 |
|
NCBI chr17:84,511,895...84,622,143
Ensembl chr17:84,511,895...84,622,138
|
|
G |
Pln |
phospholamban |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of PLN mRNA |
CTD |
PMID:17457379 |
|
NCBI chr10:53,337,686...53,345,999
Ensembl chr10:53,337,667...53,345,987
|
|
G |
Podxl |
podocalyxin-like |
increases expression affects metabolic processing |
ISO |
Puromycin Aminonucleoside results in increased expression of PODXL mRNA; Puromycin Aminonucleoside results in increased expression of PODXL protein Puromycin Aminonucleoside affects the metabolism of PODXL protein |
CTD |
PMID:8780404 PMID:11274237 |
|
NCBI chr 6:31,519,493...31,563,937
Ensembl chr 6:31,519,488...31,563,981
|
|
G |
Polb |
polymerase (DNA directed), beta |
increases expression multiple interactions |
EXP |
Puromycin Aminonucleoside results in increased expression of POLB protein 1,3-dimethylthiourea inhibits the reaction [Puromycin Aminonucleoside results in increased expression of POLB protein] |
CTD |
PMID:17035936 |
|
NCBI chr 8:22,628,119...22,653,464
Ensembl chr 8:22,628,126...22,653,435
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
multiple interactions increases expression |
ISO |
pioglitazone affects the reaction [Puromycin Aminonucleoside results in increased expression of PPARG protein] |
CTD |
PMID:16598202 |
|
NCBI chr 6:115,360,879...115,490,404
Ensembl chr 6:115,360,951...115,490,399
|
|
G |
Ppp1r12a |
protein phosphatase 1, regulatory subunit 12A |
increases phosphorylation increases expression multiple interactions |
EXP ISO |
Puromycin Aminonucleoside results in increased phosphorylation of PPP1R12A protein Puromycin Aminonucleoside results in increased expression of PPP1R12A protein modified form Y 27632 inhibits the reaction [Puromycin Aminonucleoside results in increased phosphorylation of PPP1R12A protein] fluvastatin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of PPP1R12A protein modified form] |
CTD |
PMID:16452496 PMID:18367845 |
|
NCBI chr10:108,162,092...108,279,985
Ensembl chr10:108,162,193...108,284,475
|
|
G |
Prdx3 |
peroxiredoxin 3 |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of PRDX3 protein |
CTD |
PMID:19264907 |
|
NCBI chr19:60,864,066...60,874,538
Ensembl chr19:60,864,051...60,874,556
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression affects response to substance multiple interactions |
EXP ISO |
Puromycin Aminonucleoside results in increased expression of PTGS2 mRNA; Puromycin Aminonucleoside results in increased expression of PTGS2 protein PTGS2 protein affects the susceptibility to Puromycin Aminonucleoside celecoxib inhibits the reaction [Puromycin Aminonucleoside results in increased expression of PTGS2 mRNA] |
CTD |
PMID:16396944 PMID:17890881 PMID:19194550 |
|
NCBI chr 1:150,100,031...150,108,234
Ensembl chr 1:150,100,031...150,108,227
|
|
G |
Pth |
parathyroid hormone |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of PTH protein |
CTD |
PMID:1328752 |
|
NCBI chr 7:113,385,576...113,388,672
Ensembl chr 7:113,385,580...113,388,570
|
|
G |
Ptk2 |
PTK2 protein tyrosine kinase 2 |
multiple interactions |
ISO |
Puromycin Aminonucleoside results in increased expression of and results in increased phosphorylation of PTK2 protein |
CTD |
PMID:14559718 |
|
NCBI chr15:73,205,102...73,423,820
Ensembl chr15:73,205,102...73,423,280
|
|
G |
Ptpro |
protein tyrosine phosphatase, receptor type, O |
affects expression |
ISO |
Puromycin Aminonucleoside affects the expression of PTPRO mRNA; Puromycin Aminonucleoside affects the expression of PTPRO protein |
CTD |
PMID:11961407 |
|
NCBI chr 6:137,252,299...137,464,634
Ensembl chr 6:137,252,319...137,463,233
|
|
G |
Rara |
retinoic acid receptor, alpha |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of RARA mRNA; Puromycin Aminonucleoside results in increased expression of RARA protein |
CTD |
PMID:12660332 |
|
NCBI chr11:98,927,800...98,974,942
Ensembl chr11:98,927,818...98,974,942
|
|
G |
Rbbp7 |
retinoblastoma binding protein 7, chromatin remodeling factor |
decreases expression |
EXP |
Puromycin Aminonucleoside results in decreased expression of RBBP7 protein |
CTD |
PMID:15798086 |
|
NCBI chr X:162,760,372...162,779,090
Ensembl chr X:162,760,402...162,779,092
|
|
G |
Ren1 |
renin 1 structural |
multiple interactions increases expression affects expression |
ISO |
Puromycin Aminonucleoside affects the expression of and affects the activity of REN protein; Puromycin Aminonucleoside results in increased expression of and results in increased activity of REN protein Puromycin Aminonucleoside results in increased expression of REN protein Puromycin Aminonucleoside affects the expression of REN protein |
CTD |
PMID:2236972 PMID:2267444 PMID:8446257 PMID:9171944 |
|
NCBI chr 1:133,350,674...133,360,320
Ensembl chr 1:133,350,510...133,360,325
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions increases expression |
EXP ISO |
fluvastatin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of RHOA protein] |
CTD |
PMID:16452496 |
|
NCBI chr 9:108,306,160...108,337,943
Ensembl chr 9:108,306,129...108,337,934
|
|
G |
Scnn1a |
sodium channel, nonvoltage-gated 1 alpha |
affects expression multiple interactions decreases expression affects localization |
ISO |
Puromycin Aminonucleoside affects the expression of SCNN1A mRNA Puromycin Aminonucleoside results in increased expression of and results in increased localization of SCNN1A protein Puromycin Aminonucleoside results in decreased expression of SCNN1A mRNA Puromycin Aminonucleoside affects the localization of SCNN1A protein |
CTD |
PMID:12653683 PMID:15075188 PMID:16020936 PMID:16267158 |
|
NCBI chr 6:125,314,271...125,344,943
Ensembl chr 6:125,320,659...125,344,943
|
|
G |
Scnn1b |
sodium channel, nonvoltage-gated 1 beta |
affects expression increases expression decreases expression multiple interactions affects localization |
ISO |
Puromycin Aminonucleoside affects the expression of SCNN1B mRNA Puromycin Aminonucleoside results in increased expression of SCNN1B mRNA Puromycin Aminonucleoside results in decreased expression of SCNN1B mRNA Puromycin Aminonucleoside results in increased expression of and results in increased localization of SCNN1B protein Puromycin Aminonucleoside affects the localization of SCNN1B protein |
CTD |
PMID:12653683 PMID:15075188 PMID:16020936 PMID:16267158 |
|
NCBI chr 7:121,865,038...121,918,728
Ensembl chr 7:121,865,038...121,918,514
|
|
G |
Scnn1g |
sodium channel, nonvoltage-gated 1 gamma |
multiple interactions increases expression decreases expression |
ISO |
Puromycin Aminonucleoside affects the localization of and affects the expression of SCNN1G protein; Puromycin Aminonucleoside results in increased expression of and results in increased localization of SCNN1G protein Puromycin Aminonucleoside results in increased expression of SCNN1G mRNA Puromycin Aminonucleoside results in decreased expression of SCNN1G mRNA |
CTD |
PMID:12653683 PMID:15075188 PMID:16020936 PMID:16267158 |
|
NCBI chr 7:121,734,420...121,768,482
Ensembl chr 7:121,734,479...121,768,475
|
|
G |
Serpine1 |
serine (or cysteine) peptidase inhibitor, clade E, member 1 |
multiple interactions increases expression |
ISO |
pioglitazone inhibits the reaction [Puromycin Aminonucleoside results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:16598202 |
|
NCBI chr 5:137,061,504...137,072,272
Ensembl chr 5:137,061,504...137,072,268
|
|
G |
Slc12a1 |
solute carrier family 12, member 1 |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of SLC12A1 protein |
CTD |
PMID:15075188 |
|
NCBI chr 2:125,152,510...125,230,002
Ensembl chr 2:125,152,505...125,230,002
|
|
G |
Slc12a3 |
solute carrier family 12, member 3 |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of SLC12A3 protein |
CTD |
PMID:15075188 |
|
NCBI chr 8:94,329,109...94,366,222
Ensembl chr 8:94,329,201...94,366,214
|
|
G |
Slc22a2 |
solute carrier family 22 (organic cation transporter), member 2 |
affects expression |
ISO |
Puromycin Aminonucleoside affects the expression of SLC22A2 mRNA |
CTD |
PMID:22005293 |
|
NCBI chr17:12,584,189...12,628,489
Ensembl chr17:12,584,132...12,628,488
|
|
G |
Slc29a4 |
solute carrier family 29 (nucleoside transporters), member 4 |
increases response to substance |
ISO |
SLC29A4 results in increased susceptibility to Puromycin Aminonucleoside |
CTD |
PMID:19357181 |
|
NCBI chr 5:142,692,478...142,722,490
Ensembl chr 5:142,692,512...142,722,490
|
|
G |
Slc5a3 |
solute carrier family 5 (inositol transporters), member 3 |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of SLC5A3 mRNA |
CTD |
PMID:15031335 |
|
NCBI chr16:92,058,322...92,087,473
Ensembl chr16:92,058,322...92,087,473
|
|
G |
Slc9a3 |
solute carrier family 9 (sodium/hydrogen exchanger), member 3 |
multiple interactions decreases expression affects expression |
ISO |
[piperine co-treated with Cimetidine co-treated with Pyruvates] inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of SLC9A3 protein] Puromycin Aminonucleoside affects the expression of SLC9A3 protein |
CTD |
PMID:12191963 PMID:12806184 PMID:15075188 |
|
NCBI chr13:74,086,255...74,169,442
Ensembl chr13:74,121,457...74,169,442
|
|
G |
Smad1 |
SMAD family member 1 |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of SMAD1 mRNA |
CTD |
PMID:17803470 |
|
NCBI chr 8:79,338,395...79,399,428
Ensembl chr 8:79,338,395...79,399,518
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
affects expression decreases expression multiple interactions |
EXP ISO |
Puromycin Aminonucleoside affects the expression of SOD2 protein Puromycin Aminonucleoside results in decreased expression of SOD2 protein [Methylprednisolone co-treated with Puromycin Aminonucleoside] results in increased activity of SOD2 protein |
CTD |
PMID:1942778 PMID:19264907 |
|
NCBI chr17:13,007,839...13,018,119
Ensembl chr17:13,006,846...13,040,063
|
|
G |
Sod3 |
superoxide dismutase 3, extracellular |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of SOD3 mRNA |
CTD |
PMID:20685819 |
|
NCBI chr 5:52,363,804...52,369,738
Ensembl chr 5:52,363,791...52,371,418
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions increases expression |
ISO |
Drugs, Chinese Herbal inhibits the reaction [Puromycin Aminonucleoside results in increased expression of SPP1 protein]; fluvastatin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of SPP1 mRNA] Puromycin Aminonucleoside results in increased expression of SPP1 mRNA; Puromycin Aminonucleoside results in increased expression of SPP1 protein |
CTD |
PMID:14738908 PMID:16452496 |
|
NCBI chr 5:104,435,111...104,441,053
Ensembl chr 5:104,435,118...104,441,050
|
|
G |
Src |
Rous sarcoma oncogene |
multiple interactions |
ISO |
Puromycin Aminonucleoside results in increased expression of and results in increased phosphorylation of SRC protein |
CTD |
PMID:14559718 |
|
NCBI chr 2:157,423,906...157,471,838
Ensembl chr 2:157,418,444...157,471,862
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions decreases expression |
ISO |
[FSHB protein co-treated with CGB3 protein] inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of STAR mRNA] |
CTD |
PMID:16574160 |
|
NCBI chr 8:25,808,474...25,815,982
Ensembl chr 8:25,806,555...25,815,982
|
|
G |
Synpo |
synaptopodin |
decreases expression |
EXP |
Puromycin Aminonucleoside results in decreased expression of SYNPO protein |
CTD |
PMID:15798086 |
|
NCBI chr18:60,593,981...60,660,173
Ensembl chr18:60,593,973...60,660,142
|
|
G |
Tagln |
transgelin |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of TAGLN mRNA; Puromycin Aminonucleoside results in increased expression of TAGLN protein |
CTD |
PMID:19617259 |
|
NCBI chr 9:45,929,628...45,936,058
Ensembl chr 9:45,929,619...45,936,058
|
|
G |
Tek |
TEK receptor tyrosine kinase |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of TEK mRNA |
CTD |
PMID:17667850 |
|
NCBI chr 4:94,739,086...94,874,976
Ensembl chr 4:94,739,289...94,874,976
|
|
G |
Tfam |
transcription factor A, mitochondrial |
affects expression |
ISO |
Puromycin Aminonucleoside affects the expression of TFAM mRNA |
CTD |
PMID:16609681 |
|
NCBI chr10:71,225,468...71,238,328
Ensembl chr10:71,225,464...71,238,280
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions increases expression affects expression |
ISO |
Celecoxib inhibits the reaction [Puromycin Aminonucleoside results in increased expression of TGFB1 mRNA]; Drugs, Chinese Herbal inhibits the reaction [Puromycin Aminonucleoside results in increased expression of TGFB1 protein]; Masoprocol inhibits the reaction [Puromycin Aminonucleoside results in increased expression of TGFB1 mRNA] Puromycin Aminonucleoside results in increased expression of TGFB1 mRNA; Puromycin Aminonucleoside results in increased expression of TGFB1 protein Puromycin Aminonucleoside affects the expression of TGFB1 mRNA |
CTD |
PMID:9527400 PMID:12397044 PMID:14738908 PMID:19194550 PMID:19594554 |
|
NCBI chr 7:25,687,002...25,705,077
Ensembl chr 7:25,687,002...25,705,077
|
|
G |
Timp1 |
tissue inhibitor of metalloproteinase 1 |
multiple interactions increases expression |
ISO |
FR 139317 inhibits the reaction [Puromycin Aminonucleoside results in increased expression of TIMP1 mRNA] |
CTD |
PMID:9175058 |
|
NCBI chr X:20,870,166...20,874,737
Ensembl chr X:20,870,166...20,874,735
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions increases expression affects localization |
ISO EXP |
Cyclosporine inhibits the reaction [Puromycin Aminonucleoside results in increased expression of TJP1 protein] Puromycin Aminonucleoside affects the localization of TJP1 protein |
CTD |
PMID:15744817 PMID:15798086 |
|
NCBI chr 7:65,296,165...65,527,850
Ensembl chr 7:65,296,165...65,527,781
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
ISO |
Methylprednisolone inhibits the reaction [Puromycin Aminonucleoside results in increased expression of TNF mRNA] |
CTD |
PMID:8384958 PMID:17457379 |
|
NCBI chr17:35,199,367...35,202,007
Ensembl chr17:35,199,381...35,202,007
|
|
G |
Tnnc1 |
troponin C, cardiac/slow skeletal |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of TNNC1 mRNA |
CTD |
PMID:19617259 |
|
NCBI chr14:31,208,312...31,211,729
Ensembl chr14:31,208,312...31,211,729
|
|
G |
Trf |
transferrin |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of TF mRNA |
CTD |
PMID:8413769 |
|
NCBI chr 9:103,208,876...103,230,286
Ensembl chr 9:103,204,001...103,230,444
|
|
G |
Trp53 |
transformation related protein 53 |
multiple interactions increases expression |
ISO EXP |
1,3-dimethylthiourea inhibits the reaction [Puromycin Aminonucleoside results in increased expression of TP53 protein]; Melatonin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of TP53 protein] Puromycin Aminonucleoside results in increased expression of TRP53 protein 1,3-dimethylthiourea inhibits the reaction [Puromycin Aminonucleoside results in increased expression of TRP53 protein]; Dexamethasone inhibits the reaction [Puromycin Aminonucleoside results in increased expression of TRP53 protein] |
CTD |
PMID:14993511 PMID:15113391 PMID:15987750 PMID:16152783 PMID:17035936 |
|
NCBI chr11:69,580,348...69,591,873
Ensembl chr11:69,580,359...69,591,873
|
|
G |
Ttr |
transthyretin |
increases expression |
ISO |
Puromycin Aminonucleoside results in increased expression of TTR protein |
CTD |
PMID:19264907 |
|
NCBI chr18:20,664,209...20,674,326
Ensembl chr18:20,665,280...20,674,321
|
|
G |
Ucp3 |
uncoupling protein 3 (mitochondrial, proton carrier) |
decreases expression |
EXP |
Puromycin Aminonucleoside results in decreased expression of UCP3 protein |
CTD |
PMID:19264907 |
|
NCBI chr 7:100,472,991...100,486,432
Ensembl chr 7:100,472,990...100,486,432
|
|
G |
Vcan |
versican |
decreases expression |
ISO |
Puromycin Aminonucleoside results in decreased expression of VCAN mRNA; Puromycin Aminonucleoside results in decreased expression of VCAN protein |
CTD |
PMID:15585670 |
|
NCBI chr13:89,655,309...89,743,027
Ensembl chr13:89,655,312...89,742,509
|
|
G |
Vcl |
vinculin |
affects localization increases expression |
EXP ISO |
Puromycin Aminonucleoside affects the localization of VCL protein Puromycin Aminonucleoside results in increased expression of VCL mRNA; Puromycin Aminonucleoside results in increased expression of VCL protein |
CTD |
PMID:19617259 |
|
NCBI chr14:20,929,383...21,033,676
Ensembl chr14:20,929,398...21,033,676
|
|
G |
Vegfa |
vascular endothelial growth factor A |
affects expression increases expression |
ISO |
Puromycin Aminonucleoside affects the expression of VEGFA mRNA Puromycin Aminonucleoside results in increased expression of VEGFA protein |
CTD |
PMID:11744811 PMID:14752241 |
|
NCBI chr17:46,016,993...46,032,377
Ensembl chr17:46,016,993...46,032,369
|
|
G |
Vim |
vimentin |
multiple interactions increases expression |
ISO |
fluvastatin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of VIM mRNA] |
CTD |
PMID:16452496 |
|
NCBI chr 2:13,574,311...13,582,826
Ensembl chr 2:13,573,927...13,582,826
|
|
G |
Wtip |
WT1-interacting protein |
affects localization |
EXP |
Puromycin Aminonucleoside affects the localization of WTIP protein |
CTD |
PMID:15798086 |
|
NCBI chr 7:34,109,547...34,133,268
Ensembl chr 7:34,109,543...34,133,268
|
|
G |
Xcl1 |
chemokine (C motif) ligand 1 |
affects expression |
ISO |
Puromycin Aminonucleoside affects the expression of XCL1 mRNA |
CTD |
PMID:10867541 |
|
NCBI chr 1:164,931,644...164,935,522
Ensembl chr 1:164,931,644...164,935,527
|
|
G |
Xdh |
xanthine dehydrogenase |
increases activity multiple interactions |
ISO |
Puromycin Aminonucleoside results in increased activity of XDH [Tungsten co-treated with Puromycin Aminonucleoside] results in decreased activity of XDH protein |
CTD |
PMID:7583048 PMID:11041286 |
|
NCBI chr17:73,883,895...73,950,397
Ensembl chr17:73,883,895...73,950,196
|
|
|
G |
Nat2 |
N-acetyltransferase 2 (arylamine N-acetyltransferase) |
multiple interactions |
ISO |
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone] |
CTD |
PMID:20545351 |
|
NCBI chr 8:67,494,875...67,502,644
Ensembl chr 8:67,494,858...67,502,584
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
multiple interactions |
ISO |
[NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone |
CTD |
PMID:20545351 |
|
NCBI chr 8:107,388,225...107,403,205
Ensembl chr 8:107,388,225...107,403,206
|
|
G |
P2ry1 |
purinergic receptor P2Y, G-protein coupled 1 |
decreases activity |
ISO |
Phosphoadenosine Phosphosulfate results in decreased activity of P2RY1 protein |
CTD |
PMID:22273509 |
|
NCBI chr 3:61,002,785...61,008,982
Ensembl chr 3:61,002,795...61,008,982
|
|
G |
Sult1a1 |
sulfotransferase family 1A, phenol-preferring, member 1 |
multiple interactions |
ISO |
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone] |
CTD |
PMID:20545351 |
|
NCBI chr 7:126,672,865...126,690,443
Ensembl chr 7:126,672,865...126,676,432
|
|
G |
Sult2a1 |
sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 1 |
multiple interactions |
ISO |
[Phosphoadenosine Phosphosulfate co-treated with SULT2A1 protein] affects the sulfation of Ethinyl Estradiol; Celecoxib affects the reaction [[Phosphoadenosine Phosphosulfate co-treated with SULT2A1 protein] affects the sulfation of Ethinyl Estradiol]; SULT2A1 protein affects the metabolism of [Phosphoadenosine Phosphosulfate co-treated with Ethinyl Estradiol] |
CTD |
PMID:15483193 |
|
NCBI chr 7:13,796,246...13,837,410
Ensembl chr 7:13,796,246...13,837,409
|
|
|
G |
Adora3 |
adenosine A3 receptor |
multiple interactions |
ISO EXP |
2,3-diethyl-4,5-dipropyl-6-phenylpyridine-3-thiocarboxylate-5-carboxylate inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 mRNA]]; 2,3-diethyl-4,5-dipropyl-6-phenylpyridine-3-thiocarboxylate-5-carboxylate inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 protein]]; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine binds to and results in increased activity of ADORA3 protein; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 mRNA]; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 protein] [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine binds to and results in increased activity of ADORA3 protein] which results in decreased susceptibility to Dizocilpine Maleate; [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine binds to and results in increased activity of ADORA3 protein] which results in decreased susceptibility to Scopolamine; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine binds to and results in increased activity of ADORA3 protein |
CTD |
PMID:12672554 PMID:15452191 PMID:19966059 |
|
NCBI chr 3:105,904,421...105,908,928
Ensembl chr 3:105,870,858...105,908,926
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions |
ISO |
Pertussis Toxin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in increased phosphorylation of AKT1 protein]; wortmannin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:16116186 |
|
NCBI chr12:112,653,821...112,674,884
Ensembl chr12:112,653,821...112,674,884
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression decreases response to substance |
ISO |
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of BIRC3 mRNA BIRC3 protein results in decreased susceptibility to N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine |
CTD |
PMID:16088125 |
|
NCBI chr 9:7,847,468...7,873,205
Ensembl chr 9:7,848,699...7,873,186
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases response to substance |
ISO |
BIRC5 protein results in decreased susceptibility to N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine |
CTD |
PMID:16088125 |
|
NCBI chr11:117,849,237...117,855,743
Ensembl chr11:117,849,251...117,855,743
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
multiple interactions |
ISO |
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of FOS mRNA] |
CTD |
PMID:15452191 |
|
NCBI chr12:85,473,890...85,477,274
Ensembl chr12:85,473,890...85,477,273
|
|
G |
Il12a |
interleukin 12a |
multiple interactions |
ISO |
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]; Pertussis Toxin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]]; wortmannin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]] |
CTD |
PMID:16116186 |
|
NCBI chr 3:68,690,644...68,698,550
Ensembl chr 3:68,690,644...68,698,547
|
|
G |
Il12b |
interleukin 12b |
multiple interactions |
ISO |
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]; Pertussis Toxin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]]; wortmannin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]] |
CTD |
PMID:16116186 |
|
NCBI chr11:44,400,063...44,414,677
Ensembl chr11:44,400,063...44,414,033
|
|
G |
Naip2 |
NLR family, apoptosis inhibitory protein 2 |
decreases response to substance decreases expression |
ISO |
NAIP protein results in decreased susceptibility to N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of NAIP mRNA |
CTD |
PMID:16088125 |
|
NCBI chr13:100,144,063...100,202,122
Ensembl chr13:100,144,063...100,202,092
|
|
G |
Nppa |
natriuretic peptide type A |
multiple interactions |
ISO |
2,3-diethyl-4,5-dipropyl-6-phenylpyridine-3-thiocarboxylate-5-carboxylate inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]]; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA] |
CTD |
PMID:15452191 PMID:19966059 |
|
NCBI chr 4:148,000,722...148,002,074
Ensembl chr 4:148,000,722...148,002,079
|
|
G |
Rgs2 |
regulator of G-protein signaling 2 |
multiple interactions |
ISO |
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of RGS2 mRNA] |
CTD |
PMID:15452191 |
|
NCBI chr 1:143,999,338...144,004,149
Ensembl chr 1:143,999,338...144,004,161
|
|
G |
Slc9a1 |
solute carrier family 9 (sodium/hydrogen exchanger), member 1 |
multiple interactions |
ISO |
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of SLC9A1 protein] |
CTD |
PMID:15452191 |
|
NCBI chr 4:133,369,711...133,423,702
Ensembl chr 4:133,369,706...133,423,702
|
|
|
G |
Col1a1 |
collagen, type I, alpha 1 |
decreases expression |
ISO |
5'-methylthioadenosine results in decreased expression of COL1A1 mRNA |
CTD |
PMID:15983038 |
|
NCBI chr11:94,936,224...94,953,042
Ensembl chr11:94,936,224...94,953,042
|
|
G |
Col1a2 |
collagen, type I, alpha 2 |
decreases expression |
ISO |
5'-methylthioadenosine results in decreased expression of COL1A2 mRNA |
CTD |
PMID:15983038 |
|
NCBI chr 6:4,505,618...4,541,543
Ensembl chr 6:4,504,814...4,541,544
|
|
G |
Idh2 |
isocitrate dehydrogenase 2 (NADP+), mitochondrial |
multiple interactions increases abundance |
EXP |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of 5'-methylthioadenosine] |
CTD |
PMID:27469509 |
|
NCBI chr 7:80,094,845...80,118,608
Ensembl chr 7:80,094,846...80,115,392
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of IFNG mRNA] |
CTD |
PMID:17080400 |
|
NCBI chr10:118,441,046...118,445,894
Ensembl chr10:118,441,046...118,445,892
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of IL1B mRNA] |
CTD |
PMID:17080400 |
|
NCBI chr 2:129,364,569...129,371,164
Ensembl chr 2:129,364,570...129,371,139
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
EXP |
5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of IL2 mRNA] |
CTD |
PMID:17080400 |
|
NCBI chr 3:37,120,713...37,125,954
Ensembl chr 3:37,120,523...37,125,959
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of IL6 mRNA] |
CTD |
PMID:17080400 |
|
NCBI chr 5:30,013,114...30,019,975
Ensembl chr 5:30,013,114...30,019,981
|
|
G |
Ltb |
lymphotoxin B |
multiple interactions |
EXP |
5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of LTB mRNA] |
CTD |
PMID:17080400 |
|
NCBI chr17:35,194,507...35,196,305
Ensembl chr17:35,194,439...35,196,320
|
|
|
G |
Slc29a1 |
solute carrier family 29 (nucleoside transporters), member 1 |
affects transport |
ISO |
SLC29A1 mRNA affects the transport of Methylthioinosine |
CTD |
PMID:16859645 |
|
NCBI chr17:45,585,200...45,599,618
Ensembl chr17:45,585,200...45,599,606
|
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
multiple interactions |
ISO |
7-methylguanosine triphosphate inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; 7-methylguanosine triphosphate inhibits the reaction [RNA Caps binds to EIF4E protein] |
CTD |
PMID:27592390 |
|
NCBI chr 3:138,526,191...138,559,696
Ensembl chr 3:138,526,179...138,559,696
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions affects binding |
ISO |
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one promotes the reaction [EIF4EBP1 protein binds to 7-methylguanosine triphosphate]; Sirolimus promotes the reaction [EIF4EBP1 protein binds to 7-methylguanosine triphosphate] |
CTD |
PMID:25940091 |
|
NCBI chr 8:27,260,327...27,275,656
Ensembl chr 8:27,260,329...27,276,674
|
|
G |
Eif4g1 |
eukaryotic translation initiation factor 4, gamma 1 |
multiple interactions affects binding |
ISO |
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EIF4G1 protein binds to 7-methylguanosine triphosphate]; Sirolimus inhibits the reaction [EIF4G1 protein binds to 7-methylguanosine triphosphate] |
CTD |
PMID:25940091 |
|
NCBI chr16:20,672,720...20,692,883
Ensembl chr16:20,668,313...20,692,884
|
|
|
G |
Neil1 |
nei endonuclease VIII-like 1 (E. coli) |
affects metabolic processing |
EXP |
NEIL1 protein affects the metabolism of 8,5'-cyclo-2'-deoxyadenosine |
CTD |
PMID:20067321 |
|
NCBI chr 9:57,142,788...57,148,688
Ensembl chr 9:57,142,800...57,148,305
|
|
|
G |
Ccl5 |
chemokine (C-C motif) ligand 5 |
decreases expression |
EXP |
8-chloro-2'-deoxyguanosine results in decreased expression of CCL5 mRNA |
CTD |
PMID:31066272 |
|
NCBI chr11:83,525,778...83,530,518
Ensembl chr11:83,525,778...83,530,518
|
|
G |
Il18 |
interleukin 18 |
increases expression |
EXP |
8-chloro-2'-deoxyguanosine results in increased expression of IL18 mRNA |
CTD |
PMID:31066272 |
|
NCBI chr 9:50,554,700...50,581,841
Ensembl chr 9:50,554,827...50,581,840
|
|
G |
Il1b |
interleukin 1 beta |
increases secretion increases expression |
EXP |
8-chloro-2'-deoxyguanosine results in increased secretion of IL1B protein 8-chloro-2'-deoxyguanosine results in increased expression of IL1B mRNA |
CTD |
PMID:31066272 |
|
NCBI chr 2:129,364,569...129,371,164
Ensembl chr 2:129,364,570...129,371,139
|
|
|
G |
Agt |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
increases abundance |
ISO |
AGT protein modified form results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine |
CTD |
PMID:30354818 |
|
NCBI chr 8:124,556,587...124,569,706
Ensembl chr 8:124,556,534...124,569,706
|
|
G |
Apex1 |
apurinic/apyrimidinic endonuclease 1 |
affects abundance |
ISO |
APEX1 gene SNP affects the abundance of 8-Hydroxy-2'-Deoxyguanosine |
CTD |
PMID:19896490 |
|
NCBI chr14:50,924,949...50,927,188
Ensembl chr14:50,924,968...50,927,139
|
|
G |
Brca1 |
breast cancer 1, early onset |
multiple interactions |
EXP |
[BRCA1 gene mutant form results in increased susceptibility to Ethanol] which results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine |
CTD |
PMID:26629949 |
|
NCBI chr11:101,488,761...101,551,955
Ensembl chr11:101,488,764...101,551,955
|
|
G |
Cyp2d22 |
cytochrome P450, family 2, subfamily d, polypeptide 22 |
multiple interactions |
ISO |
[Eugenol co-treated with Copper co-treated with CYP2D6 protein] results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine |
CTD |
PMID:15576237 |
|
NCBI chr15:82,370,527...82,380,260
Ensembl chr15:82,370,527...82,380,260
|
|
G |
Dnmt1 |
DNA methyltransferase (cytosine-5) 1 |
affects abundance |
ISO |
DNMT1 gene SNP affects the abundance of 8-Hydroxy-2'-Deoxyguanosine |
CTD |
PMID:19896490 |
|
NCBI chr 9:20,907,206...20,959,888
Ensembl chr 9:20,907,209...20,959,888
|
|
G |
Dnmt3b |
DNA methyltransferase 3B |
affects abundance |
ISO |
DNMT3B gene SNP affects the abundance of 8-Hydroxy-2'-Deoxyguanosine |
CTD |
PMID:19896490 |
|
NCBI chr 2:153,649,411...153,687,730
Ensembl chr 2:153,649,450...153,687,730
|
|
G |
Glrx |
glutaredoxin |
affects abundance |
ISO |
GLRX gene SNP affects the abundance of 8-Hydroxy-2'-Deoxyguanosine |
CTD |
PMID:19896490 |
|
NCBI chr13:75,839,885...75,850,151
Ensembl chr13:75,839,868...75,850,154
|
|
G |
Hras |
Harvey rat sarcoma virus oncogene |
multiple interactions increases abundance |
EXP |
PRDX1 protein inhibits the reaction [HRAS protein mutant form results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine] |
CTD |
PMID:27517622 |
|
NCBI chr 7:141,189,934...141,194,019
Ensembl chr 7:141,189,105...141,194,005
|
|
G |
Ogg1 |
8-oxoguanine DNA-glycosylase 1 |
increases cleavage multiple interactions |
ISO |
OGG1 protein results in increased cleavage of 8-Hydroxy-2'-Deoxyguanosine thymidine glycol inhibits the reaction [OGG1 protein results in increased cleavage of 8-Hydroxy-2'-Deoxyguanosine]; thymidine glycol promotes the reaction [OGG1 protein results in increased cleavage of 8-Hydroxy-2'-Deoxyguanosine] |
CTD |
PMID:19193190 |
|
NCBI chr 6:113,326,972...113,334,877
Ensembl chr 6:113,326,972...113,335,068
|
|
G |
Por |
P450 (cytochrome) oxidoreductase |
multiple interactions |
ISO |
[Nitrofurazone co-treated with POR protein co-treated with Copper] results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine |
CTD |
PMID:15488632 |
|
NCBI chr 5:135,670,040...135,735,326
Ensembl chr 5:135,670,033...135,735,326
|
|
G |
Prdx1 |
peroxiredoxin 1 |
multiple interactions |
EXP |
PRDX1 protein inhibits the reaction [HRAS protein mutant form results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine] |
CTD |
PMID:27517622 |
|
NCBI chr 4:116,685,599...116,700,000
Ensembl chr 4:116,685,544...116,700,822
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
ISO |
[[Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to 3,4-Methylenedioxyamphetamine] which results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine; [[Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to Methamphetamine] which results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine |
CTD |
PMID:21163909 |
|
NCBI chr 2:36,216,742...36,258,593
Ensembl chr 2:36,230,426...36,252,272
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[[Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to 3,4-Methylenedioxyamphetamine] which results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine; [[Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to Methamphetamine] which results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine |
CTD |
PMID:21163909 |
|
NCBI chr 1:150,100,031...150,108,234
Ensembl chr 1:150,100,031...150,108,227
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
affects abundance |
ISO |
TXNRD1 gene SNP affects the abundance of 8-Hydroxy-2'-Deoxyguanosine |
CTD |
PMID:19896490 |
|
NCBI chr10:82,833,951...82,897,724
Ensembl chr10:82,833,951...82,897,712
|
|
G |
Txnrd2 |
thioredoxin reductase 2 |
affects abundance |
ISO |
TXNRD2 gene SNP affects the abundance of 8-Hydroxy-2'-Deoxyguanosine |
CTD |
PMID:19896490 |
|
NCBI chr16:18,426,417...18,479,073
Ensembl chr16:18,426,384...18,479,073
|
|
|
G |
Egf |
epidermal growth factor |
increases abundance multiple interactions |
ISO |
EGF protein results in increased abundance of 8-hydroxyguanosine Acetylcysteine inhibits the reaction [EGF protein results in increased abundance of 8-hydroxyguanosine]; Selenium inhibits the reaction [EGF protein results in increased abundance of 8-hydroxyguanosine] |
CTD |
PMID:11158190 |
|
NCBI chr 3:129,677,574...129,755,322
Ensembl chr 3:129,677,565...129,755,316
|
|
|
G |
Hsd17b2 |
hydroxysteroid (17-beta) dehydrogenase 2 |
affects binding |
ISO |
acetoacetyl CoA binds to HSD17B2 protein |
CTD |
PMID:25526675 |
|
NCBI chr 8:117,700,982...117,759,030
Ensembl chr 8:117,701,904...117,759,027
|
|
|
G |
Acly |
ATP citrate lyase |
increases abundance |
EXP |
ACLY protein results in increased abundance of Acetyl Coenzyme A |
CTD |
PMID:28077572 |
|
NCBI chr11:100,476,352...100,528,000
Ensembl chr11:100,476,353...100,528,000
|
|
G |
App |
amyloid beta (A4) precursor protein |
affects localization increases secretion multiple interactions |
EXP ISO |
APP protein affects the localization of Acetyl Coenzyme A Acetyl Coenzyme A results in increased secretion of APP protein modified form Acetyl Coenzyme A inhibits the reaction [Hydrogen Peroxide results in decreased secretion of APP protein modified form] IL1B protein affects the reaction [APP protein affects the localization of Acetyl Coenzyme A] |
CTD |
PMID:16122837 PMID:22906069 |
|
NCBI chr16:84,952,666...85,175,255
Ensembl chr16:84,949,685...85,173,766
|
|
G |
Crat |
carnitine acetyltransferase |
decreases activity |
ISO |
Acetyl Coenzyme A deficiency results in decreased activity of CRAT protein |
CTD |
PMID:8075222 |
|
NCBI chr 2:30,400,476...30,416,017
Ensembl chr 2:30,400,471...30,415,813
|
|
G |
Ercc6 |
excision repair cross-complementing rodent repair deficiency, complementation group 6 |
decreases abundance multiple interactions |
ISO |
ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A 3-Hydroxybutyric Acid inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A] |
CTD |
PMID:25440059 |
|
NCBI chr14:32,513,291...32,580,990
Ensembl chr14:32,513,521...32,580,990
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
IL1B protein affects the reaction [APP protein affects the localization of Acetyl Coenzyme A] |
CTD |
PMID:16122837 |
|
NCBI chr 2:129,364,569...129,371,164
Ensembl chr 2:129,364,570...129,371,139
|
|
G |
Kat2b |
K(lysine) acetyltransferase 2B |
affects binding |
EXP |
Acetyl Coenzyme A binds to KAT2B protein |
CTD |
PMID:28077572 |
|
NCBI chr17:53,566,774...53,672,721
Ensembl chr17:53,566,861...53,672,720
|
|
G |
Metrnl |
meteorin, glial cell differentiation regulator-like |
multiple interactions |
EXP |
METRNL protein inhibits the reaction [Dietary Fats results in decreased abundance of Acetyl Coenzyme A] |
CTD |
PMID:30213948 |
|
NCBI chr11:121,702,427...121,717,389
Ensembl chr11:121,701,544...121,716,306
|
|
G |
Nat1 |
N-acetyl transferase 1 |
multiple interactions affects binding |
ISO |
[NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; Acetyl Coenzyme A inhibits the reaction [Cyanamide results in decreased activity of NAT1 protein]; Acetyl Coenzyme A inhibits the reaction [Iodoacetamide results in decreased activity of NAT1 protein] Acetyl Coenzyme A binds to NAT1 protein |
CTD |
PMID:20545351 PMID:22835378 |
|
NCBI chr 8:67,490,968...67,492,531
Ensembl chr 8:67,480,921...67,492,104
|
|
G |
Nat2 |
N-acetyltransferase 2 (arylamine N-acetyltransferase) |
multiple interactions |
ISO |
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone] |
CTD |
PMID:20545351 |
|
NCBI chr 8:67,494,875...67,502,644
Ensembl chr 8:67,494,858...67,502,584
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
multiple interactions |
ISO |
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone |
CTD |
PMID:20545351 |
|
NCBI chr 8:107,388,225...107,403,205
Ensembl chr 8:107,388,225...107,403,206
|
|
G |
Sult1a1 |
sulfotransferase family 1A, phenol-preferring, member 1 |
multiple interactions |
ISO |
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone] |
CTD |
PMID:20545351 |
|
NCBI chr 7:126,672,865...126,690,443
Ensembl chr 7:126,672,865...126,676,432
|
|
|
G |
Echs1 |
enoyl Coenzyme A hydratase, short chain, 1, mitochondrial |
increases abundance |
ISO |
ECHS1 gene mutant form results in increased abundance of acryloyl-coenzyme A |
CTD |
PMID:25125611 |
|
NCBI chr 7:140,105,710...140,116,421
Ensembl chr 7:140,105,710...140,116,476
|
|
G |
Hibch |
3-hydroxyisobutyryl-Coenzyme A hydrolase |
increases abundance |
ISO |
HIBCH gene mutant form results in increased abundance of acryloyl-coenzyme A |
CTD |
PMID:25125611 |
|
NCBI chr 1:52,845,038...52,920,986
Ensembl chr 1:52,844,929...52,920,986
|
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
Vidarabine results in increased activity of NR1I2 protein |
CTD |
PMID:25455453 |
|
NCBI chr16:38,248,349...38,294,849
Ensembl chr16:38,248,323...38,294,824
|
|
|
G |
Ada |
adenosine deaminase |
decreases metabolic processing increases metabolic processing |
ISO |
ADA alternative form results in decreased metabolism of Adenosine ADA protein results in increased metabolism of Adenosine |
CTD |
PMID:16221767 |
|
NCBI chr 2:163,726,571...163,750,239
Ensembl chr 2:163,726,584...163,750,239
|
|
G |
Adora1 |
adenosine A1 receptor |
multiple interactions affects binding |
ISO |
Adenosine analog binds to and affects the activity of ADORA1 protein; Adenosine analog binds to and results in decreased activity of ADORA1 protein; PD 81723 affects the reaction [Adenosine analog binds to and affects the activity of ADORA1 protein]; VUF 5455 affects the reaction [Adenosine analog binds to and affects the activity of ADORA1 protein] [lead acetate results in increased expression of ADORA1 protein] which results in increased abundance of Adenosine; Adenosine analog binds to and results in increased activity of ADORA1 protein Adenosine binds to ADORA1 protein |
CTD |
PMID:10649980 PMID:11520205 PMID:18404447 PMID:20571079 PMID:20932874 |
|
NCBI chr 1:134,199,215...134,235,457
Ensembl chr 1:134,199,223...134,235,431
|
|
G |
Adora2a |
adenosine A2a receptor |
multiple interactions affects binding |
ISO |
Adenosine analog binds to and results in decreased activity of ADORA2A protein; Adenosine promotes the reaction [Lipopolysaccharides results in increased expression of ADORA2A mRNA] Adenosine binds to ADORA2A protein |
CTD |
PMID:18404447 PMID:20067761 |
|
NCBI chr10:75,316,877...75,334,792
Ensembl chr10:75,316,877...75,334,784
|
|
G |
Adora2b |
adenosine A2b receptor |
affects response to substance |
EXP |
ADORA2B protein affects the susceptibility to Adenosine |
CTD |
PMID:16920807 |
|
NCBI chr11:62,248,984...62,266,452
Ensembl chr11:62,248,984...62,266,453
|
|
G |
Adora3 |
adenosine A3 receptor |
multiple interactions affects binding increases expression |
ISO |
Adenosine analog binds to and affects the activity of ADORA3 protein; Adenosine analog binds to and results in decreased activity of ADORA3 protein; Adenosine analog binds to and results in increased activity of ADORA3 protein; PD 81723 affects the reaction [Adenosine analog binds to and affects the activity of ADORA3 protein]; VUF 5455 affects the reaction [Adenosine analog binds to and affects the activity of ADORA3 protein] Adenosine binds to ADORA3 protein Adenosine results in increased expression of ADORA3 mRNA |
CTD |
PMID:11520205 PMID:18404447 PMID:20067761 PMID:20571079 |
|
NCBI chr 3:105,904,421...105,908,928
Ensembl chr 3:105,870,858...105,908,926
|
|
G |
Alpi |
alkaline phosphatase, intestinal |
multiple interactions |
ISO |
Adenosine inhibits the reaction [Methotrexate results in increased activity of ALPI protein] |
CTD |
PMID:16598758 |
|
NCBI chr 1:87,098,002...87,101,606
Ensembl chr 1:87,098,002...87,101,606
|
|
G |
Ampd2 |
adenosine monophosphate deaminase 2 |
multiple interactions |
ISO |
[tofacitinib results in decreased expression of AMPD2 protein] which affects the abundance of Adenosine |
CTD |
PMID:25496463 |
|
NCBI chr 3:108,074,059...108,086,687
Ensembl chr 3:108,074,062...108,086,651
|
|
G |
Bax |
BCL2-associated X protein |
increases localization multiple interactions |
ISO |
Adenosine results in increased localization of BAX protein Thymidine inhibits the reaction [Adenosine results in increased localization of BAX protein] |
CTD |
PMID:11570579 |
|
NCBI chr 7:45,461,695...45,466,903
Ensembl chr 7:45,461,697...45,466,898
|
|
G |
Bcl2l1 |
BCL2-like 1 |
decreases expression multiple interactions |
ISO |
Adenosine results in decreased expression of BCL2L1 mRNA; Adenosine results in decreased expression of BCL2L1 protein Dipyridamole inhibits the reaction [Adenosine results in decreased expression of BCL2L1 mRNA]; Dipyridamole inhibits the reaction [Adenosine results in decreased expression of BCL2L1 protein] |
CTD |
PMID:20063052 |
|
NCBI chr 2:152,758,732...152,833,803
Ensembl chr 2:152,780,668...152,831,728
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
decreases expression |
ISO |
Adenosine results in decreased expression of BIRC2 mRNA; Adenosine results in decreased expression of BIRC2 protein |
CTD |
PMID:20063052 |
|
NCBI chr 9:7,818,226...7,837,131
Ensembl chr 9:7,818,227...7,837,064
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression |
ISO |
Adenosine results in decreased expression of BIRC3 mRNA |
CTD |
PMID:20063052 |
|
NCBI chr 9:7,847,468...7,873,205
Ensembl chr 9:7,848,699...7,873,186
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO |
Dipyridamole inhibits the reaction [Adenosine results in increased activity of CASP3 protein]; Thymidine inhibits the reaction [Adenosine results in increased activity of CASP3 protein] |
CTD |
PMID:11570579 PMID:16469385 PMID:17303086 PMID:20063052 |
|
NCBI chr 8:46,617,291...46,639,698
Ensembl chr 8:46,617,291...46,639,689
|
|
G |
Casp8 |
caspase 8 |
increases activity multiple interactions |
ISO |
Adenosine results in increased activity of CASP8 protein Dipyridamole inhibits the reaction [Adenosine results in increased activity of CASP8 protein] |
CTD |
PMID:16469385 PMID:17303086 |
|
NCBI chr 1:58,795,233...58,847,503
Ensembl chr 1:58,795,374...58,847,503
|
|
G |
Casp9 |
caspase 9 |
increases activity multiple interactions |
ISO |
Adenosine results in increased activity of CASP9 protein Thymidine inhibits the reaction [Adenosine results in increased activity of CASP9 protein] |
CTD |
PMID:11570579 PMID:16469385 |
|
NCBI chr 4:141,793,612...141,815,978
Ensembl chr 4:141,793,612...141,815,976
|
|
G |
Cd14 |
CD14 antigen |
increases expression |
ISO |
Adenosine results in increased expression of CD14 mRNA |
CTD |
PMID:21538184 |
|
NCBI chr18:36,725,064...36,726,815
Ensembl chr18:36,725,067...36,726,798
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
decreases expression multiple interactions |
ISO |
Adenosine results in decreased expression of CFLAR mRNA; Adenosine results in decreased expression of CFLAR mRNA alternative form; Adenosine results in decreased expression of CFLAR protein Dipyridamole inhibits the reaction [Adenosine results in decreased expression of CFLAR mRNA alternative form]; Dipyridamole inhibits the reaction [Adenosine results in decreased expression of CFLAR mRNA]; Dipyridamole inhibits the reaction [Adenosine results in decreased expression of CFLAR protein] |
CTD |
PMID:17303086 |
|
NCBI chr 1:58,711,311...58,758,884
Ensembl chr 1:58,711,508...58,758,884
|
|
G |
Cftr |
cystic fibrosis transmembrane conductance regulator |
increases activity multiple interactions |
ISO |
Adenosine results in increased activity of CFTR protein [Isoproterenol co-treated with Adenosine] results in increased activity of CFTR protein |
CTD |
PMID:15039139 |
|
NCBI chr 6:18,170,687...18,322,770
Ensembl chr 6:18,170,687...18,322,768
|
|
G |
Cxcl15 |
chemokine (C-X-C motif) ligand 15 |
multiple interactions |
ISO |
[Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]; [Adenosine co-treated with Homocysteine] results in decreased expression of CXCL8 mRNA |
CTD |
PMID:24224954 |
|
NCBI chr 5:90,794,534...90,803,067
Ensembl chr 5:90,794,534...90,803,067
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
increases expression multiple interactions |
ISO |
Adenosine results in increased expression of DIABLO mRNA; Adenosine results in increased expression of DIABLO protein Dipyridamole inhibits the reaction [Adenosine results in increased expression of DIABLO mRNA]; Dipyridamole inhibits the reaction [Adenosine results in increased expression of DIABLO protein] |
CTD |
PMID:20063052 |
|
NCBI chr 5:123,511,330...123,524,164
Ensembl chr 5:123,509,765...123,524,176
|
|
G |
Dpp4 |
dipeptidylpeptidase 4 |
decreases expression multiple interactions |
ISO |
Adenosine results in decreased expression of DPP4 mRNA; Adenosine results in decreased expression of DPP4 protein [Adenosine results in decreased phosphorylation of MAPK1 protein] which results in decreased expression of DPP4 mRNA; [Adenosine results in decreased phosphorylation of MAPK1 protein] which results in decreased expression of DPP4 protein; [Adenosine results in decreased phosphorylation of MAPK3 protein] which results in decreased expression of DPP4 mRNA; [Adenosine results in decreased phosphorylation of MAPK3 protein] which results in decreased expression of DPP4 protein |
CTD |
PMID:16611738 |
|
NCBI chr 2:62,330,073...62,412,315
Ensembl chr 2:62,330,073...62,412,231
|
|
G |
Fadd |
Fas (TNFRSF6)-associated via death domain |
decreases expression multiple interactions |
ISO |
Adenosine results in decreased expression of FADD mRNA Dipyridamole inhibits the reaction [Adenosine results in decreased expression of FADD mRNA] |
CTD |
PMID:17303086 |
|
NCBI chr 7:144,578,323...144,582,441
Ensembl chr 7:144,577,318...144,582,463
|
|
G |
Fasl |
Fas ligand (TNF superfamily, member 6) |
increases expression multiple interactions |
ISO EXP |
Adenosine results in increased expression of FASLG protein [Adenosine co-treated with Coformycin] results in decreased expression of FASL mRNA |
CTD |
PMID:11992407 PMID:16419169 |
|
NCBI chr 1:161,780,691...161,788,495
Ensembl chr 1:161,780,689...161,788,495
|
|
G |
Gzmb |
granzyme B |
multiple interactions |
EXP |
[Adenosine co-treated with Coformycin] results in decreased expression of GZMB mRNA |
CTD |
PMID:11992407 |
|
NCBI chr14:56,258,836...56,262,334
Ensembl chr14:56,258,838...56,262,260
|
|
G |
Hif1a |
hypoxia inducible factor 1, alpha subunit |
increases expression |
ISO |
Adenosine results in increased expression of HIF1A mRNA |
CTD |
PMID:20067761 |
|
NCBI chr12:73,901,324...73,947,554
Ensembl chr12:73,901,375...73,947,530
|
|
G |
Idh2 |
isocitrate dehydrogenase 2 (NADP+), mitochondrial |
multiple interactions increases abundance |
EXP |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Adenosine] |
CTD |
PMID:27469509 |
|
NCBI chr 7:80,094,845...80,118,608
Ensembl chr 7:80,094,846...80,115,392
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
[Adenosine co-treated with Coformycin] results in decreased expression of IFNG protein |
CTD |
PMID:11992407 |
|
NCBI chr10:118,441,046...118,445,894
Ensembl chr10:118,441,046...118,445,892
|
|
G |
Il10 |
interleukin 10 |
multiple interactions increases expression |
EXP |
Adenosine promotes the reaction [Lipopolysaccharides results in increased secretion of IL10 protein] Adenosine results in increased expression of IL10 mRNA; Adenosine results in increased expression of IL10 protein |
CTD |
PMID:11023991 |
|
NCBI chr 1:131,019,845...131,024,970
Ensembl chr 1:131,019,845...131,024,974
|
|
G |
Il12b |
interleukin 12b |
decreases expression multiple interactions |
EXP |
Adenosine results in decreased expression of IL12B protein Adenosine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein] |
CTD |
PMID:11023991 |
|
NCBI chr11:44,400,063...44,414,677
Ensembl chr11:44,400,063...44,414,033
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Adenosine inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Adenosine inhibits the reaction [IL1B protein results in increased expression of IL1R1]; Adenosine inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA]; Adenosine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein] |
CTD |
PMID:24878381 |
|
NCBI chr 2:129,364,569...129,371,164
Ensembl chr 2:129,364,570...129,371,139
|
|
G |
Il1r1 |
interleukin 1 receptor, type I |
multiple interactions |
ISO |
Adenosine inhibits the reaction [IL1B protein results in increased expression of IL1R1] |
CTD |
PMID:24878381 |
|
NCBI chr 1:40,222,480...40,316,201
Ensembl chr 1:40,225,080...40,317,257
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
EXP |
[Adenosine co-treated with Coformycin] results in decreased expression of IL2 protein |
CTD |
PMID:11992407 |
|
NCBI chr 3:37,120,713...37,125,954
Ensembl chr 3:37,120,523...37,125,959
|
|
G |
Ly96 |
lymphocyte antigen 96 |
increases expression |
ISO |
Adenosine results in increased expression of LY96 mRNA |
CTD |
PMID:21538184 |
|
NCBI chr 1:16,688,456...16,709,605
Ensembl chr 1:16,688,051...16,709,611
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
[Adenosine results in decreased phosphorylation of MAPK1 protein] which results in decreased expression of DPP4 mRNA; [Adenosine results in decreased phosphorylation of MAPK1 protein] which results in decreased expression of DPP4 protein |
CTD |
PMID:16611738 |
|
NCBI chr16:16,983,382...17,047,453
Ensembl chr16:16,983,382...17,047,453
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
decreases phosphorylation multiple interactions |
ISO |
Adenosine results in decreased phosphorylation of MAPK3 protein [Adenosine results in decreased phosphorylation of MAPK3 protein] which results in decreased expression of DPP4 mRNA; [Adenosine results in decreased phosphorylation of MAPK3 protein] which results in decreased expression of DPP4 protein |
CTD |
PMID:16611738 |
|
NCBI chr 7:126,759,626...126,765,816
Ensembl chr 7:126,759,601...126,765,819
|
|
G |
Myc |
myelocytomatosis oncogene |
decreases expression multiple interactions |
ISO |
Adenosine results in decreased expression of MYC protein Thymidine inhibits the reaction [Adenosine results in decreased expression of MYC protein]; Uridine inhibits the reaction [Adenosine results in decreased expression of MYC protein] |
CTD |
PMID:9808420 |
|
NCBI chr15:61,985,341...61,990,361
Ensembl chr15:61,985,391...61,990,374
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
multiple interactions |
ISO |
[Adenosine co-treated with Homocysteine] affects the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of NFKBIA mRNA]; [Adenosine co-treated with Homocysteine] results in decreased expression of NFKBIA mRNA |
CTD |
PMID:24224954 |
|
NCBI chr12:55,489,409...55,492,647
Ensembl chr12:55,489,410...55,492,647
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
decreases stability multiple interactions |
ISO |
Adenosine results in decreased stability of NOS2 mRNA Adenosine inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA]; Adenosine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein] |
CTD |
PMID:24878381 |
|
NCBI chr11:78,920,787...78,960,226
Ensembl chr11:78,920,787...78,960,254
|
|
G |
Nt5e |
5' nucleotidase, ecto |
multiple interactions |
EXP |
[alpha,beta-methyleneadenosine 5'-diphosphate results in decreased activity of NT5E protein] inhibits the reaction [Oxygen deficiency results in increased abundance of Adenosine] |
CTD |
PMID:23437309 |
|
NCBI chr 9:88,327,609...88,372,089
Ensembl chr 9:88,327,197...88,372,092
|
|
G |
Ppargc1a |
peroxisome proliferative activated receptor, gamma, coactivator 1 alpha |
increases expression |
ISO |
Adenosine results in increased expression of PPARGC1A mRNA |
CTD |
PMID:23056435 |
|
NCBI chr 5:51,454,249...52,115,853
Ensembl chr 5:51,454,250...51,567,726
|
|
G |
Prf1 |
perforin 1 (pore forming protein) |
multiple interactions |
EXP |
[Adenosine co-treated with Coformycin] results in decreased expression of PRF1 mRNA |
CTD |
PMID:11992407 |
|
NCBI chr10:61,297,751...61,304,684
Ensembl chr10:61,297,833...61,304,680
|
|
G |
Ptgdr |
prostaglandin D receptor |
multiple interactions |
EXP |
[Prostaglandin D2 results in increased activity of PTGDR protein] which results in increased metabolism of Adenosine; [Prostaglandin D2 results in increased activity of PTGDR protein] which results in increased secretion of Adenosine |
CTD |
PMID:11562489 |
|
NCBI chr14:44,851,235...44,859,375
Ensembl chr14:44,851,235...44,859,375
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
ISO |
[Adenosine co-treated with Homocysteine] affects the reaction [TNF protein affects the localization of RELA protein modified form]; [Adenosine co-treated with Homocysteine] affects the reaction [TNF protein results in increased phosphorylation of RELA protein] |
CTD |
PMID:24224954 |
|
NCBI chr19:5,637,442...5,648,134
Ensembl chr19:5,637,483...5,648,130
|
|
G |
Ren1 |
renin 1 structural |
decreases secretion |
ISO |
Adenosine results in decreased secretion of REN protein |
CTD |
PMID:3044993 |
|
NCBI chr 1:133,350,674...133,360,320
Ensembl chr 1:133,350,510...133,360,325
|
|
G |
Ripk1 |
receptor (TNFRSF)-interacting serine-threonine kinase 1 |
multiple interactions |
ISO |
[Adenosine co-treated with Homocysteine co-treated with TNF protein] results in increased cleavage of RIPK1 protein |
CTD |
PMID:24224954 |
|
NCBI chr13:34,002,225...34,035,170
Ensembl chr13:34,002,363...34,037,147
|
|
G |
Slc28a1 |
solute carrier family 28 (sodium-coupled nucleoside transporter), member 1 |
affects transport multiple interactions |
ISO |
SLC28A1 protein affects the transport of Adenosine Adenosine inhibits the reaction [SLC28A1 protein results in increased uptake of Uridine] |
CTD |
PMID:9124315 |
|
NCBI chr 7:81,113,269...81,170,416
Ensembl chr 7:81,114,799...81,170,416
|
|
G |
Slc28a2 |
solute carrier family 28 (sodium-coupled nucleoside transporter), member 2 |
increases transport |
ISO |
SLC28A2 protein results in increased transport of Adenosine |
CTD |
PMID:10087507 |
|
NCBI chr 2:122,426,357...122,461,152
Ensembl chr 2:122,426,477...122,461,137
|
|
G |
Slc29a1 |
solute carrier family 29 (nucleoside transporters), member 1 |
multiple interactions increases uptake affects abundance |
EXP ISO |
4-nitrobenzylthioinosine inhibits the reaction [SLC29A1 protein alternative form results in increased uptake of Adenosine]; 4-nitrobenzylthioinosine inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]; [4-nitrobenzylthioinosine results in decreased activity of SLC29A1 protein] inhibits the reaction [Oxygen deficiency results in increased abundance of Adenosine]; [SLC29A1 co-treated with Oxygen deficiency] affects the abundance of Adenosine; Dipyridamole inhibits the reaction [SLC29A1 protein alternative form results in increased uptake of Adenosine]; Dipyridamole inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]; Dipyridamole promotes the reaction [[SLC29A1 co-treated with Oxygen deficiency] affects the abundance of Adenosine] SLC29A1 protein alternative form results in increased uptake of Adenosine; SLC29A1 protein results in increased uptake of Adenosine cilostazol inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]; Dipyridamole inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]; draflazine inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]; Ethanol promotes the reaction [SLC29A1 protein alternative form results in increased uptake of Adenosine]; Ethanol promotes the reaction [SLC29A1 protein results in increased uptake of Adenosine]; Ticagrelor inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine] Adenosine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine] SLC29A1 affects the abundance of Adenosine |
CTD |
PMID:9353301 PMID:9396714 PMID:11179696 PMID:21283641 PMID:21872611 PMID:23437309 PMID:28041785 |
|
NCBI chr17:45,585,200...45,599,618
Ensembl chr17:45,585,200...45,599,606
|
|
G |
Slc29a2 |
solute carrier family 29 (nucleoside transporters), member 2 |
increases uptake |
ISO |
SLC29A2 protein results in increased uptake of Adenosine |
CTD |
PMID:9396714 |
|
NCBI chr19:5,019,057...5,031,972
Ensembl chr19:5,023,860...5,031,972
|
|
G |
Slc29a3 |
solute carrier family 29 (nucleoside transporters), member 3 |
affects transport |
ISO |
SLC29A3 protein affects the transport of Adenosine |
CTD |
PMID:19164483 |
|
NCBI chr10:60,712,072...60,752,849
Ensembl chr10:60,712,072...60,752,794
|
|
G |
Slc5a5 |
solute carrier family 5 (sodium iodide symporter), member 5 |
increases expression |
ISO |
Adenosine results in increased expression of SLC5A5 mRNA; Adenosine results in increased expression of SLC5A5 protein |
CTD |
PMID:16954431 |
|
NCBI chr 8:70,882,885...70,892,785
Ensembl chr 8:70,882,889...70,892,757
|
|
G |
Tlr4 |
toll-like receptor 4 |
increases expression affects localization multiple interactions |
ISO |
Adenosine results in increased expression of TLR4 mRNA Adenosine affects the localization of TLR4 protein Adenosine promotes the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of TLR4 protein] |
CTD |
PMID:21538184 |
|
NCBI chr 4:66,827,551...66,846,581
Ensembl chr 4:66,827,584...66,930,284
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
ISO EXP |
5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine inhibits the reaction [Adenosine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; [Adenosine co-treated with Homocysteine co-treated with TNF protein] results in increased cleavage of RIPK1 protein; [Adenosine co-treated with Homocysteine] affects the reaction [TNF protein affects the localization of RELA protein modified form]; [Adenosine co-treated with Homocysteine] affects the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; [Adenosine co-treated with Homocysteine] affects the reaction [TNF protein results in increased phosphorylation of RELA protein]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of NFKBIA mRNA]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of TNFAIP3 mRNA]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein]; [Adenosine co-treated with Homocysteine] results in increased susceptibility to TNF protein; Adenosine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF mRNA]; Adenosine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]; ZM 241385 inhibits the reaction [Adenosine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]] Adenosine results in decreased expression of TNF protein |
CTD |
PMID:11023991 PMID:21538184 PMID:24224954 |
|
NCBI chr17:35,199,367...35,202,007
Ensembl chr17:35,199,381...35,202,007
|
|
G |
Tnfaip3 |
tumor necrosis factor, alpha-induced protein 3 |
multiple interactions |
ISO |
[Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of TNFAIP3 mRNA]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein]; [Adenosine co-treated with Homocysteine] results in decreased expression of TNFAIP3 mRNA; [Adenosine co-treated with Homocysteine] results in decreased expression of TNFAIP3 protein |
CTD |
PMID:24224954 |
|
NCBI chr10:19,000,910...19,015,410
Ensembl chr10:19,000,910...19,015,657
|
|
G |
Tnfsf10 |
tumor necrosis factor (ligand) superfamily, member 10 |
multiple interactions |
EXP |
[Adenosine co-treated with Coformycin] results in decreased expression of TNFSF10 mRNA |
CTD |
PMID:11992407 |
|
NCBI chr 3:27,317,077...27,339,665
Ensembl chr 3:27,317,028...27,342,427
|
|
G |
Upp1 |
uridine phosphorylase 1 |
increases metabolic processing |
EXP |
UPP1 protein results in increased metabolism of Adenosine |
CTD |
PMID:15772079 |
|
NCBI chr11:9,118,008...9,136,170
Ensembl chr11:9,118,103...9,136,170
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases expression increases secretion |
ISO |
Adenosine promotes the reaction [Dipyridamole results in increased secretion of VEGFA protein] Adenosine results in increased expression of VEGFA mRNA Adenosine results in increased secretion of VEGFA protein |
CTD |
PMID:20067761 |
|
NCBI chr17:46,016,993...46,032,377
Ensembl chr17:46,016,993...46,032,369
|
|
|
G |
Sult1a1 |
sulfotransferase family 1A, phenol-preferring, member 1 |
multiple interactions |
ISO |
Glutathione Disulfide affects the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT1A1 protein]; Glutathione Disulfide affects the reaction [Polychlorinated Biphenyls analog affects the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT1A1 protein]]; Polychlorinated Biphenyls analog affects the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT1A1 protein] |
CTD |
PMID:21130751 |
|
NCBI chr 7:126,672,865...126,690,443
Ensembl chr 7:126,672,865...126,676,432
|
|
G |
Sult1e1 |
sulfotransferase family 1E, member 1 |
multiple interactions |
ISO |
[2,2',4,4'-tetrabromodiphenyl ether metabolite co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein; [Estradiol co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein; [tetrabromobisphenol A co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein; Estradiol inhibits the reaction [[tetrabromobisphenol A co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein]; tetrabromobisphenol A inhibits the reaction [[Estradiol co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein] |
CTD |
PMID:23959441 |
|
NCBI chr 5:87,575,968...87,591,611
Ensembl chr 5:87,575,969...87,591,594
|
|
G |
Sult2a1 |
sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 1 |
affects binding multiple interactions |
ISO |
adenosine 3'-phosphate-5'-phosphate binds to SULT2A1 protein Benzoquinones analog inhibits the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT2A1 protein]; Dehydroepiandrosterone inhibits the reaction [Benzoquinones analog inhibits the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT2A1 protein]] |
CTD |
PMID:24059442 |
|
NCBI chr 7:13,796,246...13,837,410
Ensembl chr 7:13,796,246...13,837,409
|
|
|
G |
Nudt10 |
nudix (nucleoside diphosphate linked moiety X)-type motif 10 |
multiple interactions |
ISO |
[NUDT11 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of adenosine 5'-pentaphosphate |
CTD |
PMID:12121577 |
|
NCBI chr X:6,168,696...6,173,009
Ensembl chr X:6,168,696...6,173,015 Ensembl chr X:6,168,696...6,173,015
|
|
|
G |
Cd80 |
CD80 antigen |
increases expression |
EXP |
adenosine 5'-O-(3-thiotriphosphate) results in increased expression of CD80 protein |
CTD |
PMID:15944274 |
|
NCBI chr16:38,457,430...38,495,958
Ensembl chr16:38,455,561...38,496,335
|
|
G |
Cd86 |
CD86 antigen |
increases expression |
EXP |
adenosine 5'-O-(3-thiotriphosphate) results in increased expression of CD86 protein |
CTD |
PMID:15944274 |
|
NCBI chr16:36,568,956...36,666,158
Ensembl chr16:36,603,869...36,666,081
|
|
G |
Cxcl15 |
chemokine (C-X-C motif) ligand 15 |
multiple interactions |
ISO |
[adenosine 5'-O-(3-thiotriphosphate) binds to and results in increased activity of P2RY11 protein] which results in increased expression of CXCL8 protein |
CTD |
PMID:19815812 |
|
NCBI chr 5:90,794,534...90,803,067
Ensembl chr 5:90,794,534...90,803,067
|
|
G |
Il10 |
interleukin 10 |
decreases expression |
EXP |
adenosine 5'-O-(3-thiotriphosphate) results in decreased expression of IL10 protein |
CTD |
PMID:15944274 |
|
NCBI chr 1:131,019,845...131,024,970
Ensembl chr 1:131,019,845...131,024,974
|
|
G |
Il12b |
interleukin 12b |
increases expression |
EXP |
adenosine 5'-O-(3-thiotriphosphate) results in increased expression of IL12B protein |
CTD |
PMID:15944274 |
|
NCBI chr11:44,400,063...44,414,677
Ensembl chr11:44,400,063...44,414,033
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
EXP |
adenosine 5'-O-(3-thiotriphosphate) results in increased expression of IL1B protein |
CTD |
PMID:15944274 |
|
NCBI chr 2:129,364,569...129,371,164
Ensembl chr 2:129,364,570...129,371,139
|
|
G |
P2rx7 |
purinergic receptor P2X, ligand-gated ion channel, 7 |
affects response to substance |
EXP |
P2RX7 protein affects the susceptibility to adenosine 5'-O-(3-thiotriphosphate) |
CTD |
PMID:12873706 |
|
NCBI chr 5:122,643,927...122,692,336
Ensembl chr 5:122,643,911...122,691,432
|
|
G |
Ptgdr |
prostaglandin D receptor |
multiple interactions |
ISO |
adenosine 5'-O-(3-thiotriphosphate) inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] |
CTD |
PMID:9579725 |
|
NCBI chr14:44,851,235...44,859,375
Ensembl chr14:44,851,235...44,859,375
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
increases activity multiple interactions |
ISO |
adenosine 5'-O-(3-thiotriphosphate) results in increased activity of TRPV1 protein Capsaicin promotes the reaction [adenosine 5'-O-(3-thiotriphosphate) results in increased activity of TRPV1 protein]; capsazepine inhibits the reaction [adenosine 5'-O-(3-thiotriphosphate) results in increased activity of TRPV1 protein] |
CTD |
PMID:11140687 |
|
NCBI chr11:73,234,149...73,261,322
Ensembl chr11:73,234,292...73,261,242
|
|
|
G |
Abcc9 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 9 |
multiple interactions |
EXP |
Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]] |
CTD |
PMID:11390963 |
|
NCBI chr 6:142,587,862...142,702,766
Ensembl chr 6:142,587,862...142,702,315
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase family 1, subfamily A1 |
multiple interactions |
ISO |
[4-dimethylaminocinnamaldehyde co-treated with Adenosine Monophosphate] binds to ALDH1A1 protein |
CTD |
PMID:10609638 |
|
NCBI chr19:20,492,583...20,643,463
Ensembl chr19:20,492,715...20,643,465
|
|
G |
Ercc6 |
excision repair cross-complementing rodent repair deficiency, complementation group 6 |
increases abundance |
EXP |
ERCC6 gene mutant form results in increased abundance of Adenosine Monophosphate |
CTD |
PMID:25440059 |
|
NCBI chr14:32,513,291...32,580,990
Ensembl chr14:32,513,521...32,580,990
|
|
G |
Kcnj11 |
potassium inwardly rectifying channel, subfamily J, member 11 |
multiple interactions |
EXP |
Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]] |
CTD |
PMID:11390963 |
|
NCBI chr 7:46,097,123...46,100,952
Ensembl chr 7:46,093,953...46,100,764
|
|
G |
Nudt10 |
nudix (nucleoside diphosphate linked moiety X)-type motif 10 |
multiple interactions |
ISO |
[NUDT11 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate; [NUDT11 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate |
CTD |
PMID:12121577 |
|
NCBI chr X:6,168,696...6,173,009
Ensembl chr X:6,168,696...6,173,015 Ensembl chr X:6,168,696...6,173,015
|
|
G |
Ppargc1a |
peroxisome proliferative activated receptor, gamma, coactivator 1 alpha |
increases expression |
ISO |
Adenosine Monophosphate results in increased expression of PPARGC1A mRNA |
CTD |
PMID:23056435 |
|
NCBI chr 5:51,454,249...52,115,853
Ensembl chr 5:51,454,250...51,567,726
|
|
G |
Trp73 |
transformation related protein 73 |
affects abundance |
EXP |
TP73 protein affects the abundance of Adenosine Monophosphate |
CTD |
PMID:25554796 |
|
NCBI chr 4:154,056,249...154,139,875
Ensembl chr 4:154,056,253...154,140,208 Ensembl chr 4:154,056,253...154,140,208
|
|
|
G |
Abcc1 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 |
multiple interactions affects binding |
ISO |
estradiol-17 beta-glucuronide inhibits the reaction [Adenosine Diphosphate binds to ABCC1 protein mutant form]; estradiol-17 beta-glucuronide inhibits the reaction [Adenosine Diphosphate binds to ABCC1 protein]; Vanadates promotes the reaction [Adenosine Diphosphate binds to ABCC1 protein] Adenosine Diphosphate binds to ABCC1 protein; Adenosine Diphosphate binds to ABCC1 protein mutant form |
CTD |
PMID:18336795 |
|
NCBI chr16:14,361,453...14,474,878
Ensembl chr16:14,361,558...14,475,737
|
|
G |
Ahr |
aryl-hydrocarbon receptor |
multiple interactions |
ISO |
Adenosine Diphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein] |
CTD |
PMID:1848756 |
|
NCBI chr12:35,497,979...35,534,989
Ensembl chr12:35,497,974...35,535,038
|
|
G |
Ak1 |
adenylate kinase 1 |
increases abundance |
EXP |
AK1 protein results in increased abundance of Adenosine Diphosphate |
CTD |
PMID:11390963 |
|
NCBI chr 2:32,621,758...32,635,058
Ensembl chr 2:32,621,758...32,635,058
|
|
G |
Alb |
albumin |
decreases secretion multiple interactions |
ISO |
Adenosine Diphosphate results in decreased secretion of ALB protein Aspirin inhibits the reaction [Adenosine Diphosphate results in decreased secretion of ALB protein] |
CTD |
PMID:17303692 |
|
NCBI chr 5:90,460,870...90,476,602
Ensembl chr 5:90,460,897...90,476,602
|
|
G |
Axl |
AXL receptor tyrosine kinase |
decreases response to substance |
ISO |
AXL protein results in decreased susceptibility to Adenosine Diphosphate |
CTD |
PMID:15733062 |
|
NCBI chr 7:25,756,500...25,788,924
Ensembl chr 7:25,757,273...25,788,705
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
CAT protein inhibits the reaction [Adenosine Diphosphate results in increased glutathionylation of PTPN1 protein] |
CTD |
PMID:16781456 |
|
NCBI chr 2:103,453,904...103,485,153
Ensembl chr 2:103,453,849...103,485,160
|
|
G |
Cd40lg |
CD40 ligand |
increases expression multiple interactions |
ISO EXP |
Adenosine Diphosphate results in increased expression of CD40LG protein clopidogrel inhibits the reaction [Adenosine Diphosphate results in increased expression of CD40LG protein] |
CTD |
PMID:11297035 PMID:17043144 |
|
NCBI chr X:57,212,143...57,224,042
Ensembl chr X:57,212,143...57,224,042
|
|
G |
Cftr |
cystic fibrosis transmembrane conductance regulator |
multiple interactions |
ISO |
Adenosine Diphosphate binds to and results in decreased activity of CFTR protein; P(1),P(5)-di(adenosine-5'-)pentaphosphate inhibits the reaction [Adenosine Diphosphate binds to and results in decreased activity of CFTR protein] |
CTD |
PMID:15684079 |
|
NCBI chr 6:18,170,687...18,322,770
Ensembl chr 6:18,170,687...18,322,768
|
|
G |
Chordc1 |
cysteine and histidine-rich domain (CHORD)-containing, zinc-binding protein 1 |
multiple interactions |
EXP |
Adenosine Diphosphate binds to and affects the folding of CHORDC1 protein; Adenosine Diphosphate promotes the reaction [CHORDC1 protein binds to CHORDC1 protein]; Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein] |
CTD |
PMID:23184943 |
|
NCBI chr 9:18,292,267...18,314,000
Ensembl chr 9:18,292,125...18,317,442
|
|
G |
Cyp2c38 |
cytochrome P450, family 2, subfamily c, polypeptide 38 |
multiple interactions |
ISO |
CYP2C19 gene affects the susceptibility to [Adenosine Diphosphate co-treated with clopidogrel]; CYP2C19 gene SNP affects the reaction [Adenosine Diphosphate results in increased expression of SELP protein]; CYP2C19 gene SNP affects the susceptibility to [Adenosine Diphosphate co-treated with Arachidonic Acid] |
CTD |
PMID:16772608 PMID:18004210 PMID:18394438 |
|
NCBI chr19:39,389,556...39,463,103
Ensembl chr19:39,389,556...39,463,075
|
|
G |
Dtymk |
deoxythymidylate kinase |
multiple interactions |
ISO |
DTYMK protein binds to [N1-(4-bis(pivaloyloxymethyl)phosphinylbuten-2-yl)thymine co-treated with Adenosine Diphosphate] |
CTD |
PMID:21128666 |
|
NCBI chr 1:93,792,576...93,802,068
Ensembl chr 1:93,792,576...93,801,934
|
|
G |
Epha4 |
Eph receptor A4 |
increases phosphorylation multiple interactions |
ISO |
Adenosine Diphosphate results in increased phosphorylation of EPHA4 protein Benzoic Acid analog inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of EPHA4 protein] |
CTD |
PMID:22273509 |
|
NCBI chr 1:77,367,182...77,515,107
Ensembl chr 1:77,367,185...77,515,088
|
|
G |
Ern1 |
endoplasmic reticulum (ER) to nucleus signalling 1 |
multiple interactions decreases activity |
EXP |
Adenosine Diphosphate inhibits the reaction [ERN1 protein binds to ERN1 protein] Adenosine Diphosphate results in decreased activity of ERN1 protein |
CTD |
PMID:25164867 |
|
NCBI chr11:106,397,620...106,487,796
Ensembl chr11:106,394,650...106,487,852
|
|
G |
F2 |
coagulation factor II |
increases abundance multiple interactions |
ISO |
F2 protein results in increased abundance of Adenosine Diphosphate Quercetin inhibits the reaction [F2 protein results in increased abundance of Adenosine Diphosphate]; resveratrol inhibits the reaction [F2 protein results in increased abundance of Adenosine Diphosphate] |
CTD |
PMID:15342215 |
|
NCBI chr 2:91,612,397...91,636,457
Ensembl chr 2:91,625,320...91,636,414
|
|
G |
Fga |
fibrinogen alpha chain |
multiple interactions increases secretion |
ISO |
Aspirin promotes the reaction [Adenosine Diphosphate results in increased secretion of FGA protein] |
CTD |
PMID:17303692 |
|
NCBI chr 3:83,026,153...83,033,627
Ensembl chr 3:83,026,076...83,033,627
|
|
G |
Fgb |
fibrinogen beta chain |
decreases secretion multiple interactions |
ISO |
Adenosine Diphosphate results in decreased secretion of FGB protein Aspirin inhibits the reaction [Adenosine Diphosphate results in decreased secretion of FGB protein] |
CTD |
PMID:17303692 |
|
NCBI chr 3:83,042,246...83,049,863
Ensembl chr 3:83,040,141...83,049,863
|
|
G |
Fgg |
fibrinogen gamma chain |
increases secretion multiple interactions |
ISO |
Adenosine Diphosphate results in increased secretion of FGG protein Aspirin promotes the reaction [Adenosine Diphosphate results in increased secretion of FGG protein] |
CTD |
PMID:17303692 |
|
NCBI chr 3:83,007,724...83,015,056
Ensembl chr 3:83,007,724...83,015,049
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions |
ISO |
Adenosine Diphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog] |
CTD |
PMID:15788719 |
|
NCBI chr 6:125,161,852...125,166,467
Ensembl chr 6:125,161,715...125,166,467
|
|
G |
Gas6 |
growth arrest specific 6 |
increases response to substance |
ISO |
GAS6 protein results in increased susceptibility to Adenosine Diphosphate |
CTD |
PMID:15733062 |
|
NCBI chr 8:13,465,374...13,494,535
Ensembl chr 8:13,465,374...13,494,490
|
|
G |
Hras |
Harvey rat sarcoma virus oncogene |
multiple interactions |
ISO |
Adenosine Diphosphate binds to and affects the folding of HRAS protein |
CTD |
PMID:16388579 |
|
NCBI chr 7:141,189,934...141,194,019
Ensembl chr 7:141,189,105...141,194,005
|
|
G |
Hsp90aa1 |
heat shock protein 90, alpha (cytosolic), class A member 1 |
multiple interactions |
EXP |
Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Calcium promotes the reaction [Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]] |
CTD |
PMID:23184943 |
|
NCBI chr12:110,691,036...110,696,395
Ensembl chr12:110,690,605...110,702,728
|
|
G |
Idh2 |
isocitrate dehydrogenase 2 (NADP+), mitochondrial |
multiple interactions increases abundance |
EXP |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Adenosine Diphosphate] |
CTD |
PMID:27469509 |
|
NCBI chr 7:80,094,845...80,118,608
Ensembl chr 7:80,094,846...80,115,392
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
EXP |
Adenosine Diphosphate results in increased expression of IL6 protein MRS 2211 inhibits the reaction [Adenosine Diphosphate results in increased expression of IL6 protein] |
CTD |
PMID:24849676 |
|
NCBI chr 5:30,013,114...30,019,975
Ensembl chr 5:30,013,114...30,019,981
|
|
G |
Itga2 |
integrin alpha 2 |
multiple interactions |
ISO |
ITGA2 gene SNP affects the susceptibility to [Aspirin co-treated with clopidogrel co-treated with Adenosine Diphosphate] |
CTD |
PMID:16214444 |
|
NCBI chr13:114,833,081...114,932,100
Ensembl chr13:114,833,081...114,932,100
|
|
G |
Itga2b |
integrin alpha 2b |
multiple interactions |
ISO |
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]] |
CTD |
PMID:18404433 |
|
NCBI chr11:102,453,297...102,469,883
Ensembl chr11:102,453,297...102,470,122
|
|
G |
Itgb1bp2 |
integrin beta 1 binding protein 2 |
multiple interactions |
EXP |
Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein]; Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to ITGB1BP2 protein]; Calcium promotes the reaction [Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]] |
CTD |
PMID:23184943 |
|
NCBI chr X:101,449,088...101,466,122
Ensembl chr X:101,449,088...101,453,541
|
|
G |
Itgb3 |
integrin beta 3 |
multiple interactions |
ISO |
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]] |
CTD |
PMID:18404433 |
|
NCBI chr11:104,608,000...104,670,476
Ensembl chr11:104,608,000...104,670,476
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
increases phosphorylation |
ISO |
Adenosine Diphosphate results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:15034929 |
|
NCBI chr16:16,983,382...17,047,453
Ensembl chr16:16,983,382...17,047,453
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
increases phosphorylation |
ISO |
Adenosine Diphosphate results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:15034929 |
|
NCBI chr 7:126,759,626...126,765,816
Ensembl chr 7:126,759,601...126,765,819
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
Dicumarol inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:24466103 |
|
NCBI chr14:33,377,898...33,447,353
Ensembl chr14:33,377,898...33,447,158
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
Dicumarol inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:24466103 |
|
NCBI chr11:49,846,728...49,886,421
Ensembl chr11:49,846,751...49,886,421
|
|
G |
Mertk |
MER proto-oncogene tyrosine kinase |
increases response to substance |
ISO |
MERTK protein results in increased susceptibility to Adenosine Diphosphate |
CTD |
PMID:15733062 |
|
NCBI chr 2:128,698,915...128,803,162
Ensembl chr 2:128,698,956...128,802,894
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
EXP |
NOS2 protein affects the susceptibility to [Phenylephrine co-treated with Adenosine Diphosphate] |
CTD |
PMID:11498454 |
|
NCBI chr11:78,920,787...78,960,226
Ensembl chr11:78,920,787...78,960,254
|
|
G |
Nt5e |
5' nucleotidase, ecto |
decreases activity |
ISO |
Adenosine Diphosphate analog results in decreased activity of NT5E protein |
CTD |
PMID:18404487 |
|
NCBI chr 9:88,327,609...88,372,089
Ensembl chr 9:88,327,197...88,372,092
|
|
G |
P2ry12 |
purinergic receptor P2Y, G-protein coupled 12 |
affects response to substance increases response to substance multiple interactions |
ISO EXP |
P2RY12 gene polymorphism affects the susceptibility to Adenosine Diphosphate; P2RY12 protein affects the susceptibility to Adenosine Diphosphate P2RY12 protein results in increased susceptibility to Adenosine Diphosphate Epinephrine inhibits the reaction [P2RY12 gene mutant form results in decreased susceptibility to Adenosine Diphosphate] P2RY12 protein affects the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein] |
CTD |
PMID:11196645 PMID:11413167 PMID:18404433 PMID:23849096 |
|
NCBI chr 3:59,216,271...59,262,985
Ensembl chr 3:59,216,272...59,262,871
|
|
G |
Pdgfb |
platelet derived growth factor, B polypeptide |
increases secretion multiple interactions |
ISO |
Adenosine Diphosphate results in increased secretion of PDGFB protein Aspirin promotes the reaction [Adenosine Diphosphate results in increased secretion of PDGFB protein] |
CTD |
PMID:17303692 |
|
NCBI chr15:79,995,865...80,024,614
Ensembl chr15:79,995,874...80,014,977
|
|
G |
Pf4 |
platelet factor 4 |
increases secretion |
ISO |
Adenosine Diphosphate results in increased secretion of PF4 protein |
CTD |
PMID:19428933 |
|
NCBI chr 5:90,772,435...90,773,383
Ensembl chr 5:90,772,435...90,773,383
|
|
G |
Pfkm |
phosphofructokinase, muscle |
multiple interactions |
ISO |
Adenosine Diphosphate inhibits the reaction [resveratrol results in decreased activity of PFKM protein] |
CTD |
PMID:23454376 |
|
NCBI chr15:98,092,589...98,132,447
Ensembl chr15:98,092,589...98,132,451
|
|
G |
Pgp |
phosphoglycolate phosphatase |
decreases phosphorylation |
EXP |
PGP protein results in decreased phosphorylation of Adenosine Diphosphate |
CTD |
PMID:24338473 |
|
NCBI chr17:24,470,426...24,473,110
Ensembl chr17:24,470,392...24,473,110
|
|
G |
Ppbp |
pro-platelet basic protein |
increases secretion |
ISO |
Adenosine Diphosphate results in increased secretion of PPBP protein |
CTD |
PMID:19428933 |
|
NCBI chr 5:90,768,518...90,770,063
Ensembl chr 5:90,768,518...90,770,063
|
|
G |
Ppp5c |
protein phosphatase 5, catalytic subunit |
multiple interactions |
ISO |
Adenosine Diphosphate binds to and affects the folding of PPP5C protein |
CTD |
PMID:23184943 |
|
NCBI chr 7:17,004,640...17,027,914
Ensembl chr 7:17,004,640...17,027,924
|
|
G |
Ptpn1 |
protein tyrosine phosphatase, non-receptor type 1 |
increases glutathionylation multiple interactions |
ISO |
Adenosine Diphosphate results in increased glutathionylation of PTPN1 protein CAT protein inhibits the reaction [Adenosine Diphosphate results in increased glutathionylation of PTPN1 protein] |
CTD |
PMID:16781456 |
|
NCBI chr 2:167,930,750...167,979,385
Ensembl chr 2:167,932,057...167,979,385
|
|
G |
Selp |
selectin, platelet |
multiple interactions increases expression |
ISO |
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; CYP2C19 gene SNP affects the reaction [Adenosine Diphosphate results in increased expression of SELP protein]; Heparin promotes the reaction [Adenosine Diphosphate affects the localization of SELP protein]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]]; P2RY12 protein affects the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; Quercetin inhibits the reaction [Adenosine Diphosphate results in increased expression of SELP protein] |
CTD |
PMID:9740346 PMID:18394438 PMID:18404433 PMID:23249183 |
|
NCBI chr 1:164,115,264...164,150,026
Ensembl chr 1:164,115,264...164,150,026
|
|
G |
Sirt3 |
sirtuin 3 |
decreases abundance |
EXP |
SIRT3 protein results in decreased abundance of Adenosine Diphosphate |
CTD |
PMID:23166782 |
|
NCBI chr 7:140,863,663...140,882,309
Ensembl chr 7:140,863,666...140,882,309
|
|
G |
Taldo1 |
transaldolase 1 |
increases abundance |
EXP |
TALDO1 gene mutant form results in increased abundance of Adenosine Diphosphate |
CTD |
PMID:19436114 |
|
NCBI chr 7:141,392,160...141,402,976
Ensembl chr 7:141,392,199...141,402,968
|
|
G |
Thbs1 |
thrombospondin 1 |
increases secretion |
ISO |
Adenosine Diphosphate results in increased secretion of THBS1 protein |
CTD |
PMID:17303692 |
|
NCBI chr 2:118,111,876...118,127,133
Ensembl chr 2:118,111,876...118,127,133
|
|
G |
Tyro3 |
TYRO3 protein tyrosine kinase 3 |
increases response to substance |
ISO |
TYRO3 protein results in increased susceptibility to Adenosine Diphosphate |
CTD |
PMID:15733062 |
|
NCBI chr 2:119,797,740...119,818,104
Ensembl chr 2:119,797,733...119,818,104
|
|
G |
Vasp |
vasodilator-stimulated phosphoprotein |
multiple interactions increases phosphorylation |
ISO |
N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of VASP protein] |
CTD |
PMID:25329809 |
|
NCBI chr 7:19,256,929...19,271,854
Ensembl chr 7:19,256,929...19,271,817
|
|
|
G |
Adprh |
ADP-ribosylarginine hydrolase |
increases hydrolysis |
ISO |
ADPRH protein results in increased hydrolysis of Adenosine Diphosphate Ribose metabolite |
CTD |
PMID:21498885 |
|
NCBI chr16:38,445,399...38,452,689
Ensembl chr16:38,444,030...38,452,703
|
|
G |
Adprs |
ADP-ribosylserine hydrolase |
increases hydrolysis multiple interactions |
ISO |
ADPRS protein results in increased hydrolysis of Adenosine Diphosphate Ribose metabolite Adenosine Diphosphate Ribose inhibits the reaction [ADPRS protein results in increased hydrolysis of O-Acetyl-ADP-Ribose] |
CTD |
PMID:21498885 |
|
NCBI chr 4:126,316,351...126,321,703
Ensembl chr 4:126,316,047...126,321,703
|
|
G |
Nos1 |
nitric oxide synthase 1, neuronal |
multiple interactions |
EXP |
NOS1 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased ribosylation of Adenosine Diphosphate Ribose] |
CTD |
PMID:10318960 |
|
NCBI chr 5:117,866,839...117,958,840
Ensembl chr 5:117,781,032...117,958,840
|
|
G |
Trpm2 |
transient receptor potential cation channel, subfamily M, member 2 |
multiple interactions increases activity |
ISO EXP |
Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]; Clotrimazole inhibits the reaction [Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]]; Flufenamic Acid inhibits the reaction [Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]] Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein 2-aminoethoxydiphenyl borate inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Copper Sulfate inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; ferrous chloride inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; lead nitrate inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Mercuric Chloride inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Miconazole inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Selenium Oxides inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein] TRPM2 protein promotes the reaction [Adenosine Diphosphate Ribose results in increased uptake of Calcium] |
CTD |
PMID:18204483 PMID:20878536 PMID:21900507 PMID:22750002 |
|
NCBI chr10:77,907,722...77,969,909
Ensembl chr10:77,907,722...77,970,563
|
|
|
G |
Ahr |
aryl-hydrocarbon receptor |
multiple interactions |
ISO |
Adenylyl Imidodiphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein] |
CTD |
PMID:1848756 |
|
NCBI chr12:35,497,979...35,534,989
Ensembl chr12:35,497,974...35,535,038
|
|
G |
Cftr |
cystic fibrosis transmembrane conductance regulator |
affects activity |
ISO |
Adenylyl Imidodiphosphate affects the activity of CFTR protein |
CTD |
PMID:15657297 |
|
NCBI chr 6:18,170,687...18,322,770
Ensembl chr 6:18,170,687...18,322,768
|
|
G |
Ptgdr |
prostaglandin D receptor |
multiple interactions |
ISO |
Adenylyl Imidodiphosphate inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] |
CTD |
PMID:9579725 |
|
NCBI chr14:44,851,235...44,859,375
Ensembl chr14:44,851,235...44,859,375
|
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
arachidonyl-coenzyme A binds to and results in increased activity of PPARA protein |
CTD |
PMID:11139385 |
|
NCBI chr15:85,734,910...85,806,851
Ensembl chr15:85,734,983...85,802,819
|
|
|
G |
Abca8b |
ATP-binding cassette, sub-family A (ABC1), member 8b |
multiple interactions |
ISO |
Adenosine Triphosphate affects the reaction [ABCA8 protein results in increased uptake of estradiol-17 beta-glucuronide] |
CTD |
PMID:12379217 |
|
NCBI chr11:109,932,206...109,996,274
Ensembl chr11:109,932,190...109,995,845
|
|
G |
Abcb11 |
ATP-binding cassette, sub-family B (MDR/TAP), member 11 |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [ABCB11 protein results in increased uptake of fexofenadine] |
CTD |
PMID:18245269 |
|
NCBI chr 2:69,238,282...69,342,616
Ensembl chr 2:69,238,282...69,342,616
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
multiple interactions increases hydrolysis |
ISO |
[Cobalt results in increased activity of ABCB1 protein] which results in increased hydrolysis of Adenosine Triphosphate; [Magnesium results in increased activity of ABCB1 protein] which results in increased hydrolysis of Adenosine Triphosphate; [Manganese results in increased activity of ABCB1 protein] which results in increased hydrolysis of Adenosine Triphosphate; ABCB1 protein binds to and results in increased hydrolysis of Adenosine Triphosphate; aurapten promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; crizotinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; Disulfiram affects the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; lapatinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; nobiletin promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate] [Rifampin metabolite results in decreased activity of ABCB1A protein] which results in decreased abundance of Adenosine Triphosphate |
CTD |
PMID:2900677 PMID:14978246 PMID:18829547 PMID:18955043 PMID:22233293 PMID:23685082 |
|
NCBI chr 5:8,567,091...8,748,575
Ensembl chr 5:8,660,077...8,748,575
|
|
G |
Abcc1 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 |
multiple interactions affects activity increases hydrolysis affects binding |
ISO EXP |
[Adenosine Triphosphate affects the activity of ABCC1 protein] which results in increased transport of Acetaminophen metabolite; ABCC1 protein binds to and results in increased degradation of Adenosine Triphosphate; ABCC1 protein binds to and results in increased hydrolysis of Adenosine Triphosphate; ABCC1 protein mutant form binds to and results in increased hydrolysis of Adenosine Triphosphate; Adenosine Triphosphate binds to and affects the folding of ABCC1 protein; Adenosine Triphosphate promotes the reaction [ABCC1 protein affects the transport of Bilirubin]; Adenosine Triphosphate promotes the reaction [ABCC1 protein affects the transport of estradiol-17 beta-glucuronide]; Adenosine Triphosphate promotes the reaction [ABCC1 protein affects the transport of Leukotriene C4]; daidzein promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Disulfiram affects the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; hesperetin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; naringenin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; nobiletin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Quercetin affects the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Resveratrol promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Silymarin inhibits the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate] Daunorubicin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Vanadates inhibits the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate] Adenosine Triphosphate binds to ABCC1 protein |
CTD |
PMID:10856430 PMID:11278000 PMID:14978246 PMID:15245331 PMID:15355964 PMID:15459206 PMID:15737336 PMID:15838832 PMID:16156793 PMID:18336795 PMID:18955043 PMID:32472168 |
|
NCBI chr16:14,361,453...14,474,878
Ensembl chr16:14,361,558...14,475,737
|
|
G |
Abcc2 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 |
multiple interactions affects activity affects metabolic processing |
ISO EXP |
Adenosine Triphosphate promotes the reaction [ABCC2 protein results in increased secretion of Fluo-3]; Adenosine Triphosphate promotes the reaction [ABCC2 protein results in increased transport of temocaprilat] Adenosine Triphosphate affects the activity of ABCC2 protein [Adenosine Triphosphate affects the activity of ABCC2 protein] which results in increased transport of Acetaminophen metabolite; [Adenosine Triphosphate co-treated with ABCC2 protein] results in increased uptake of estradiol-17 beta-glucuronide; Adenosine Triphosphate affects the reaction [ABCC2 protein results in increased transport of Mercury]; verlukast inhibits the reaction [[Adenosine Triphosphate co-treated with ABCC2 protein] results in increased uptake of estradiol-17 beta-glucuronide] ABCC2 protein affects the metabolism of Adenosine Triphosphate Adenosine Triphosphate promotes the reaction [ABCC2 protein results in increased transport of S-1,2-dichlorovinyl-N-acetylcysteine] |
CTD |
PMID:9067317 PMID:9794919 PMID:20060011 PMID:22027652 PMID:24039982 PMID:32003934 PMID:32472168 |
|
NCBI chr19:43,782,308...43,838,332
Ensembl chr19:43,782,192...43,840,740
|
|
G |
Abcc3 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 3 |
multiple interactions |
EXP |
Adenosine Triphosphate promotes the reaction [ABCC3 protein affects the transport of fexofenadine] |
CTD |
PMID:18245269 |
|
NCBI chr11:94,343,295...94,393,017
Ensembl chr11:94,343,295...94,392,997
|
|
G |
Abcc4 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 4 |
multiple interactions affects activity increases hydrolysis |
ISO |
[Adenosine Triphosphate affects the activity of ABCC4 protein] which results in increased transport of Acetaminophen metabolite; ABCC4 protein binds to and results in increased hydrolysis of Adenosine Triphosphate; daidzein promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Disulfiram inhibits the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; hesperetin promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; naringenin promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Quercetin affects the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Quercetin inhibits the reaction [Alprostadil promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]]; Resveratrol promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Silymarin inhibits the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Silymarin inhibits the reaction [Alprostadil promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]] |
CTD |
PMID:14978246 PMID:16156793 PMID:32472168 |
|
NCBI chr14:118,482,692...118,707,856
Ensembl chr14:118,482,692...118,706,219
|
|
G |
Abcc6 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 6 |
affects binding |
ISO |
Adenosine Triphosphate binds to ABCC6 protein |
CTD |
PMID:11880368 |
|
NCBI chr 7:45,974,110...46,030,491
Ensembl chr 7:45,967,555...46,030,302
|
|
G |
Abcc8 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 8 |
multiple interactions |
ISO |
Adenosine Triphosphate deficiency inhibits the reaction [Estradiol inhibits the reaction [Glyburide binds to ABCC8 protein]] |
CTD |
PMID:19095654 |
|
NCBI chr 7:46,104,523...46,180,039
Ensembl chr 7:46,104,523...46,180,033
|
|
G |
Abcc9 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 9 |
multiple interactions |
ISO EXP |
Adenosine Triphosphate results in decreased activity of [KCNJ8 protein binds to ABCC9 protein] Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]] |
CTD |
PMID:11390963 PMID:28842488 |
|
NCBI chr 6:142,587,862...142,702,766
Ensembl chr 6:142,587,862...142,702,315
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 (Junior blood group) |
increases hydrolysis multiple interactions |
ISO |
ABCG2 protein results in increased hydrolysis of Adenosine Triphosphate [Adenosine Triphosphate co-treated with ABCG2 protein] results in increased uptake of estrone sulfate; Lapatinib promotes the reaction [ABCG2 protein results in increased hydrolysis of Adenosine Triphosphate]; Sulfasalazine inhibits the reaction [[Adenosine Triphosphate co-treated with ABCG2 protein] results in increased uptake of estrone sulfate] |
CTD |
PMID:18829547 PMID:32003934 |
|
NCBI chr 6:58,584,491...58,692,451
Ensembl chr 6:58,584,523...58,695,676
|
|
G |
Abl1 |
c-abl oncogene 1, non-receptor tyrosine kinase |
multiple interactions |
ISO |
[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; sorafenib inhibits the reaction [[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein] |
CTD |
PMID:19366808 |
|
NCBI chr 2:31,688,244...31,807,093
Ensembl chr 2:31,688,376...31,804,227
|
|
G |
Adcyap1 |
adenylate cyclase activating polypeptide 1 |
increases secretion |
ISO |
ADCYAP1 protein results in increased secretion of Adenosine Triphosphate |
CTD |
PMID:18563302 |
|
NCBI chr17:93,198,245...93,206,541
Ensembl chr17:93,199,017...93,206,537
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
decreases expression multiple interactions |
ISO |
Adenosine Triphosphate results in decreased expression of AGTR1A mRNA Adenosine Triphosphate results in decreased expression of and results in decreased activity of AGTR1A protein; ARRB2 protein affects the reaction [Adenosine Triphosphate results in decreased activity of AGTR1A protein]; CABIN1 protein inhibits the reaction [Adenosine Triphosphate results in decreased expression of and results in decreased activity of AGTR1A protein]; Cyclosporine inhibits the reaction [Adenosine Triphosphate results in decreased expression of AGTR1A mRNA]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Adenosine Triphosphate results in decreased expression of AGTR1A mRNA]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Adenosine Triphosphate results in decreased expression of AGTR1A protein] |
CTD |
PMID:21464294 |
|
NCBI chr13:30,336,356...30,382,867
Ensembl chr13:30,336,441...30,382,867
|
|
G |
Ahr |
aryl-hydrocarbon receptor |
multiple interactions |
ISO |
Adenosine Triphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein] |
CTD |
PMID:1848756 |
|
NCBI chr12:35,497,979...35,534,989
Ensembl chr12:35,497,974...35,535,038
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
decreases activity multiple interactions |
ISO |
Adenosine Triphosphate results in decreased activity of AKT1 protein Alcohols inhibits the reaction [Adenosine Triphosphate results in decreased activity of AKT1 protein] |
CTD |
PMID:24300283 |
|
NCBI chr12:112,653,821...112,674,884
Ensembl chr12:112,653,821...112,674,884
|
|
G |
Aldh5a1 |
aldhehyde dehydrogenase family 5, subfamily A1 |
increases abundance |
EXP |
ALDH5A1 gene mutant form results in increased abundance of Adenosine Triphosphate |
CTD |
PMID:29031482 |
|
NCBI chr13:24,907,579...24,937,661
Ensembl chr13:24,907,579...24,937,661
|
|
G |
Alk |
anaplastic lymphoma kinase |
affects binding multiple interactions |
ISO |
ALK protein binds to Adenosine Triphosphate [ALK protein mutant form promotes the reaction [ALK protein binds to Adenosine Triphosphate]] which results in decreased susceptibility to crizotinib; ALK protein mutant form promotes the reaction [ALK protein binds to Adenosine Triphosphate] |
CTD |
PMID:22072639 |
|
NCBI chr17:71,868,988...72,604,702
Ensembl chr17:71,868,972...72,604,627
|
|
G |
Alpl |
alkaline phosphatase, liver/bone/kidney |
multiple interactions increases response to substance |
EXP |
ALPL gene mutant form promotes the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA] ALPL gene mutant form results in increased susceptibility to Adenosine Triphosphate |
CTD |
PMID:27466191 |
|
NCBI chr 4:137,741,731...137,796,384
Ensembl chr 4:137,741,733...137,796,384
|
|
G |
Anxa1 |
annexin A1 |
multiple interactions |
ISO |
[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein; arsenite affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein]; Cadmium affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein]; chromium hexavalent ion affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein]; Lead affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein] |
CTD |
PMID:20655937 |
|
NCBI chr19:20,373,434...20,390,671
Ensembl chr19:20,373,428...20,390,944
|
|
G |
App |
amyloid beta (A4) precursor protein |
multiple interactions increases secretion |
ISO |
Adenosine Triphosphate inhibits the reaction [Hydrogen Peroxide results in decreased secretion of APP protein modified form]; Adenosine Triphosphate inhibits the reaction [Rotenone results in decreased secretion of APP protein modified form]; Rotenone inhibits the reaction [Adenosine Triphosphate results in increased secretion of APP protein modified form]; Sodium Azide inhibits the reaction [Adenosine Triphosphate results in increased secretion of APP protein modified form] |
CTD |
PMID:22906069 |
|
NCBI chr16:84,952,666...85,175,255
Ensembl chr16:84,949,685...85,173,766
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]]; ARRB2 protein affects the reaction [Adenosine Triphosphate results in decreased activity of AGTR1A protein] |
CTD |
PMID:21464294 |
|
NCBI chr11:70,432,485...70,440,828
Ensembl chr11:70,432,635...70,440,828
|
|
G |
Asic1 |
acid-sensing (proton-gated) ion channel 1 |
multiple interactions |
ISO |
[Acids binds to and affects the activity of ASIC1 protein] which results in increased secretion of Adenosine Triphosphate |
CTD |
PMID:19860742 |
|
NCBI chr15:99,670,197...99,701,130
Ensembl chr15:99,670,368...99,701,130
|
|
G |
Asic2 |
acid-sensing (proton-gated) ion channel 2 |
multiple interactions |
ISO |
[Acids binds to and affects the activity of ASIC2 protein] which results in increased secretion of Adenosine Triphosphate |
CTD |
PMID:19860742 |
|
NCBI chr11:80,880,163...81,968,396
Ensembl chr11:80,880,169...81,968,457
|
|
G |
Asic3 |
acid-sensing (proton-gated) ion channel 3 |
multiple interactions |
ISO |
[Acids binds to and affects the activity of ASIC3 protein] which results in increased secretion of Adenosine Triphosphate |
CTD |
PMID:19860742 |
|
NCBI chr 5:24,413,451...24,417,840
Ensembl chr 5:24,413,392...24,417,835
|
|
G |
Atp7a |
ATPase, Cu++ transporting, alpha polypeptide |
multiple interactions |
ISO |
[Copper co-treated with Adenosine Triphosphate] results in increased phosphorylation of ATP7A protein |
CTD |
PMID:20964302 |
|
NCBI chr X:106,027,224...106,128,161
Ensembl chr X:106,027,276...106,124,926
|
|
G |
Atp7b |
ATPase, Cu++ transporting, beta polypeptide |
multiple interactions increases phosphorylation |
ISO |
[Copper co-treated with Adenosine Triphosphate] results in increased phosphorylation of ATP7B protein Adenosine Triphosphate results in increased phosphorylation of ATP7B protein |
CTD |
PMID:19405516 PMID:20964302 |
|
NCBI chr 8:21,992,783...22,060,074
Ensembl chr 8:21,992,785...22,060,305
|
|
G |
Atp8b1 |
ATPase, class I, type 8B, member 1 |
increases hydrolysis |
ISO |
ATP8B1 protein results in increased hydrolysis of Adenosine Triphosphate |
CTD |
PMID:11584374 |
|
NCBI chr18:64,528,979...64,661,272
Ensembl chr18:64,528,967...64,661,267
|
|
G |
Avp |
arginine vasopressin |
multiple interactions increases secretion |
ISO |
Adenosine Triphosphate promotes the reaction [Phenylephrine results in increased secretion of AVP protein]; bisindolylmaleimide I inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]; Dactinomycin inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased secretion of AVP protein] |
CTD |
PMID:11102496 |
|
NCBI chr 2:130,580,620...130,582,588
Ensembl chr 2:130,580,620...130,582,554
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions |
ISO |
[Adenosine Triphosphate binds to P2RY11 protein] which results in decreased expression of BCL2 protein |
CTD |
PMID:21503959 |
|
NCBI chr 1:106,538,176...106,714,290
Ensembl chr 1:106,538,178...106,714,274
|
|
G |
Bcr |
BCR activator of RhoGEF and GTPase |
multiple interactions |
ISO |
[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; sorafenib inhibits the reaction [[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein] |
CTD |
PMID:19366808 |
|
NCBI chr10:75,060,560...75,184,923
Ensembl chr10:75,060,592...75,184,921
|
|
G |
Cabin1 |
calcineurin binding protein 1 |
multiple interactions |
ISO |
CABIN1 protein inhibits the reaction [Adenosine Triphosphate results in decreased expression of and results in decreased activity of AGTR1A protein] |
CTD |
PMID:21464294 |
|
NCBI chr10:75,646,110...75,764,357
Ensembl chr10:75,646,112...75,764,341
|
|
G |
Calca |
calcitonin/calcitonin-related polypeptide, alpha |
increases secretion multiple interactions |
ISO |
Adenosine Triphosphate results in increased secretion of CALCA protein Adenosine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein]; Flurbiprofen inhibits the reaction [Adenosine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein]]; Suramin inhibits the reaction [Adenosine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein]] |
CTD |
PMID:12044622 |
|
NCBI chr 7:114,625,981...114,636,910
Ensembl chr 7:114,631,478...114,636,357
|
|
G |
Casp1 |
caspase 1 |
increases activity multiple interactions |
ISO EXP |
Adenosine Triphosphate results in increased activity of CASP1 mRNA; Adenosine Triphosphate results in increased activity of CASP1 protein [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP1 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein; fraxinellone inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; KN 62 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP1 mRNA]; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP1 protein] [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [PML protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein; Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP1 protein]; Arsenic Trioxide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein] |
CTD |
PMID:18604214 PMID:19130485 PMID:21832250 PMID:23430110 PMID:24149798 PMID:25288807 PMID:25448682 PMID:26431797 PMID:26586371 |
|
NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290
|
|
G |
Casp3 |
caspase 3 |
increases expression multiple interactions |
ISO |
Adenosine Triphosphate results in increased expression of CASP3 Suramin inhibits the reaction [Adenosine Triphosphate results in increased expression of CASP3] |
CTD |
PMID:19448140 |
|
NCBI chr 8:46,617,291...46,639,698
Ensembl chr 8:46,617,291...46,639,689
|
|
G |
Casp4 |
caspase 4, apoptosis-related cysteine peptidase |
multiple interactions |
ISO EXP |
[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP4 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP4 protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP4 mRNA]; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP4 protein] Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP4 protein] |
CTD |
PMID:24149798 PMID:25288807 |
|
NCBI chr 9:5,308,849...5,336,791
Ensembl chr 9:5,308,828...5,336,783
|
|
G |
Cat |
catalase |
increases expression |
ISO |
Adenosine Triphosphate results in increased expression of CAT mRNA |
CTD |
PMID:22129738 |
|
NCBI chr 2:103,453,904...103,485,153
Ensembl chr 2:103,453,849...103,485,160
|
|
G |
Ccl3 |
chemokine (C-C motif) ligand 3 |
increases secretion multiple interactions |
EXP |
Adenosine Triphosphate results in increased secretion of CCL3 protein azetidine inhibits the reaction [Adenosine Triphosphate results in increased secretion of CCL3 protein] |
CTD |
PMID:26522449 |
|
NCBI chr11:83,647,843...83,649,378
Ensembl chr11:83,647,844...83,649,355
|
|
G |
Cftr |
cystic fibrosis transmembrane conductance regulator |
multiple interactions |
ISO |
3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone inhibits the reaction [Adenosine Triphosphate promotes the reaction [CFTR protein results in increased export of Chlorides]]; [Phosphatidylinositol 4,5-Diphosphate co-treated with Adenosine Triphosphate] results in increased activity of CFTR protein; Adenosine Triphosphate affects the reaction [Curcumin results in increased activity of CFTR protein mutant form]; Adenosine Triphosphate binds to and results in increased activity of CFTR protein; Adenosine Triphosphate promotes the reaction [CFTR protein results in increased export of Chlorides] |
CTD |
PMID:14710196 PMID:15623556 PMID:17178710 PMID:20675434 |
|
NCBI chr 6:18,170,687...18,322,770
Ensembl chr 6:18,170,687...18,322,768
|
|
G |
Chordc1 |
cysteine and histidine-rich domain (CHORD)-containing, zinc-binding protein 1 |
multiple interactions |
ISO EXP |
Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to PPP5C protein]; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to SUGT1 protein] Adenosine Triphosphate binds to and affects the folding of CHORDC1 protein; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to CHORDC1 protein]; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to HSP90AA1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein] |
CTD |
PMID:23184943 |
|
NCBI chr 9:18,292,267...18,314,000
Ensembl chr 9:18,292,125...18,317,442
|
|
G |
Comt |
catechol-O-methyltransferase |
multiple interactions |
ISO |
[Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased activity of COMT protein] which results in decreased abundance of Adenosine Triphosphate; [tolcapone results in decreased activity of COMT protein] which results in decreased abundance of Adenosine Triphosphate |
CTD |
PMID:14975680 |
|
NCBI chr16:18,406,882...18,426,716
Ensembl chr16:18,406,886...18,426,852
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
multiple interactions |
ISO |
[Bezafibrate results in increased activity of CPT2 protein] which results in increased abundance of Adenosine Triphosphate; Carnitine promotes the reaction [[Bezafibrate results in increased activity of CPT2 protein] which results in increased abundance of Adenosine Triphosphate] |
CTD |
PMID:21816645 |
|
NCBI chr 4:107,903,982...107,923,589
Ensembl chr 4:107,903,981...107,923,610
|
|
G |
Crkl |
v-crk avian sarcoma virus CT10 oncogene homolog-like |
multiple interactions |
ISO |
[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; [BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; sorafenib inhibits the reaction [[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]; sorafenib inhibits the reaction [[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein] |
CTD |
PMID:19366808 |
|
NCBI chr16:17,451,985...17,487,440
Ensembl chr16:17,451,987...17,487,434
|
|
G |
Csnk2a1 |
casein kinase 2, alpha 1 polypeptide |
multiple interactions affects binding |
ISO |
5-(3-chlorophenylamino)benzo(c)(2,6)naphthyridine-8-carboxylic acid inhibits the reaction [Adenosine Triphosphate binds to [CSNK2A1 protein binds to CSNK2A1 protein binds to CSNK2B protein binds to CSNK2B protein]] |
CTD |
PMID:21174434 |
|
NCBI chr 2:152,226,535...152,281,856
Ensembl chr 2:152,226,839...152,281,852
|
|
G |
Csnk2b |
casein kinase 2, beta polypeptide |
multiple interactions affects binding |
ISO |
5-(3-chlorophenylamino)benzo(c)(2,6)naphthyridine-8-carboxylic acid inhibits the reaction [Adenosine Triphosphate binds to [CSNK2A1 protein binds to CSNK2A1 protein binds to CSNK2B protein binds to CSNK2B protein]] |
CTD |
PMID:21174434 |
|
NCBI chr17:35,116,195...35,122,053
Ensembl chr17:35,116,196...35,122,053
|
|
G |
Cstb |
cystatin B |
multiple interactions |
EXP |
Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP1 protein]; Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP4 protein] |
CTD |
PMID:25288807 |
|
NCBI chr10:78,425,670...78,427,622
Ensembl chr10:78,425,669...78,427,622
|
|
G |
Ctsb |
cathepsin B |
increases activity multiple interactions |
EXP |
Adenosine Triphosphate results in increased activity of CTSB protein azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of CTSB protein] |
CTD |
PMID:26522449 |
|
NCBI chr14:63,122,462...63,145,923
Ensembl chr14:63,122,462...63,145,923
|
|
G |
Cxcl2 |
chemokine (C-X-C motif) ligand 2 |
increases secretion multiple interactions |
EXP |
Adenosine Triphosphate results in increased secretion of CXCL2 protein azetidine inhibits the reaction [Adenosine Triphosphate results in increased secretion of CXCL2 protein] |
CTD |
PMID:26522449 |
|
NCBI chr 5:90,903,899...90,905,938
Ensembl chr 5:90,903,871...90,905,938
|
|
G |
Dmd |
dystrophin, muscular dystrophy |
increases secretion multiple interactions |
EXP |
DMD gene mutant form results in increased secretion of Adenosine Triphosphate Nifedipine inhibits the reaction [DMD gene mutant form results in increased secretion of Adenosine Triphosphate] |
CTD |
PMID:24349043 |
|
NCBI chr X:82,814,664...85,205,050
Ensembl chr X:82,948,870...85,206,141
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions increases phosphorylation |
ISO |
sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased phosphorylation of EGFR protein] |
CTD |
PMID:26104857 |
|
NCBI chr11:16,752,203...16,913,907
Ensembl chr11:16,752,203...16,918,158
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions increases expression |
ISO |
Iodoacetates inhibits the reaction [Adenosine Triphosphate results in increased expression of EGR1 mRNA]; Potassium Cyanide inhibits the reaction [Adenosine Triphosphate results in increased expression of EGR1 mRNA]; Sodium Azide inhibits the reaction [Adenosine Triphosphate results in increased expression of EGR1 mRNA] |
CTD |
PMID:10723097 |
|
NCBI chr18:34,861,207...34,864,956
Ensembl chr18:34,859,823...34,864,984
|
|
G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [Toluene 2,4-Diisocyanate results in increased expression of ENPP2 protein] |
CTD |
PMID:26072274 |
|
NCBI chr15:54,838,901...54,952,789
Ensembl chr15:54,838,901...54,952,892
|
|
G |
Enpp7 |
ectonucleotide pyrophosphatase/phosphodiesterase 7 |
decreases activity |
ISO |
Adenosine Triphosphate results in decreased activity of ENPP7 protein |
CTD |
PMID:12885774 |
|
NCBI chr11:118,988,181...118,993,221
Ensembl chr11:118,988,188...118,993,221
|
|
G |
Ercc6 |
excision repair cross-complementing rodent repair deficiency, complementation group 6 |
decreases abundance multiple interactions |
EXP |
ERCC6 gene mutant form results in decreased abundance of Adenosine Triphosphate nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:25440059 |
|
NCBI chr14:32,513,291...32,580,990
Ensembl chr14:32,513,521...32,580,990
|
|
G |
F2 |
coagulation factor II |
multiple interactions increases transport increases abundance increases secretion |
ISO EXP |
calmidazolium affects the reaction [F2 protein results in increased secretion of Adenosine Triphosphate]; Fendiline affects the reaction [F2 protein results in increased secretion of Adenosine Triphosphate]; Quercetin inhibits the reaction [F2 protein results in increased abundance of Adenosine Triphosphate]; resveratrol inhibits the reaction [F2 protein results in increased abundance of Adenosine Triphosphate] STXBP2 protein affects the reaction [F2 protein results in increased transport of Adenosine Triphosphate] |
CTD |
PMID:2030746 PMID:15342215 PMID:30696774 |
|
NCBI chr 2:91,612,397...91,636,457
Ensembl chr 2:91,625,320...91,636,414
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions decreases abundance |
ISO |
FASN protein promotes the reaction [rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]]; Protein Kinase Inhibitors inhibits the reaction [FASN protein results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:26670611 |
|
NCBI chr11:120,805,958...120,825,166
Ensembl chr11:120,805,846...120,824,547
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
increases expression multiple interactions |
ISO EXP |
Adenosine Triphosphate results in increased expression of FOS mRNA ALPL gene mutant form promotes the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA] [Phenylephrine co-treated with Adenosine Triphosphate] results in increased expression of FOS mRNA; Glucose affects the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]; Iodoacetates inhibits the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]; Potassium Cyanide inhibits the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]; Sodium Azide inhibits the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA] |
CTD |
PMID:10723097 PMID:19463813 PMID:27466191 |
|
NCBI chr12:85,473,890...85,477,274
Ensembl chr12:85,473,890...85,477,273
|
|
G |
Fscn1 |
fascin actin-bundling protein 1 |
increases expression multiple interactions |
ISO EXP |
Adenosine Triphosphate results in increased expression of FSCN1 mRNA Niclosamide inhibits the reaction [Adenosine Triphosphate results in increased expression of FSCN1 mRNA] |
CTD |
PMID:29733962 |
|
NCBI chr 5:142,960,355...142,973,189
Ensembl chr 5:142,960,343...142,973,185
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions |
ISO |
Adenosine Triphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog] |
CTD |
PMID:15788719 |
|
NCBI chr 6:125,161,852...125,166,467
Ensembl chr 6:125,161,715...125,166,467
|
|
G |
Gh |
growth hormone |
multiple interactions increases secretion |
ISO |
NCS1 protein promotes the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]; oxophenylarsine inhibits the reaction [NCS1 protein promotes the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]] oxophenylarsine inhibits the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]; Phosphatidylinositol 4,5-Diphosphate affects the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein] |
CTD |
PMID:12471042 |
|
NCBI chr11:106,300,261...106,303,703
Ensembl chr11:106,300,271...106,301,865
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
increases export |
ISO |
GJA1 protein mutant form results in increased export of Adenosine Triphosphate; GJA1 protein results in increased export of Adenosine Triphosphate |
CTD |
PMID:17687502 |
|
NCBI chr10:56,377,300...56,390,419
Ensembl chr10:56,377,330...56,402,513
|
|
G |
Gm40318 |
predicted gene, 40318 |
increases expression |
ISO |
Adenosine Triphosphate results in increased expression of S100P mRNA |
CTD |
PMID:29733962 |
|
NCBI chr 5:36,762,504...36,767,419
Ensembl chr 5:36,762,617...36,766,695
|
|
G |
Gstp1 |
glutathione S-transferase, pi 1 |
multiple interactions |
ISO |
[GSTP1 protein co-treated with Glutathione] inhibits the reaction [[Adenosine Triphosphate results in increased metabolism of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased abundance of 2-amino-1-methyl-6-phenolimidazo(4,5-b)pyridine-DNA adduct]; [GSTP1 protein co-treated with Glutathione] inhibits the reaction [Adenosine Triphosphate results in increased activity of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine] |
CTD |
PMID:11196146 |
|
NCBI chr19:4,035,411...4,037,912
Ensembl chr19:4,035,407...4,037,985
|
|
G |
Hif1a |
hypoxia inducible factor 1, alpha subunit |
multiple interactions |
ISO |
Adenosine Triphosphate inhibits the reaction [protoporphyrin IX results in decreased activity of HIF1A protein] |
CTD |
PMID:23624237 |
|
NCBI chr12:73,901,324...73,947,554
Ensembl chr12:73,901,375...73,947,530
|
|
G |
Hmgb1 |
high mobility group box 1 |
affects chemical synthesis multiple interactions |
EXP |
HMGB1 protein affects the chemical synthesis of Adenosine Triphosphate Adenosine Triphosphate promotes the reaction [fullerene C60 results in increased secretion of HMGB1 protein]; Adenosine Triphosphate promotes the reaction [graphene oxide results in increased secretion of HMGB1 protein]; Adenosine Triphosphate promotes the reaction [Nanotubes, Carbon results in increased secretion of HMGB1 protein] |
CTD |
PMID:21641551 PMID:31504961 |
|
NCBI chr 5:149,046,702...149,053,057
Ensembl chr 5:149,046,702...149,184,489
|
|
G |
Hsp90aa1 |
heat shock protein 90, alpha (cytosolic), class A member 1 |
multiple interactions |
EXP |
Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to HSP90AA1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]] |
CTD |
PMID:23184943 |
|
NCBI chr12:110,691,036...110,696,395
Ensembl chr12:110,690,605...110,702,728
|
|
G |
Hspa5 |
heat shock protein 5 |
multiple interactions |
ISO |
[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 mRNA]; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 protein] |
CTD |
PMID:24149798 |
|
NCBI chr 2:34,772,090...34,776,529
Ensembl chr 2:34,771,970...34,777,547
|
|
G |
Hspb1 |
heat shock protein 1 |
affects chemical synthesis |
EXP |
HSPB1 protein affects the chemical synthesis of Adenosine Triphosphate |
CTD |
PMID:21641551 |
|
NCBI chr 5:135,887,919...135,889,563
Ensembl chr 5:135,887,919...135,889,563
|
|
G |
Hspd1 |
heat shock protein 1 (chaperonin) |
multiple interactions increases expression |
ISO |
bisindolylmaleimide I inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]; chelerythrine inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]; Neomycin inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]; Resveratrol inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]; tricyclodecane-9-yl-xanthogenate inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein] |
CTD |
PMID:16178011 |
|
NCBI chr 1:55,077,833...55,088,243
Ensembl chr 1:55,077,835...55,088,243
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
Adenosine Triphosphate inhibits the reaction [Fructose results in increased expression of ICAM1 protein] |
CTD |
PMID:18508964 |
|
NCBI chr 9:21,015,940...21,028,814
Ensembl chr 9:21,015,985...21,028,817
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
Adenosine Triphosphate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone] |
CTD |
PMID:14623498 |
|
NCBI chr10:118,441,046...118,445,894
Ensembl chr10:118,441,046...118,445,892
|
|
G |
Il12b |
interleukin 12b |
multiple interactions |
ISO |
Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B protein] |
CTD |
PMID:17707769 |
|
NCBI chr11:44,400,063...44,414,677
Ensembl chr11:44,400,063...44,414,033
|
|
G |
Il18 |
interleukin 18 |
multiple interactions increases secretion |
ISO EXP |
[Adenosine Triphosphate co-treated with K-12 lipopolysaccharide] results in increased secretion of IL18 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL18 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein; resveratrol promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 mRNA]; resveratrol promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein] Adenosine Triphosphate results in increased secretion of IL18 protein 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL18 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL18 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 mRNA; Acetylcysteine inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL18 protein]; diphenyleneiodonium inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL18 protein] |
CTD |
PMID:17404311 PMID:24149798 PMID:26431797 PMID:27311643 |
|
NCBI chr 9:50,554,700...50,581,841
Ensembl chr 9:50,554,827...50,581,840
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
EXP |
(N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1A protein]; (N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) inhibits the reaction [Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1A protein]]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1A protein; Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1A protein] |
CTD |
PMID:26068648 |
|
NCBI chr 2:129,299,609...129,310,186
Ensembl chr 2:129,299,610...129,309,972
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases secretion decreases abundance |
ISO EXP |
Enzyme Inhibitors inhibits the reaction [IL1B protein results in decreased abundance of Adenosine Triphosphate]; IL1B protein inhibits the reaction [Adenosine Triphosphate results in increased secretion of INS1 protein]; Quercetin inhibits the reaction [IL1B protein inhibits the reaction [Adenosine Triphosphate results in increased secretion of INS1 protein]] Adenosine Triphosphate results in increased secretion of IL1B protein (N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; (N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) inhibits the reaction [Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL1B protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased activity of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; Acetylcysteine inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL1B protein]; Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; Adenosine Triphosphate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone]; Adenosine Triphosphate promotes the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; Adenosine Triphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Arsenic Trioxide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; diphenyleneiodonium inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL1B protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; Okadaic Acid inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; PML protein promotes the reaction [[resiquimod co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; zinc chloride inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]] [Adenosine Triphosphate co-treated with K-12 lipopolysaccharide] results in increased secretion of IL1B protein modified form; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased cleavage of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; [Tetradecanoylphorbol Acetate co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; Adenosine Triphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Adenosine Triphosphate results in increased cleavage of and results in increased secretion of IL1B protein; Apigenin inhibits the reaction [Adenosine Triphosphate results in increased cleavage of and results in increased secretion of IL1B protein]; flavone analog inhibits the reaction [Adenosine Triphosphate results in increased cleavage of and results in increased secretion of IL1B protein]; KN 62 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein]; MitoTEMPO inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA]; Resveratrol promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; tyrosyl-valyl-alanyl-aspartic acid fluoromethyl ketone analog inhibits the reaction [Adenosine Triphosphate results in increased cleavage of and results in increased secretion of IL1B protein] |
CTD |
PMID:10365824 PMID:14623498 PMID:17404311 PMID:18604214 PMID:19130485 PMID:22221676 PMID:23430110 PMID:24149798 PMID:24158569 PMID:24685903 PMID:26068648 PMID:26086368 PMID:26431797 PMID:26586371 PMID:26968431 PMID:27311643 PMID:29960001 |
|
NCBI chr 2:129,364,569...129,371,164
Ensembl chr 2:129,364,570...129,371,139
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO EXP |
Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; NF157 compound inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]; sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]; Suramin inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein] Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]; coomassie Brilliant Blue inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; resveratrol inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; SB 203580 inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]] azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]; MRS 2211 inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein] |
CTD |
PMID:17707769 PMID:24793913 PMID:24849676 PMID:25348860 PMID:26104857 PMID:26522449 |
|
NCBI chr 5:30,013,114...30,019,975
Ensembl chr 5:30,013,114...30,019,981
|
|
G |
Ins1 |
insulin I |
multiple interactions |
EXP |
Adenosine Triphosphate inhibits the reaction [Glucose results in increased secretion of INS1 protein] |
CTD |
PMID:10535451 |
|
NCBI chr19:52,264,297...52,265,015
Ensembl chr19:52,264,297...52,265,476
|
|
G |
Ins2 |
insulin II |
multiple interactions |
ISO |
[ammonium ferrous sulfate results in increased activity of INS protein modified form] which results in increased secretion of Adenosine Triphosphate; [chromic chloride results in increased activity of INS protein modified form] which results in increased secretion of Adenosine Triphosphate; INS protein inhibits the reaction [Acetaminophen results in decreased abundance of Adenosine Triphosphate]; Mannose inhibits the reaction [[chromic chloride results in increased activity of INS protein modified form] which results in increased secretion of Adenosine Triphosphate]; Phloretin inhibits the reaction [[chromic chloride results in increased activity of INS protein modified form] which results in increased secretion of Adenosine Triphosphate] |
CTD |
PMID:17965850 PMID:26739624 |
|
NCBI chr 7:142,678,656...142,679,726
Ensembl chr 7:142,678,656...142,743,381
|
|
G |
Itgb1bp2 |
integrin beta 1 binding protein 2 |
multiple interactions |
ISO EXP |
Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to PPP5C protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]] Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to ITGB1BP2 protein]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]] |
CTD |
PMID:23184943 |
|
NCBI chr X:101,449,088...101,466,122
Ensembl chr X:101,449,088...101,453,541
|
|
G |
Jun |
jun proto-oncogene |
multiple interactions |
ISO |
[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of JUN protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of JUN protein] |
CTD |
PMID:24149798 |
|
NCBI chr 4:95,049,036...95,052,222
Ensembl chr 4:95,049,034...95,052,222
|
|
G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
decreases activity |
ISO |
Adenosine Triphosphate deficiency results in decreased activity of KCNH2 protein |
CTD |
PMID:12531891 |
|
NCBI chr 5:24,319,589...24,351,684
Ensembl chr 5:24,319,589...24,351,604
|
|
G |
Kcnj11 |
potassium inwardly rectifying channel, subfamily J, member 11 |
multiple interactions decreases response to substance |
EXP |
Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]] KCNJ11 protein mutant form results in decreased susceptibility to Adenosine Triphosphate |
CTD |
PMID:11390963 PMID:28842488 |
|
NCBI chr 7:46,097,123...46,100,952
Ensembl chr 7:46,093,953...46,100,764
|
|
G |
Kcnj15 |
potassium inwardly-rectifying channel, subfamily J, member 15 |
increases activity |
ISO |
Adenosine Triphosphate results in increased activity of KCNJ15 protein |
CTD |
PMID:15328350 |
|
NCBI chr16:95,257,558...95,300,260
Ensembl chr16:95,257,558...95,300,260
|
|
G |
Kcnj8 |
potassium inwardly-rectifying channel, subfamily J, member 8 |
decreases response to substance multiple interactions |
ISO |
KCNJ8 protein mutant form results in decreased susceptibility to Adenosine Triphosphate Adenosine Triphosphate results in decreased activity of [KCNJ8 protein binds to ABCC9 protein] |
CTD |
PMID:28842488 |
|
NCBI chr 6:142,564,837...142,571,614
Ensembl chr 6:142,564,837...142,571,614
|
|
G |
Khk |
ketohexokinase |
multiple interactions |
ISO |
KHK protein promotes the reaction [Fructose results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:19158351 |
|
NCBI chr 5:30,921,436...30,931,248
Ensembl chr 5:30,921,431...30,931,248
|
|
G |
Kif5a |
kinesin family member 5A |
multiple interactions increases hydrolysis |
ISO |
Adenosine Triphosphate inhibits the reaction [zinc chloride results in decreased activity of KIF5A protein]; Cadmium Chloride inhibits the reaction [KIF5A protein results in increased hydrolysis of Adenosine Triphosphate]; Egtazic Acid inhibits the reaction [Cadmium Chloride inhibits the reaction [KIF5A protein results in increased hydrolysis of Adenosine Triphosphate]] |
CTD |
PMID:24239783 PMID:28122263 |
|
NCBI chr10:127,225,695...127,266,348
Ensembl chr10:127,225,696...127,263,348
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
[[Glucose co-treated with INS1 protein] results in increased abundance of Adenosine Triphosphate] which results in increased secretion of LEP protein; [Deoxyglucose results in decreased abundance of Adenosine Triphosphate] which results in decreased secretion of LEP protein |
CTD |
PMID:10780946 |
|
NCBI chr 6:29,060,221...29,073,876
Ensembl chr 6:29,060,220...29,073,877
|
|
G |
Lipe |
lipase, hormone sensitive |
increases activity |
ISO |
Adenosine Triphosphate results in increased activity of LIPE protein |
CTD |
PMID:7155675 |
|
NCBI chr 7:25,379,527...25,398,486
Ensembl chr 7:25,379,527...25,398,710
|
|
G |
Lpl |
lipoprotein lipase |
affects response to substance |
ISO |
LPL protein affects the susceptibility to Adenosine Triphosphate |
CTD |
PMID:11786490 |
|
NCBI chr 8:68,880,555...68,906,932
Ensembl chr 8:68,880,491...68,907,448
|
|
G |
Map2k1 |
mitogen-activated protein kinase kinase 1 |
affects binding |
EXP |
Adenosine Triphosphate binds to MAP2K1 protein |
CTD |
PMID:17693661 |
|
NCBI chr 9:64,185,769...64,253,605
Ensembl chr 9:64,185,770...64,253,631
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions increases phosphorylation increases activity |
ISO EXP |
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK1 protein]; [Alcohols co-treated with Adenosine Triphosphate] results in increased activity of MAPK1 protein; Alcohols inhibits the reaction [Adenosine Triphosphate results in increased activity of MAPK1 protein]; sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK1 protein] azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:12513686 PMID:15034929 PMID:21503959 PMID:24300283 PMID:26104857 PMID:26522449 PMID:30502331 |
|
NCBI chr16:16,983,382...17,047,453
Ensembl chr16:16,983,382...17,047,453
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions increases phosphorylation increases activity |
ISO EXP |
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK3 protein]; [Alcohols co-treated with Adenosine Triphosphate] results in increased activity of MAPK3 protein; Alcohols inhibits the reaction [Adenosine Triphosphate results in increased activity of MAPK3 protein]; sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK3 protein] azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:12513686 PMID:15034929 PMID:21503959 PMID:24300283 PMID:26104857 PMID:26522449 PMID:30502331 |
|
NCBI chr 7:126,759,626...126,765,816
Ensembl chr 7:126,759,601...126,765,819
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
ISO |
[annonacin results in decreased abundance of Adenosine Triphosphate] which affects the localization of MAPT protein |
CTD |
PMID:17634376 |
|
NCBI chr11:104,229,409...104,332,090
Ensembl chr11:104,231,390...104,332,090
|
|
G |
Metrnl |
meteorin, glial cell differentiation regulator-like |
multiple interactions |
EXP |
METRNL protein inhibits the reaction [Dietary Fats results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:30213948 |
|
NCBI chr11:121,702,427...121,717,389
Ensembl chr11:121,701,544...121,716,306
|
|
G |
Mfn2 |
mitofusin 2 |
decreases response to substance multiple interactions increases chemical synthesis |
EXP ISO |
MFN2 results in decreased susceptibility to Adenosine Triphosphate deficiency MFN2 protein inhibits the reaction [TNF protein results in decreased chemical synthesis of Adenosine Triphosphate] MFN2 protein results in increased chemical synthesis of Adenosine Triphosphate MFN2 protein inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased chemical synthesis of Adenosine Triphosphate] |
CTD |
PMID:22292091 PMID:24898700 PMID:25416777 |
|
NCBI chr 4:147,873,586...147,904,909
Ensembl chr 4:147,873,599...147,904,704
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases activity increases secretion |
ISO EXP |
1,10-phenanthroline inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein]; SB 3CT compound inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein]; wortmannin inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein] azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of MMP9 protein] Adenosine Triphosphate results in increased secretion of MMP9 protein |
CTD |
PMID:20195827 PMID:26522449 |
|
NCBI chr 2:164,940,326...164,955,850
Ensembl chr 2:164,940,780...164,955,850
|
|
G |
mt-Atp6 |
ATP synthase 6, mitochondrial |
affects abundance |
ISO |
ATP6 protein affects the abundance of Adenosine Triphosphate |
CTD |
PMID:18273840 |
|
NCBI chr MT:7,927...8,607
Ensembl chr MT:7,927...8,607
|
|
G |
mt-Co3 |
cytochrome c oxidase III, mitochondrial |
increases abundance |
ISO |
COX3 protein results in increased abundance of Adenosine Triphosphate |
CTD |
PMID:17428446 |
|
NCBI chr MT:8,607...9,390
Ensembl chr MT:8,607...9,390
|
|
G |
Mvd |
mevalonate (diphospho) decarboxylase |
increases hydrolysis |
ISO |
MVD protein results in increased hydrolysis of Adenosine Triphosphate |
CTD |
PMID:9392419 |
|
NCBI chr 8:122,433,596...122,443,422
Ensembl chr 8:122,433,601...122,443,422
|
|
G |
Mvk |
mevalonate kinase |
multiple interactions increases hydrolysis |
ISO |
3,3-dimethylallyl pyrophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; dolichol monophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; Farnesol inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; farnesyl pyrophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; geranyl diphosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; geranylgeranyl pyrophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; isopentenyl pyrophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate] |
CTD |
PMID:9392419 |
|
NCBI chr 5:114,444,264...114,460,591
Ensembl chr 5:114,444,269...114,460,591
|
|
G |
Myh7 |
myosin, heavy polypeptide 7, cardiac muscle, beta |
increases abundance |
ISO |
MYH7 gene mutant form results in increased abundance of Adenosine Triphosphate |
CTD |
PMID:29741611 |
|
NCBI chr14:54,970,684...54,994,626
Ensembl chr14:54,970,684...54,994,626
|
|
G |
Nadsyn1 |
NAD synthetase 1 |
multiple interactions |
ISO |
[Ammonium Chloride co-treated with nicotinic acid adenine dinucleotide co-treated with Adenosine Triphosphate] results in increased activity of NADSYN1 protein; [NADSYN1 protein co-treated with Ammonium Chloride co-treated with nicotinic acid adenine dinucleotide co-treated with Adenosine Triphosphate] results in increased chemical synthesis of NAD |
CTD |
PMID:12547821 |
|
NCBI chr 7:143,795,589...143,822,862
Ensembl chr 7:143,795,584...143,822,849
|
|
G |
Ncs1 |
neuronal calcium sensor 1 |
multiple interactions increases response to substance |
ISO |
NCS1 protein promotes the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]; oxophenylarsine inhibits the reaction [NCS1 protein promotes the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]] NCS1 protein results in increased susceptibility to Adenosine Triphosphate |
CTD |
PMID:12471042 |
|
NCBI chr 2:31,245,708...31,295,989
Ensembl chr 2:31,245,823...31,295,989
|
|
G |
Nfatc1 |
nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1 |
affects localization multiple interactions |
ISO EXP |
Adenosine Triphosphate affects the localization of NFATC1 protein azetidine analog inhibits the reaction [Adenosine Triphosphate affects the localization of NFATC1 protein] |
CTD |
PMID:21464294 PMID:26522449 |
|
NCBI chr18:80,606,205...80,713,071
Ensembl chr18:80,606,205...80,713,071
|
|
G |
Nfatc3 |
nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 3 |
affects localization |
ISO |
Adenosine Triphosphate affects the localization of NFATC3 protein |
CTD |
PMID:21464294 |
|
NCBI chr 8:106,058,818...106,130,537
Ensembl chr 8:106,058,840...106,130,537
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]] [Adenosine Triphosphate co-treated with Lipopolysaccharides] affects the localization of NFKBIA protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] affects the localization of NFKBIA protein] |
CTD |
PMID:21464294 PMID:24149798 |
|
NCBI chr12:55,489,409...55,492,647
Ensembl chr12:55,489,410...55,492,647
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
ISO |
[NGF protein co-treated with Adenosine Triphosphate] results in increased uptake of Calcium |
CTD |
PMID:1374475 |
|
NCBI chr 3:102,469,919...102,521,013
Ensembl chr 3:102,469,919...102,521,013
|
|
G |
Nlrp1a |
NLR family, pyrin domain containing 1A |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Adenosine Triphosphate co-treated with resveratrol] results in increased expression of NLRP1 mRNA |
CTD |
PMID:24149798 |
|
NCBI chr11:71,091,197...71,144,969
Ensembl chr11:71,092,236...71,144,704
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO EXP |
[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased activity of NLRP3 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate co-treated with resveratrol] results in increased expression of NLRP3 mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein; KN 62 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein] [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PML protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]] |
CTD |
PMID:18604214 PMID:23430110 PMID:24149798 PMID:26086368 PMID:26586371 |
|
NCBI chr11:59,541,569...59,566,955
Ensembl chr11:59,541,568...59,566,956
|
|
G |
Nolc1 |
nucleolar and coiled-body phosphoprotein 1 |
multiple interactions |
ISO |
Adenosine Triphosphate affects the reaction [Doxorubicin binds to NOLC1 protein] |
CTD |
PMID:17129415 |
|
NCBI chr19:46,075,847...46,085,543
Ensembl chr19:46,075,863...46,085,530
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions increases expression |
ISO EXP |
NOS2 protein affects the reaction [Adenosine Triphosphate results in increased metabolism of RELA protein] azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of NOS2 protein] [Adenosine Triphosphate results in increased expression of NOS2 protein] promotes the reaction [NOS2 protein binds to RELA protein]; Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]]; Cyclosporine inhibits the reaction [[Adenosine Triphosphate results in increased expression of NOS2 protein] promotes the reaction [NOS2 protein binds to RELA protein]]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Adenosine Triphosphate results in increased expression of NOS2 protein]; NOS2 protein affects the reaction [Adenosine Triphosphate results in increased abundance of Nitric Oxide] |
CTD |
PMID:21464294 PMID:26522449 |
|
NCBI chr11:78,920,787...78,960,226
Ensembl chr11:78,920,787...78,960,254
|
|
G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
multiple interactions |
ISO |
Adenosine Triphosphate affects the reaction [Alcohols affects the phosphorylation of NOS3 protein]; Adenosine Triphosphate inhibits the reaction [Alcohols results in decreased expression of NOS3 protein] |
CTD |
PMID:24300283 |
|
NCBI chr 5:24,364,816...24,384,474
Ensembl chr 5:24,364,810...24,384,474
|
|
G |
Npy |
neuropeptide Y |
affects response to substance |
ISO |
NPY protein affects the susceptibility to Adenosine Triphosphate |
CTD |
PMID:15003356 |
|
NCBI chr 6:49,822,710...49,829,507
Ensembl chr 6:49,822,710...49,829,507
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
increases expression |
ISO |
Adenosine Triphosphate results in increased expression of NR4A1 mRNA |
CTD |
PMID:10723097 |
|
NCBI chr15:101,253,902...101,274,795
Ensembl chr15:101,254,269...101,274,795
|
|
G |
Oas1g |
2'-5' oligoadenylate synthetase 1G |
multiple interactions |
ISO |
[OAS1 protein results in increased metabolism of Adenosine Triphosphate] which results in increased chemical synthesis of 2',5'-oligoadenylate |
CTD |
PMID:15732009 |
|
NCBI chr 5:120,876,142...120,887,613
Ensembl chr 5:120,876,142...120,887,613
|
|
G |
Oxt |
oxytocin |
multiple interactions increases secretion |
ISO |
Adenosine Triphosphate promotes the reaction [Phenylephrine results in increased secretion of OXT protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of OXT protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased secretion of OXT protein] |
CTD |
PMID:11102496 |
|
NCBI chr 2:130,574,519...130,577,054
Ensembl chr 2:130,576,173...130,577,054
|
|
G |
P2rx1 |
purinergic receptor P2X, ligand-gated ion channel, 1 |
multiple interactions |
ISO |
geldanamycin promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX1]; herbimycin promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX1]; monorden promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX1] |
CTD |
PMID:11930156 |
|
NCBI chr11:72,999,056...73,015,200
Ensembl chr11:72,999,103...73,015,200
|
|
G |
P2rx2 |
purinergic receptor P2X, ligand-gated ion channel, 2 |
multiple interactions increases activity affects response to substance |
ISO EXP |
1-amino-4-(3-(4,6-dichloro(1,3,5)triazine-2-ylamino)phenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Acetylcysteine inhibits the reaction [Hydrogen Peroxide promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; Acetylcysteine inhibits the reaction [Rotenone promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; Cadmium Chloride affects the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; cobaltous chloride affects the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Copper promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; cupric chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Dithiothreitol inhibits the reaction [Hydrogen Peroxide promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; Hydrogen Peroxide promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Mercuric Chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Mercury promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; methyl methanethiosulfonate inhibits the reaction [Hydrogen Peroxide promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; methyl methanethiosulfonate inhibits the reaction [Mercury promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; myxothiazol promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; nickel chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; palladium chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Rotenone promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; zinc chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Zinc promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein] P2RX2 protein affects the susceptibility to Adenosine Triphosphate |
CTD |
PMID:15081800 PMID:16190872 PMID:19793987 PMID:21207957 |
|
NCBI chr 5:110,339,812...110,343,320
Ensembl chr 5:110,339,812...110,343,212
|
|
G |
P2rx3 |
purinergic receptor P2X, ligand-gated ion channel, 3 |
multiple interactions affects activity |
ISO |
Eugenol inhibits the reaction [P2RX3 protein affects the activity of Adenosine Triphosphate] |
CTD |
PMID:19967073 |
|
NCBI chr 2:84,996,549...85,037,108
Ensembl chr 2:84,998,583...85,037,462
|
|
G |
P2rx4 |
purinergic receptor P2X, ligand-gated ion channel 4 |
multiple interactions increases activity |
ISO EXP |
[Cadmium co-treated with Zinc] promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; [Mercury co-treated with Copper] inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Cadmium promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Cobalt promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Copper inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Copper inhibits the reaction [Zinc promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]]; Mercury inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Zinc promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein] 5-(3-bromophenyl)-1,3-dihydro-2H-benzofuro(3,2-e)-1,4-diazepin-2-one inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; [ginsenoside M1 co-treated with Adenosine Triphosphate] results in increased activity of P2RX4 protein; [Resveratrol co-treated with Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX4 mRNA; [Resveratrol co-treated with Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX4 protein; ginsenoside M1 promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; ginsenoside Rb1 promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; ginsenoside Rd promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Ivermectin promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein] |
CTD |
PMID:10737610 PMID:15629187 PMID:19793987 PMID:21638035 PMID:24149798 PMID:30545933 |
|
NCBI chr 5:122,707,518...122,729,739
Ensembl chr 5:122,707,544...122,729,738
|
|
G |
P2rx7 |
purinergic receptor P2X, ligand-gated ion channel, 7 |
multiple interactions increases expression decreases response to substance increases response to substance increases activity |
ISO EXP |
[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX7 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX7 protein; AZ10606120 inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein]; P2RX7 protein affects the reaction [Adenosine Triphosphate results in increased secretion of SELL protein]; P2RX7 protein affects the reaction [Adenosine Triphosphate results in increased transport of Barium]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX7 mRNA]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX7 protein] Adenosine Triphosphate results in increased expression of P2RX7 protein P2RX7 gene mutant form results in decreased susceptibility to Adenosine Triphosphate P2RX7 protein results in increased susceptibility to Adenosine Triphosphate 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein]; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of P2RX7 protein]; coomassie Brilliant Blue inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein] |
CTD |
PMID:11003599 PMID:17728465 PMID:19023039 PMID:21638035 PMID:23565201 PMID:24101734 PMID:24149798 PMID:26522449 PMID:27466191 PMID:30545933 PMID:31504961 |
|
NCBI chr 5:122,643,927...122,692,336
Ensembl chr 5:122,643,911...122,691,432
|
|
G |
P2ry1 |
purinergic receptor P2Y, G-protein coupled 1 |
multiple interactions affects activity |
ISO EXP |
[Adenosine Triphosphate binds to and results in increased activity of P2RY1 protein] which results in increased abundance of Calcium; Adenosine Triphosphate binds to and results in increased activity of P2RY1 protein; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [P2RY1 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]]; P2RY1 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]; Trichloroethylene inhibits the reaction [[Adenosine Triphosphate binds to and results in increased activity of P2RY1 protein] which results in increased abundance of Calcium] [N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate binds to and results in decreased activity of P2RY1 protein] inhibits the reaction [Adenosine Triphosphate results in increased uptake of Calcium] Adenosine Triphosphate affects the activity of P2RY1 protein |
CTD |
PMID:12694404 PMID:15243297 PMID:16973929 PMID:22129738 |
|
NCBI chr 3:61,002,785...61,008,982
Ensembl chr 3:61,002,795...61,008,982
|
|
G |
P2ry13 |
purinergic receptor P2Y, G-protein coupled 13 |
multiple interactions |
ISO |
MRS 2211 inhibits the reaction [P2RY13 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]]; P2RY13 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide] |
CTD |
PMID:22129738 |
|
NCBI chr 3:59,207,892...59,210,882
Ensembl chr 3:59,207,892...59,210,882
|
|
G |
P2ry2 |
purinergic receptor P2Y, G-protein coupled 2 |
multiple interactions affects activity increases activity |
ISO EXP |
[Adenosine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Calcium [Adenosine Triphosphate results in increased activity of P2RY2 protein] which results in increased uptake of Calcium Adenosine Triphosphate affects the activity of P2RY2 protein |
CTD |
PMID:11527950 PMID:15243297 PMID:17003265 |
|
NCBI chr 7:100,996,568...101,012,053
Ensembl chr 7:100,996,568...101,012,866
|
|
G |
P2ry4 |
pyrimidinergic receptor P2Y, G-protein coupled, 4 |
multiple interactions |
ISO |
[Adenosine Triphosphate binds to and results in increased activity of P2RY4 protein] which results in increased abundance of Calcium; Adenosine Triphosphate binds to and results in increased activity of P2RY4 protein; Trichloroethylene inhibits the reaction [[Adenosine Triphosphate binds to and results in increased activity of P2RY4 protein] which results in increased abundance of Calcium] |
CTD |
PMID:12694404 |
|
NCBI chr X:100,588,358...100,594,927
Ensembl chr X:100,590,154...100,594,869
|
|
G |
P2ry6 |
pyrimidinergic receptor P2Y, G-protein coupled, 6 |
multiple interactions |
ISO |
N,N''-1,4-butanediylbis(N'-(3-isothiocyanatophenyl))thiourea inhibits the reaction [P2RY6 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]]; P2RY6 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide] |
CTD |
PMID:22129738 |
|
NCBI chr 7:100,937,630...100,975,498
Ensembl chr 7:100,937,630...100,974,649
|
|
G |
Panx1 |
pannexin 1 |
decreases activity multiple interactions increases export |
ISO EXP |
Adenosine Triphosphate results in decreased activity of PANX1 protein Carbenoxolone inhibits the reaction [PANX1 protein results in increased export of Adenosine Triphosphate]; Probenecid inhibits the reaction [PANX1 protein results in increased export of Adenosine Triphosphate] |
CTD |
PMID:19023039 PMID:19213873 |
|
NCBI chr 9:15,005,785...15,045,478
Ensembl chr 9:15,002,128...15,045,478
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase family, member 1 |
multiple interactions increases expression |
ISO EXP |
PARP1 mutant form inhibits the reaction [Cadmium results in decreased abundance of Adenosine Triphosphate] PARP1 protein affects the reaction [pyrithione zinc results in decreased abundance of Adenosine Triphosphate]; PARP1 protein affects the reaction [Zinc results in decreased abundance of Adenosine Triphosphate] Adenosine Triphosphate results in increased expression of PARP1 protein |
CTD |
PMID:17728843 PMID:19809895 PMID:21767558 PMID:22253048 |
|
NCBI chr 1:180,568,891...180,600,999
Ensembl chr 1:180,568,924...180,601,254
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase, isoenzyme 1 |
multiple interactions affects response to substance |
EXP |
[PDK1 protein affects the susceptibility to Adenosine Triphosphate] which affects the abundance of Calcium; Adenosine Triphosphate promotes the reaction [PDK1 protein affects the abundance of Calcium]; tubacin affects the reaction [[PDK1 protein affects the susceptibility to Adenosine Triphosphate] which affects the abundance of Calcium] |
CTD |
PMID:28887310 |
|
NCBI chr 2:71,873,215...71,903,858
Ensembl chr 2:71,873,224...71,903,858
|
|
G |
Pfkm |
phosphofructokinase, muscle |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [resveratrol results in decreased activity of PFKM protein] |
CTD |
PMID:23454376 |
|
NCBI chr15:98,092,589...98,132,447
Ensembl chr15:98,092,589...98,132,451
|
|
G |
Pgp |
phosphoglycolate phosphatase |
decreases phosphorylation |
EXP |
PGP protein results in decreased phosphorylation of Adenosine Triphosphate |
CTD |
PMID:24338473 |
|
NCBI chr17:24,470,426...24,473,110
Ensembl chr17:24,470,392...24,473,110
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
multiple interactions affects binding |
ISO |
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine inhibits the reaction [Adenosine Triphosphate binds to PIK3CA protein]; Adenosine Triphosphate inhibits the reaction [resveratrol results in decreased activity of [PIK3R1 protein binds to PIK3CA protein]] |
CTD |
PMID:17550345 PMID:18754654 |
|
NCBI chr 3:32,397,065...32,466,112
Ensembl chr 3:32,397,671...32,468,486
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
multiple interactions |
ISO |
Adenosine Triphosphate inhibits the reaction [resveratrol results in decreased activity of [PIK3R1 protein binds to PIK3CA protein]] |
CTD |
PMID:17550345 |
|
NCBI chr13:101,680,761...101,768,217
Ensembl chr13:101,680,563...101,768,217
|
|
G |
Pla2g4a |
phospholipase A2, group IVA (cytosolic, calcium-dependent) |
increases activity |
EXP |
Adenosine Triphosphate results in increased activity of PLA2G4A protein |
CTD |
PMID:10535451 |
|
NCBI chr 1:149,829,618...149,961,290
Ensembl chr 1:149,829,618...149,961,290
|
|
G |
Plau |
plasminogen activator, urokinase |
increases secretion |
EXP |
Adenosine Triphosphate results in increased secretion of PLAU protein |
CTD |
PMID:20177776 |
|
NCBI chr14:20,836,662...20,843,388
Ensembl chr14:20,836,660...20,843,385
|
|
G |
Plpp3 |
phospholipid phosphatase 3 |
decreases chemical synthesis |
EXP |
PLPP3 gene mutant form results in decreased chemical synthesis of Adenosine Triphosphate |
CTD |
PMID:28982073 |
|
NCBI chr 4:105,157,347...105,232,767
Ensembl chr 4:105,157,347...105,232,764
|
|
G |
Pml |
promyelocytic leukemia |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PML protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [PML protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PML protein; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased abundance of Reactive Oxygen Species]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; PML protein promotes the reaction [[resiquimod co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein] |
CTD |
PMID:23430110 |
|
NCBI chr 9:58,217,179...58,249,796
Ensembl chr 9:58,218,076...58,249,786
|
|
G |
Pmvk |
phosphomevalonate kinase |
increases hydrolysis |
ISO |
PMVK protein results in increased hydrolysis of Adenosine Triphosphate |
CTD |
PMID:9392419 |
|
NCBI chr 3:89,454,541...89,469,014
Ensembl chr 3:89,454,541...89,469,013
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
[Fenofibrate results in increased activity of PPARA protein] which results in decreased abundance of Adenosine Triphosphate |
CTD |
PMID:19593819 |
|
NCBI chr15:85,734,910...85,806,851
Ensembl chr15:85,734,983...85,802,819
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
multiple interactions decreases abundance |
ISO |
FASN protein promotes the reaction [rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]]; rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]; UCP1 protein promotes the reaction [PPARG protein mutant form results in decreased abundance of Adenosine Triphosphate]; UCP1 protein promotes the reaction [rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]] PPARG protein mutant form results in decreased abundance of Adenosine Triphosphate; PPARG protein results in decreased abundance of Adenosine Triphosphate |
CTD |
PMID:26670611 |
|
NCBI chr 6:115,360,879...115,490,404
Ensembl chr 6:115,360,951...115,490,399
|
|
G |
Ppp5c |
protein phosphatase 5, catalytic subunit |
multiple interactions |
ISO |
Adenosine Triphosphate binds to and affects the folding of PPP5C protein; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to PPP5C protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to PPP5C protein] |
CTD |
PMID:23184943 |
|
NCBI chr 7:17,004,640...17,027,914
Ensembl chr 7:17,004,640...17,027,924
|
|
G |
Prdx2 |
peroxiredoxin 2 |
increases expression |
ISO |
Adenosine Triphosphate results in increased expression of PRDX2 protein modified form |
CTD |
PMID:16178011 |
|
NCBI chr 8:84,969,622...84,974,811
Ensembl chr 8:84,969,587...84,974,834
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions |
ISO |
[[Adenosine Triphosphate co-treated with PRKCA protein] results in increased phosphorylation of RALBP1 protein] which results in increased transport of Doxorubicin |
CTD |
PMID:16087181 |
|
NCBI chr11:107,933,387...108,343,888
Ensembl chr11:107,933,387...108,343,928
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein] |
CTD |
PMID:24149798 |
|
NCBI chr 1:150,100,031...150,108,234
Ensembl chr 1:150,100,031...150,108,227
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
ISO EXP |
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of PYCARD mRNA; resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of PYCARD mRNA] [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]]; PYCARD gene mutant form inhibits the reaction [Adenosine Triphosphate results in increased abundance of G(M3) Ganglioside]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein] |
CTD |
PMID:18604214 PMID:23430110 PMID:24149798 PMID:24475307 |
|
NCBI chr 7:127,991,373...127,993,867
Ensembl chr 7:127,989,708...127,993,867
|
|
G |
Ralbp1 |
ralA binding protein 1 |
multiple interactions |
ISO |
[[Adenosine Triphosphate co-treated with PRKCA protein] results in increased phosphorylation of RALBP1 protein] which results in increased transport of Doxorubicin; Adenosine Triphosphate promotes the reaction [RALBP1 protein affects the transport of Leukotriene C4] |
CTD |
PMID:15386349 PMID:16087181 |
|
NCBI chr17:65,848,415...65,885,755
Ensembl chr17:65,848,418...65,885,798
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
ISO |
[Adenosine Triphosphate results in increased expression of NOS2 protein] promotes the reaction [NOS2 protein binds to RELA protein]; Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]; Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]; Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]]; Cyclosporine inhibits the reaction [[Adenosine Triphosphate results in increased expression of NOS2 protein] promotes the reaction [NOS2 protein binds to RELA protein]] [Adenosine Triphosphate co-treated with Lipopolysaccharides] affects the localization of RELA protein; NOS2 protein affects the reaction [Adenosine Triphosphate results in increased metabolism of RELA protein]; resveratrol promotes the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] affects the localization of RELA protein]; S-Nitrosoglutathione promotes the reaction [Adenosine Triphosphate results in increased metabolism of RELA protein] |
CTD |
PMID:21464294 PMID:24149798 |
|
NCBI chr19:5,637,442...5,648,134
Ensembl chr19:5,637,483...5,648,130
|
|
G |
Rhof |
ras homolog family member F (in filopodia) |
increases expression multiple interactions |
ISO EXP |
Adenosine Triphosphate results in increased expression of RHOF mRNA Niclosamide inhibits the reaction [Adenosine Triphosphate results in increased expression of RHOF mRNA] |
CTD |
PMID:29733962 |
|
NCBI chr 5:123,118,180...123,141,808
Ensembl chr 5:123,103,044...123,132,692
|
|
G |
S100a10 |
S100 calcium binding protein A10 (calpactin) |
increases expression |
ISO |
Adenosine Triphosphate results in increased expression of S100A10 mRNA |
CTD |
PMID:29733962 |
|
NCBI chr 3:93,555,117...93,564,645
Ensembl chr 3:93,555,080...93,564,643
|
|
G |
S100a11 |
S100 calcium binding protein A11 |
increases expression |
ISO |
Adenosine Triphosphate results in increased expression of S100A11 mRNA |
CTD |
PMID:29733962 |
|
NCBI chr 3:93,520,496...93,526,288
Ensembl chr 3:93,520,488...93,526,287
|
|
G |
S100a4 |
S100 calcium binding protein A4 |
multiple interactions increases expression |
EXP ISO |
Adenosine Triphosphate results in increased expression of and results in increased secretion of S100A4 protein; Niclosamide inhibits the reaction [Adenosine Triphosphate results in increased expression of S100A4 protein] Adenosine Triphosphate results in increased expression of S100A4 mRNA |
CTD |
PMID:29733962 |
|
NCBI chr 3:90,603,770...90,606,045
Ensembl chr 3:90,603,771...90,606,045
|
|
G |
S100a6 |
S100 calcium binding protein A6 (calcyclin) |
increases expression |
ISO |
Adenosine Triphosphate results in increased expression of S100A6 mRNA |
CTD |
PMID:29733962 |
|
NCBI chr 3:90,612,894...90,614,414
Ensembl chr 3:90,612,882...90,624,181
|
|
G |
Sell |
selectin, lymphocyte |
multiple interactions |
ISO |
P2RX7 protein affects the reaction [Adenosine Triphosphate results in increased secretion of SELL protein] |
CTD |
PMID:11003599 |
|
NCBI chr 1:164,061,987...164,082,930
Ensembl chr 1:164,061,982...164,084,181
|
|
G |
Sftpa1 |
surfactant associated protein A1 |
multiple interactions |
ISO |
[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]; Ozone inhibits the reaction [[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]]; Ozone inhibits the reaction [SFTPA1 protein polymorphism inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]] |
CTD |
PMID:15065867 |
|
NCBI chr14:41,131,788...41,136,373
Ensembl chr14:41,131,782...41,136,452
|
|
G |
Sftpb |
surfactant associated protein B |
increases secretion multiple interactions |
EXP ISO |
Adenosine Triphosphate results in increased secretion of SFTPB protein Ro 31-8220 inhibits the reaction [Adenosine Triphosphate results in increased secretion of SFTPB protein] |
CTD |
PMID:11704537 PMID:14565945 |
|
NCBI chr 6:72,304,610...72,314,373
Ensembl chr 6:72,304,610...72,314,371
|
|
G |
Sftpc |
surfactant associated protein C |
increases secretion multiple interactions |
ISO EXP |
Adenosine Triphosphate results in increased secretion of SFTPC protein Ro 31-8220 inhibits the reaction [Adenosine Triphosphate results in increased secretion of SFTPC protein] |
CTD |
PMID:11704537 PMID:14565945 |
|
NCBI chr14:70,520,941...70,524,081
Ensembl chr14:70,520,949...70,524,081
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
[SIRT1 protein results in decreased expression of UCP2 mRNA] promotes the reaction [Glucose results in increased abundance of Adenosine Triphosphate]; SIRT1 protein promotes the reaction [[Glucose results in increased abundance of Adenosine Triphosphate] which results in increased expression of INS1 protein]; SIRT1 protein promotes the reaction [Glucose results in increased abundance of Adenosine Triphosphate] |
CTD |
PMID:16366736 |
|
NCBI chr10:63,319,005...63,339,035
Ensembl chr10:63,319,005...63,381,704
|
|
G |
Sirt3 |
sirtuin 3 |
multiple interactions |
EXP |
SIRT3 protein inhibits the reaction [Metformin results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:23166782 |
|
NCBI chr 7:140,863,663...140,882,309
Ensembl chr 7:140,863,666...140,882,309
|
|
G |
Slc25a14 |
solute carrier family 25 (mitochondrial carrier, brain), member 14 |
decreases chemical synthesis |
ISO |
SLC25A14 protein results in decreased chemical synthesis of Adenosine Triphosphate |
CTD |
PMID:20600837 |
|
NCBI chr X:48,623,418...48,662,298
Ensembl chr X:48,623,413...48,662,294
|
|
G |
Slc2a1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
decreases stability |
ISO |
Adenosine Triphosphate results in decreased stability of SLC2A1 protein |
CTD |
PMID:11420438 |
|
NCBI chr 4:119,108,745...119,137,330
Ensembl chr 4:119,108,711...119,137,983
|
|
G |
Slc46a1 |
solute carrier family 46, member 1 |
multiple interactions |
ISO |
[SLC46A1 protein results in increased susceptibility to N-((5-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo(2,3-d)pyrimidin-6-yl)propyl)thiophen-2-yl)carbonyl)glutamic acid] which results in decreased chemical synthesis of Adenosine Triphosphate |
CTD |
PMID:21879757 |
|
NCBI chr11:78,465,701...78,471,945
Ensembl chr11:78,465,697...78,472,059
|
|
G |
Slc5a5 |
solute carrier family 5 (sodium iodide symporter), member 5 |
multiple interactions |
ISO |
Adenosine Triphosphate inhibits the reaction [TSHB protein results in increased expression of SLC5A5 protein] |
CTD |
PMID:16439463 |
|
NCBI chr 8:70,882,885...70,892,785
Ensembl chr 8:70,882,889...70,892,757
|
|
G |
Snca |
synuclein, alpha |
multiple interactions decreases abundance |
ISO |
GW8510 inhibits the reaction [SNCA protein results in decreased abundance of Adenosine Triphosphate]; SB 216763 inhibits the reaction [SNCA protein results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:24989254 |
|
NCBI chr 6:60,731,573...60,829,855
Ensembl chr 6:60,731,575...60,829,855
|
|
G |
Sod1 |
superoxide dismutase 1, soluble |
increases expression |
ISO |
Adenosine Triphosphate results in increased expression of SOD1 protein |
CTD |
PMID:16178011 PMID:22129738 |
|
NCBI chr16:90,220,762...90,226,333
Ensembl chr16:90,220,754...90,226,329
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
affects chemical synthesis decreases abundance multiple interactions |
EXP |
SOD2 protein affects the chemical synthesis of Adenosine Triphosphate SOD2 gene mutant form results in decreased abundance of Adenosine Triphosphate MK-886 promotes the reaction [SOD2 gene mutant form results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:20638473 PMID:25362851 |
|
NCBI chr17:13,007,839...13,018,119
Ensembl chr17:13,006,846...13,040,063
|
|
G |
Stxbp2 |
syntaxin binding protein 2 |
multiple interactions |
EXP |
STXBP2 protein affects the reaction [F2 protein results in increased transport of Adenosine Triphosphate] |
CTD |
PMID:30696774 |
|
NCBI chr 8:3,630,960...3,643,998
Ensembl chr 8:3,630,955...3,643,644
|
|
G |
Sugt1 |
SGT1, suppressor of G2 allele of SKP1 (S. cerevisiae) |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to SUGT1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]] |
CTD |
PMID:23184943 |
|
NCBI chr14:79,587,660...79,630,797
Ensembl chr14:79,587,691...79,635,196
|
|
G |
Syn2 |
synapsin II |
multiple interactions |
EXP |
SYN2 mutant form inhibits the reaction [Adenosine Triphosphate results in increased abundance of Calcium] |
CTD |
PMID:18701217 |
|
NCBI chr 6:115,134,902...115,282,626
Ensembl chr 6:115,134,902...115,282,006
|
|
G |
Tac1 |
tachykinin 1 |
increases secretion multiple interactions |
ISO |
Adenosine Triphosphate results in increased secretion of TAC1 protein Iloprost promotes the reaction [Adenosine Triphosphate results in increased secretion of TAC1 protein] |
CTD |
PMID:16039053 |
|
NCBI chr 6:7,555,061...7,562,978
Ensembl chr 6:7,554,879...7,565,834
|
|
G |
Taldo1 |
transaldolase 1 |
increases abundance |
EXP |
TALDO1 gene mutant form results in increased abundance of Adenosine Triphosphate |
CTD |
PMID:19436114 |
|
NCBI chr 7:141,392,160...141,402,976
Ensembl chr 7:141,392,199...141,402,968
|
|
G |
Tas2r115 |
taste receptor, type 2, member 115 |
increases activity |
EXP |
Adenosine Triphosphate results in increased activity of TAS2R115 protein |
CTD |
PMID:29347925 |
|
NCBI chr 6:132,737,054...132,737,986
Ensembl chr 6:132,737,003...132,738,035
|
|
G |
Tas2r131 |
taste receptor, type 2, member 131 |
increases activity |
EXP |
Adenosine Triphosphate results in increased activity of TAS2R131 protein |
CTD |
PMID:29347925 |
|
NCBI chr 6:132,956,912...132,957,844
Ensembl chr 6:132,956,884...132,957,919
|
|
G |
Tas2r143 |
taste receptor, type 2, member 143 |
increases activity |
EXP |
Adenosine Triphosphate results in increased activity of TAS2R143 protein |
CTD |
PMID:29347925 |
|
NCBI chr 6:42,400,238...42,401,119
Ensembl chr 6:42,400,238...42,401,119
|
|
G |
Timm17a |
translocase of inner mitochondrial membrane 17a |
multiple interactions decreases expression |
ISO |
1,10-phenanthroline inhibits the reaction [Adenosine Triphosphate results in decreased expression of TIMM17A protein] |
CTD |
PMID:24315374 |
|
NCBI chr 1:135,301,535...135,313,737
Ensembl chr 1:135,295,213...135,313,778
|
|
G |
Timp1 |
tissue inhibitor of metalloproteinase 1 |
decreases secretion multiple interactions |
EXP |
Adenosine Triphosphate results in decreased secretion of TIMP1 protein azetidine analog inhibits the reaction [Adenosine Triphosphate results in decreased secretion of TIMP1 protein] |
CTD |
PMID:26522449 |
|
NCBI chr X:20,870,166...20,874,737
Ensembl chr X:20,870,166...20,874,735
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases chemical synthesis |
EXP ISO |
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of TNF protein; Adenosine Triphosphate deficiency inhibits the reaction [TNF protein results in increased transport of Chlorides]; Adenosine Triphosphate deficiency inhibits the reaction [TNF protein results in increased transport of Potassium]; Adenosine Triphosphate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone]; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased secretion of TNF protein] TNF protein promotes the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased chemical synthesis of Adenosine Triphosphate] TNF protein results in decreased chemical synthesis of Adenosine Triphosphate [Asbestos, Amosite co-treated with TNF protein] results in increased metabolism of Adenosine Triphosphate; Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; MFN2 protein inhibits the reaction [TNF protein results in decreased chemical synthesis of Adenosine Triphosphate]; Rosiglitazone inhibits the reaction [TNF protein results in decreased chemical synthesis of Adenosine Triphosphate]; Vitamin K 3 promotes the reaction [[Asbestos, Amosite co-treated with TNF protein] results in increased metabolism of Adenosine Triphosphate] |
CTD |
PMID:8817062 PMID:10783394 PMID:14623498 PMID:17707769 PMID:23430110 PMID:24898700 PMID:26522449 |
|
NCBI chr17:35,199,367...35,202,007
Ensembl chr17:35,199,381...35,202,007
|
|
G |
Tnfsf11 |
tumor necrosis factor (ligand) superfamily, member 11 |
increases abundance |
EXP |
TNFSF11 protein results in increased abundance of Adenosine Triphosphate |
CTD |
PMID:26287518 |
|
NCBI chr14:78,277,446...78,308,043
Ensembl chr14:78,277,445...78,308,043
|
|
G |
Top2a |
topoisomerase (DNA) II alpha |
multiple interactions increases hydrolysis |
ISO |
Cannabidiol metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]; copper-thiosemicarbazone complex analog inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]; Dithiothreitol inhibits the reaction [Cannabidiol metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]]; Emodin inhibits the reaction [TOP2A results in increased hydrolysis of Adenosine Triphosphate]; Etoposide metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]; Thiosemicarbazones analog inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate] TOP2A protein results in increased hydrolysis of Adenosine Triphosphate; TOP2A results in increased hydrolysis of Adenosine Triphosphate |
CTD |
PMID:20855424 PMID:26982206 PMID:27533850 PMID:29272108 |
|
NCBI chr11:98,992,947...99,024,199
Ensembl chr11:98,992,943...99,024,189
|